

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/025589

International filing date: 06 August 2004 (06.08.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/493,561  
Filing date: 08 August 2003 (08.08.2003)

Date of receipt at the International Bureau: 10 September 2004 (10.09.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



**BEST AVAILABLE COPY**

World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1218504

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*August 27, 2004*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/493,561**

**FILING DATE: August 08, 2003**

**RELATED PCT APPLICATION NUMBER: PCT/US04/25589**

Certified by



Jon W Dudas

Acting Under Secretary of Commerce  
for Intellectual Property  
and Acting Director of the U.S.  
Patent and Trademark Office



**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 CFR § 1.53(c).

Express Mail No. EV 334703960US

Docket No.  
03-764  
(400/124)Type a plus sign (+)  
inside this box:

+

00746 U.S. PTO  
60/493561

INVENTOR(S)/APPLICANTS(S)			
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (City and either state or foreign country)
Chowira	Bharat	M.	576 Manorwood Lane Louisville, CO 80027
McSwiggen	James		4866 Franklin Drive Boulder, Colorado 80301
TITLE OF THE INVENTION (280 character maximum)			
RNA Interference Mediated Inhibition of XIAP Gene Expression Using Short Interfering Nucleic Acid (siNA)			
CUSTOMER NUMBER			
 20306 PATENT TRADEMARK OFFICE McDonnell Boehnen Hulbert & Berghoff			
ENCLOSED APPLICATION PARTS (check all that apply)			
<input checked="" type="checkbox"/> Specification Number of Pages 144 <input checked="" type="checkbox"/> Drawings Number of Sheets 13			
<input checked="" type="checkbox"/> Other: Certificate of Express Mail; Return Receipt Postcard			
METHOD OF PAYMENT FOR THIS PROVISIONAL APPLICATION FOR PATENT			
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		PROVISIONAL APPLICATION FOR PATENT FILING FEE AMOUNT (\$)	\$80.00
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the Provisional Filing Fee.			
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number: 13-2490.			
CERTIFICATE OF MAILING			
I hereby certify that, under 37 CFR § 1.10, I directed that the correspondence identified above be deposited with the United States Postal Service as "Express Mail Post Office to Addressee," addressed to the Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.			

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.  
\_\_\_\_ No. \_\_\_\_ Yes, the name of the U.S. Government agency and the Government contract number are: \_\_\_\_

Respectfully submitted,

SIGNATURE:

Date: August 8, 2003

TYPED or PRINTED NAME Anita J. Terpstra

REG. NO. 47,132

☐ Additional inventors are being named on separately numbered sheets attached hereto.


**CERTIFICATE OF MAILING**

**(PATENT)**

**Express Mail No. EV 334703960 US**

**Deposited August 8, 2003**

I hereby certify that the attached correspondence, identified below, is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop Provisional Patent Application, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BY:   
Anita J. Terpstra Reg. No. 47,132

Application for Provisional Patent of

Title: RNA Interference Mediated Inhibition of XIAP Gene Expression Using Short Interfering Nucleic Acid (siNA)

- ☒ Provisional Patent Application (including cover sheet, 144 pages of specification and 13 pages of drawings)
- ☒ Provisional Patent Cover Sheet (in duplicate)
- ☒ Return Receipt Postcard
- ☒ Check in the amount of \$80.00

Docket No. 03-764 (400/124)



**RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE  
EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)**

Field Of The Invention

The present invention concerns compounds, compositions, and methods for the  
5 study, diagnosis, and treatment of conditions and diseases that respond to the modulation  
of X-linked inhibitor of apoptosis protein (XIAP) gene expression and/or activity. The  
present invention also concerns compounds, compositions, and methods relating to  
conditions and diseases that respond to the modulation of expression and/or activity of  
genes involved in XIAP pathways. Specifically, the invention relates to small nucleic  
10 acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA  
(siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA  
(shRNA) molecules capable of mediating RNA interference (RNAi) against XIAP gene  
expression.

Background Of The Invention

15 The following is a discussion of relevant art pertaining to RNAi. The discussion is  
provided only for understanding of the invention that follows. The summary is not an  
admission that any of the work described below is prior art to the claimed invention.

RNA interference refers to the process of sequence-specific post-transcriptional  
gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire *et al.*,  
20 1998, *Nature*, 391, 806; Hamilton *et al.*, 1999, *Science*, 286, 950-951). The  
corresponding process in plants is commonly referred to as post-transcriptional gene  
silencing or RNA silencing and is also referred to as quelling in fungi. The process of  
post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular  
defense mechanism used to prevent the expression of foreign genes and is commonly  
25 shared by diverse flora and phyla (Fire *et al.*, 1999, *Trends Genet.*, 15, 358). Such  
protection from foreign gene expression may have evolved in response to the production  
of double-stranded RNAs (dsRNAs) derived from viral infection or from the random  
integration of transposon elements into a host genome via a cellular response that  
specifically destroys homologous single-stranded RNA or viral genomic RNA. The  
30 presence of dsRNA in cells triggers the RNAi response through a mechanism that has yet  
to be fully characterized. This mechanism appears to be different from the interferon

response that results from dsRNA-mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Hamilton *et al.*, *supra*; Bernstein *et al.*, 2001, *Nature*, 409, 363). Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes (Hamilton *et al.*, *supra*; Elbashir *et al.*, 2001, *Genes Dev.*, 15, 188). Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner *et al.*, 2001, *Science*, 293, 834). The RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir *et al.*, 2001, *Genes Dev.*, 15, 188).

RNAi has been studied in a variety of systems. Fire *et al.*, 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. elegans*. Bahramian and Zarbl, 1999, *Molecular and Cellular Biology*, 19, 274-283 and Wianny and Goetz, 1999, *Nature Cell Biol.*, 2, 70, describe RNAi mediated by dsRNA in mammalian systems. Hammond *et al.*, 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells transfected with dsRNA. Elbashir *et al.*, 2001, *Nature*, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877) has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21-nucleotide siRNA duplexes are most active when containing 3'-terminal dinucleotide overhangs. Furthermore, complete substitution of one or both siRNA strands with 2'-deoxy (2'-H) or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3'-terminal siRNA overhang nucleotides with 2'-deoxy nucleotides (2'-H) was shown to be tolerated. Single mismatch sequences in the

center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end of the guide sequence (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen *et al.*, 2001, *Cell*, 107, 309).

Studies have shown that replacing the 3'-terminal nucleotide overhanging segments of a 21-mer siRNA duplex having two nucleotide 3'-overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to four nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well tolerated, whereas complete substitution with deoxyribonucleotides results in no RNAi activity (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877). In addition, Elbashir *et al.*, *supra*, also report that substitution of siRNA with 2'-O-methyl nucleotides completely abolishes RNAi activity. Li *et al.*, International PCT Publication No. WO 00/44914, and Beach *et al.*, International PCT Publication No. WO 01/68836 preliminarily suggest that siRNA may include modifications to either the phosphate-sugar backbone or the nucleoside to include at least one of a nitrogen or sulfur heteroatom, however, neither application postulates to what extent such modifications would be tolerated in siRNA molecules, nor provides any further guidance or examples of such modified siRNA. Kreutzer *et al.*, Canadian Patent Application No. 2,359,180, also describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double-stranded RNA-dependent protein kinase PKR, specifically 2'-amino or 2'-O-methyl nucleotides, and nucleotides containing a 2'-O or 4'-C methylene bridge. However, Kreutzer *et al.* similarly fails to provide examples or guidance as to what extent these modifications would be tolerated in siRNA molecules.

Parrish *et al.*, 2000, *Molecular Cell*, 6, 1977-1087, tested certain chemical modifications targeting the unc-22 gene in *C. elegans* using long (>25 nt) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that RNAs with two phosphorothioate modified bases also had substantial decreases in effectiveness as RNAi. Further, Parrish *et al.* reported

that phosphorothioate modification of more than two residues greatly destabilized the RNAs *in vitro* such that interference activities could not be assayed. *Id.* at 1081. The authors also tested certain modifications at the 2'-position of the nucleotide sugar in the long siRNA transcripts and found that substituting deoxynucleotides for ribonucleotides produced a substantial decrease in interference activity, especially in the case of Uridine to Thymidine and/or Cytidine to deoxy-Cytidine substitutions. *Id.* In addition, the authors tested certain base modifications, including substituting, in sense and antisense strands of the siRNA, 4-thiouracil, 5-bromouracil, 5-iodouracil, and 3-(aminoallyl)uracil for uracil, and inosine for guanosine. Whereas 4-thiouracil and 5-bromouracil substitution appeared to be tolerated, Parrish reported that inosine produced a substantial decrease in interference activity when incorporated in either strand. Parrish also reported that incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in a substantial decrease in RNAi activity as well.

The use of longer dsRNA has been described. For example, Beach *et al.*, International PCT Publication No. WO 01/68836, describes specific methods for attenuating gene expression using endogenously-derived dsRNA. Tuschl *et al.*, International PCT Publication No. WO 01/75164, describe a *Drosophila in vitro* RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001, *Chem. Biochem.*, 2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due to the danger of activating interferon response. Li *et al.*, International PCT Publication No. WO 00/44914, describe the use of specific dsRNAs for attenuating the expression of certain target genes. Zernicka-Goetz *et al.*, International PCT Publication No. WO 01/36646, describe certain methods for inhibiting the expression of particular genes in mammalian cells using certain dsRNA molecules. Fire *et al.*, International PCT Publication No. WO 99/32619, describe particular methods for introducing certain dsRNA molecules into cells for use in inhibiting gene expression. Plaetinck *et al.*, International PCT Publication No. WO 00/01846, describe certain methods for identifying specific genes responsible for conferring a particular phenotype in a cell using specific dsRNA molecules. Mello *et al.*, International PCT Publication No. WO 01/29058, describe the identification of specific genes involved in dsRNA-mediated RNAi. Deschamps Depaillette *et al.*, International PCT Publication No. WO 99/07409, describe specific compositions consisting of particular dsRNA molecules combined with certain anti-viral

agents. Waterhouse *et al.*, International PCT Publication No. 99/53050, describe certain methods for decreasing the phenotypic expression of a nucleic acid in plant cells using certain dsRNAs. Driscoll *et al.*, International PCT Publication No. WO 01/49844, describe specific DNA constructs for use in facilitating gene silencing in targeted  
 5 organisms.

Others have reported on various RNAi and gene-silencing systems. For example, Parrish *et al.*, 2000, *Molecular Cell*, 6, 1977-1087, describe specific chemically-modified siRNA constructs targeting the unc-22 gene of *C. elegans*. Grossniklaus, International PCT Publication No. WO 01/38551, describes certain methods for regulating polycomb  
 10 gene expression in plants using certain dsRNAs. Churikov *et al.*, International PCT Publication No. WO 01/42443, describe certain methods for modifying genetic characteristics of an organism using certain dsRNAs. Cogoni *et al.*, International PCT Publication No. WO 01/53475, describe certain methods for isolating a *Neurospora* silencing gene and uses thereof. Reed *et al.*, International PCT Publication No. WO  
 15 01/68836, describe certain methods for gene silencing in plants. Honer *et al.*, International PCT Publication No. WO 01/70944, describe certain methods of drug screening using transgenic nematodes as Parkinson's Disease models using certain dsRNAs. Deak *et al.*, International PCT Publication No. WO 01/72774, describe certain *Drosophila*-derived gene products that may be related to RNAi in *Drosophila*. Arndt *et al.*, International PCT Publication No. WO 01/92513 describe certain methods for  
 20 mediating gene suppression by using factors that enhance RNAi. Tuschl *et al.*, International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs. Pachuk *et al.*, International PCT Publication No. WO 00/63364, and Satishchandran *et al.*, International PCT Publication No. WO 01/04313, describe certain  
 25 methods and compositions for inhibiting the function of certain polynucleotide sequences using certain dsRNAs. Echeverri *et al.*, International PCT Publication No. WO 02/38805, describe certain *C. elegans* genes identified via RNAi. Kreutzer *et al.*, International PCT Publications Nos. WO 02/055692, WO 02/055693, and EP 1144623 B1 describes certain methods for inhibiting gene expression using RNAi. Graham *et al.*,  
 30 International PCT Publications Nos. WO 99/49029 and WO 01/70949, and AU 4037501 describe certain vector expressed siRNA molecules. Fire *et al.*, US 6,506,559, describe certain methods for inhibiting gene expression in vitro using certain long dsRNA (greater than 25 nucleotide) constructs that mediate RNAi.

## SUMMARY OF THE INVENTION

This invention relates to compounds, compositions, and methods useful for modulating the expression of genes, such as those genes associated with inhibitor of apoptosis proteins (IAPs), for example XIAP (X-linked inhibitor of apoptosis protein) and related genes, such as HIAP1 (human inhibitor of apoptosis 1), HIAP2 (human inhibitor of apoptosis 2), NAIP (neuronal apoptosis inhibitor protein) and other IAP's (inhibitors of apoptosis proteins), using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of XIAP genes, or genes involved in XIAP pathways of gene expression and/or XIAP activity by RNA interference (RNAi) using small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of XIAP genes. A siNA of the invention can be unmodified or chemically-modified. A siNA of the instant invention can be chemically synthesized, expressed from a vector or enzymatically synthesized.

The instant invention also features various chemically-modified synthetic short interfering nucleic acid (siNA) molecules capable of modulating XIAP gene expression or activity in cells by RNA interference (RNAi). The use of chemically-modified siNA improves various properties of native siNA molecules through increased resistance to nuclease degradation *in vivo* and/or through improved cellular uptake. Further, contrary to earlier published studies, siNA having multiple chemical modifications retains its RNAi activity. The siNA molecules of the instant invention provide useful reagents and methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.

In one embodiment, the invention features one or more siNA molecules and methods that independently or in combination modulate the expression of gene(s) encoding proteins, such as XIAP, HIAP1, HIAP2, and/or NAIP, associated with the maintenance and/or development of cancer and other proliferative disorders, such as

ovarian cancer; cancers of non-lymphoid parenchymal organs including the heart, placenta, skeletal muscle and lung; breast cancer, cancers of the head and neck including various lymphomas such as mantle cell lymphoma, non-Hodgkins lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma, cancers of the retina, cancers of the esophagus, multiple myeloma, melanoma, colorectal cancer, lung cancer, bladder cancer, prostate cancer, glioblastoma; and proliferative diseases and conditions such as restenosis and polycystic kidney disease; and any other indications that can respond to the level of a XIAP gene in a cell or tissue, such as genes encoding sequences comprising those sequences referred to by GenBank Accession Nos. shown in Table I, referred to herein generally as XIAP. The description below of the various aspects and embodiments of the invention is provided with reference to the exemplary XIAP gene referred to herein generally as XIAP, which is also known as BIRC4. However, the various aspects and embodiments are also directed to other apoptosis inhibitor genes such as HIAP1, HIAP2, and NAIP, and other XIAP genes, such as mutant XIAP genes, splice variants of XIAP genes, or genes encoding any XIAP ligands and receptors. The various aspects and embodiments are also directed to other genes that are involved in XIAP mediated pathways of signal transduction or gene expression, such as HIAP1, HIAP2, AND NAIP, that are involved in the progression, development, and/or maintenance of disease (e.g., cancers and proliferative conditions such as ovarian cancer; cancers of non-lymphoid parenchymal organs including the heart, placenta, skeletal muscle and lung; breast cancer, cancers of the head and neck including various lymphomas such as mantle cell lymphoma, non-Hodgkins lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma, cancers of the retina, cancers of the esophagus, multiple myeloma, melanoma, colorectal cancer, lung cancer, bladder cancer, prostate cancer, glioblastoma; and proliferative diseases and conditions such as restenosis and polycystic kidney disease; and any other indications that can respond to the level of a XIAP gene in a cell or tissue). These additional genes can be analyzed for target sites using the methods described for XIAP genes herein. Thus, the modulation of other genes and the effects of such modulation of the other genes can be performed and measured as described herein.

In one embodiment, the invention features a siNA molecule that down-regulates expression of a XIAP gene, for example, wherein the XIAP gene comprises XIAP encoding sequence.



In one embodiment, the invention features a siNA molecule having RNAi activity against XIAP RNA, wherein the siNA molecule comprises a sequence complementary to any RNA having XIAP or other XIAP encoding sequence, such as those sequences having GenBank Accession Nos. shown in Table I. In another embodiment, the invention features a siNA molecule having RNAi activity against XIAP RNA, wherein the siNA molecule comprises a sequence complementary to an RNA having other XIAP encoding sequence, for example mutant XIAP genes, splice variants of XIAP genes, variants with conservative substitutions, and homologous XIAP ligands and receptors. Chemical modifications as shown in Tables III and IV or otherwise described herein can be applied to any siNA construct of the invention.

In another embodiment, the invention features a siNA molecule having RNAi activity against an XIAP gene, wherein the siNA molecule comprises nucleotide sequence complementary to nucleotide sequence of a XIAP gene, such as those XIAP sequences having GenBank Accession Nos. shown in Table I or other XIAP encoding sequence, such as mutant XIAP genes, splice variants of XIAP genes, variants with conservative substitutions, and homologous XIAP ligands and receptors.

In another embodiment, a siNA molecule of the invention includes nucleotide sequence that can interact with nucleotide sequence of a XIAP gene and thereby mediate silencing of XIAP gene expression, for example, wherein the siNA mediates regulation of XIAP gene expression by cellular processes that modulate the chromatin structure of the XIAP gene and prevent transcription of the XIAP gene.

In another embodiment, the invention features a siNA molecule comprising nucleotide sequence, for example, nucleotide sequence in the antisense region of the siNA molecule that is complementary to a nucleotide sequence or portion of sequence of a XIAP gene. In another embodiment, the invention features a siNA molecule comprising a region, for example, the antisense region of the siNA construct, complementary to a sequence or portion of sequence comprising a XIAP gene sequence or a portion thereof.

In one embodiment, the antisense region of XIAP siNA constructs can comprise a sequence complementary to sequence having any of SEQ ID NOs. 1-467 or 935-938. In one embodiment, the antisense region can also comprise sequence having any of SEQ ID

NOs. 468-934, 943-946, 951-954, 959-962, 967-970, 975-978, 989, 991, 933, or 996. In another embodiment, the sense region of XIAP constructs can comprise sequence having any of SEQ ID NOs. 1-467, 935-942, 947-950, 955-958, 963-966, 971-974, 988, 990, 992, 994 or 995. The sense region can comprise a sequence of SEQ ID NO. 979 and the  
5 antisense region can comprise a sequence of SEQ ID NO. 980. The sense region can comprise a sequence of SEQ ID NO. 981 and the antisense region can comprise a sequence of SEQ ID NO. 982. The sense region can comprise a sequence of SEQ ID NO. 983 and the antisense region can comprise a sequence of SEQ ID NO. 984. The sense region can comprise a sequence of SEQ ID NO. 985 and the antisense region can  
10 comprise a sequence of SEQ ID NO. 982. The sense region can comprise a sequence of SEQ ID NO. 986 and the antisense region can comprise a sequence of SEQ ID NO. 982. The sense region can comprise a sequence of SEQ ID NO. 985 and the antisense region can comprise a sequence of SEQ ID NO. 987.

In one embodiment, a siNA molecule of the invention comprises any of SEQ ID  
15 NOs. 1-996. The sequences shown in SEQ ID NOs: 1-996 are not limiting. A siNA molecule of the invention can comprise any contiguous XIAP sequence (e.g., about 19 to about 25, or about 19, 20, 21, 22, 23, 24 or 25 contiguous XIAP nucleotides).

In yet another embodiment, the invention features a siNA molecule comprising a sequence, for example, the antisense sequence of the siNA construct, complementary to a  
20 sequence or portion of sequence comprising sequence represented by GenBank Accession Nos. shown in **Table I**. Chemical modifications in **Tables III and IV** and described herein can be applied to any siNA construct of the invention.

In one embodiment of the invention a siNA molecule comprises an antisense strand having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or  
25 29) nucleotides, wherein the antisense strand is complementary to a RNA sequence encoding a XIAP protein, and wherein said siNA further comprises a sense strand having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29) nucleotides, and wherein said sense strand and said antisense strand are distinct nucleotide sequences with at least about 19 complementary nucleotides.

30 In another embodiment of the invention a siNA molecule of the invention comprises an antisense region having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23,

24, 25, 26, 27, 28 or 29) nucleotides, wherein the antisense region is complementary to a RNA sequence encoding a XIAP protein, and wherein said siNA further comprises a sense region having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or more) nucleotides, wherein said sense region and said antisense region  
5 comprise a linear molecule with at least about 19 complementary nucleotides.

In one embodiment of the invention a siNA molecule comprises an antisense strand comprising a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof encoding a XIAP protein. The siNA further comprises a sense strand, wherein said sense strand comprises a nucleotide sequence of a XIAP gene or a  
10 portion thereof.

In another embodiment, a siNA molecule comprises an antisense region comprising a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof encoding a XIAP protein. The siNA molecule further comprises a sense region, wherein said sense region comprises a nucleotide sequence of a XIAP gene or a  
15 portion thereof.

In one embodiment, a siNA molecule of the invention has RNAi activity that modulates expression of RNA encoded by a XIAP gene. Because XIAP genes can share some degree of sequence homology with each other, siNA molecules can be designed to target a class of XIAP genes (and associated receptor or ligand genes) or alternately  
20 specific XIAP genes by selecting sequences that are either shared amongst different XIAP targets or alternatively that are unique for a specific XIAP target. Therefore, in one embodiment, the siNA molecule can be designed to target conserved regions of XIAP RNA sequence having homology between several XIAP genes so as to target several XIAP genes (e.g., different XIAP isoforms, splice variants, mutant genes etc.)  
25 with one siNA molecule. In another embodiment, the siNA molecule can be designed to target a sequence that is unique to a specific XIAP RNA sequence due to the high degree of specificity that the siNA molecule requires to mediate RNAi activity.

In one embodiment, nucleic acid molecules of the invention that act as mediators of the RNA interference gene silencing response are double-stranded nucleic acid  
30 molecules. In another embodiment, the siNA molecules of the invention consist of duplexes containing about 19 base pairs between oligonucleotides comprising about 19

to about 25 (*e.g.*, about 19, 20, 21, 22, 23, 24 or 25) nucleotides. In yet another embodiment, siNA molecules of the invention comprise duplexes with overhanging ends of about about 1 to about 3 (*e.g.*, about 1, 2, or 3) nucleotides, for example, about 21-nucleotide duplexes with about 19 base pairs and 3'-terminal mononucleotide, 5 dinucleotide, or trinucleotide overhangs.

In one embodiment, the invention features one or more chemically-modified siNA constructs having specificity for XIAP expressing nucleic acid molecules, such as RNA encoding a XIAP protein. Non-limiting examples of such chemical modifications include without limitation phosphorothioate internucleotide linkages, 2'-deoxyribonucleotides, 2'-O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, 10 "universal base" nucleotides, "acyclic" nucleotides, 5-C-methyl nucleotides, and terminal glyceryl and/or inverted deoxy abasic residue incorporation. These chemical modifications, when used in various siNA constructs, are shown to preserve RNAi activity in cells while at the same time, dramatically increasing the serum stability of 15 these compounds. Furthermore, contrary to the data published by Parrish *et al.*, *supra*, applicant demonstrates that multiple (greater than one) phosphorothioate substitutions are well-tolerated and confer substantial increases in serum stability for modified siNA constructs.

In one embodiment, a siNA molecule of the invention comprises modified 20 nucleotides while maintaining the ability to mediate RNAi. The modified nucleotides can be used to improve *in vitro* or *in vivo* characteristics such as stability, activity, and/or bioavailability. For example, a siNA molecule of the invention can comprise modified nucleotides as a percentage of the total number of nucleotides present in the siNA molecule. As such, a siNA molecule of the invention can generally comprise about 5% 25 to about 100% modified nucleotides (*e.g.*, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified nucleotides). The actual percentage of modified nucleotides present in a given siNA molecule will depend on the total number of nucleotides present in the siNA. If the siNA molecule is single stranded, the percent modification can be based upon the total number 30 of nucleotides present in the single stranded siNA molecules. Likewise, if the siNA molecule is double stranded, the percent modification can be based upon the total

number of nucleotides present in the sense strand, antisense strand, or both the sense and antisense strands.

One aspect of the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a XIAP gene. In one embodiment, a double stranded siNA molecule comprises one or more chemical  
5 modifications and each strand of the double-stranded siNA is about 21 nucleotides long. In one embodiment, the double-stranded siNA molecule does not contain any ribonucleotides. In another embodiment, the double-stranded siNA molecule comprises one or more ribonucleotides. In one embodiment, each strand of the double-stranded  
10 siNA molecule comprises about 19 to about 23 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein each strand comprises about 19 nucleotides that are complementary to the nucleotides of the other strand. In one embodiment, one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof of the XIAP gene, and the  
15 second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or a portion thereof of the XIAP gene.

In another embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a XIAP gene, wherein the siNA molecule comprises an antisense region comprising a nucleotide sequence that  
20 is complementary to a nucleotide sequence or a portion thereof of the XIAP gene, and wherein the siNA further comprises a sense region, wherein the sense region comprises a nucleotide sequence substantially similar to the nucleotide sequence or a portion thereof of the XIAP gene. In one embodiment, the antisense region and the sense region each comprise about 19 to about 23 (about 19, 20, 21, 22, or 23) nucleotides, wherein the  
25 antisense region comprises about 19 nucleotides that are complementary to nucleotides of the sense region.

In another embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a XIAP gene, wherein the siNA molecule comprises a sense region and an antisense region and wherein the  
30 antisense region comprises a nucleotide sequence that is complementary to a nucleotide

sequence or a portion thereof of RNA encoded by the XIAP gene and the sense region comprises a nucleotide sequence that is complementary to the antisense region.

5 In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a XIAP gene, wherein the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule. The sense region can be connected to the antisense region via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker.

10 In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a XIAP gene, wherein the siNA molecule comprises a sense region and an antisense region and wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof of RNA encoded by the XIAP gene or a portion thereof,  
15 and the sense region comprises a nucleotide sequence that is complementary to the antisense region, and wherein the siNA molecule has one or more modified pyrimidine and/or purine nucleotides. In one embodiment, the pyrimidine nucleotides in the sense region are 2'-O-methyl pyrimidine nucleotides or 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-deoxy purine  
20 nucleotides. In another embodiment, the pyrimidine nucleotides in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-O-methyl purine nucleotides. In another embodiment, the pyrimidine nucleotides in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-deoxy purine nucleotides. In one  
25 embodiment, the pyrimidine nucleotides in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the antisense region are 2'-O-methyl or 2'-deoxy purine nucleotides. In another embodiment of any of the above described siNA molecules, any nucleotides present in a non-complementary region of the sense strand (e.g. overhang region) are 2'-deoxy nucleotides.

30 In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a XIAP gene, wherein

the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule, and wherein the fragment comprising the sense region includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the fragment comprising the sense region. In another embodiment, the terminal cap moiety is an inverted deoxy abasic moiety or glyceryl moiety. In another embodiment, each of the two fragments of the siNA molecule comprise about 21 nucleotides.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a XIAP gene, wherein the siNA molecule comprises a sense region and an antisense region and wherein the antisense region comprises a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof of RNA encoded by the XIAP gene and the sense region comprises a nucleotide sequence that is complementary to the antisense region, and wherein the purine nucleotides present in the antisense region comprise 2'-deoxy- purine nucleotides. In an alternative embodiment, the purine nucleotides present in the antisense region comprise 2'-O-methyl purine nucleotides. In either of the above embodiments, the antisense region can comprise a phosphorothioate internucleotide linkage at the 3' end of the antisense region. Alternatively, in either of the above embodiments, the antisense region can comprise a glyceryl modification at the 3' end of the antisense region. In another embodiment of any of the above described siNA molecules, any nucleotides present in a non-complementary region of the antisense strand (e.g. overhang region) are 2'-deoxy nucleotides.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a XIAP gene, wherein the siNA molecule is assembled from two separate oligonucleotide fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of the siNA molecule. In another embodiment about 19 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule and wherein at least two 3' terminal nucleotides of each fragment of the siNA molecule are not base-paired to the nucleotides of the other fragment of the siNA molecule. In one embodiment, each of the two 3' terminal



nucleotides of each fragment of the siNA molecule is a 2'-deoxy-pyrimidine nucleotide, such as a 2'-deoxy-thymidine. In another embodiment, all 21 nucleotides of each fragment of the siNA molecule are base-paired to the complementary nucleotides of the other fragment of the siNA molecule. In another embodiment, about 19 nucleotides of the antisense region are base-paired to the nucleotide sequence or a portion thereof of the RNA encoded by the XIAP gene. In another embodiment, about 21 nucleotides of the antisense region are base-paired to the nucleotide sequence or a portion thereof of the RNA encoded by the XIAP gene. In any of the above embodiments, the 5'-end of the fragment comprising said antisense region can optionally includes a phosphate group.

10 In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of a XIAP RNA sequence (e.g., wherein said target RNA sequence is encoded by a XIAP gene involved in the XIAP pathway), wherein the siNA molecule does not contain any ribonucleotides and wherein each strand of the double-stranded siNA molecule is about 21 nucleotides long.

15 Examples of non-ribonucleotide containing siNA constructs are combinations of stabilization chemistries shown in Table IV in any combination of Sense/Antisense chemistries, such as Stab 7/8, Stab 7/11, Stab 8/8, Stab 18/8, Stab 18/11, Stab 12/13, Stab 7/13, or Stab 18/13.

In one embodiment, the invention features a medicament comprising a siNA molecule of the invention.

In one embodiment, the invention features an active ingredient comprising a siNA molecule of the invention.

In one embodiment, the invention features the use of a double-stranded short interfering nucleic acid (siNA) molecule to down-regulate expression of a XIAP gene, wherein the siNA molecule comprises one or more chemical modifications and each strand of the double-stranded siNA is about 21 nucleotides long.

In one embodiment, an apoptosis inhibitor gene contemplated by the invention is a XIAP, HIAP1, HIAP2, or NAIP gene.

In one embodiment, the invention features the use of a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a XIAP gene,

wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of XIAP RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a XIAP gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of XIAP RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification. .

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a XIAP gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of XIAP RNA that encodes a protein or portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification. In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a XIAP gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of XIAP RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification. In one embodiment, each strand of the siNA molecule comprises about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein each strand comprises about 19 nucleotides that are complementary to the nucleotides of

the other strand. In another embodiment, the siNA molecule is assembled from two oligonucleotide fragments, wherein one fragment comprises the nucleotide sequence of the antisense strand of the siNA molecule and a second fragment comprises nucleotide sequence of the sense region of the siNA molecule. In yet another embodiment, the sense strand is connected to the antisense strand via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker. In a further embodiment, the pyrimidine nucleotides present in the sense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-deoxy purine nucleotides. In another embodiment, the pyrimidine nucleotides present in the sense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine nucleotides present in the sense region are 2'-O-methyl purine nucleotides. In still another embodiment, the pyrimidine nucleotides present in the antisense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and any purine nucleotides present in the antisense strand are 2'-deoxy purine nucleotides. In another embodiment, the antisense strand comprises one or more 2'-deoxy-2'-fluoro pyrimidine nucleotides and one or more 2'-O-methyl purine nucleotides. In another embodiment, the pyrimidine nucleotides present in the antisense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and any purine nucleotides present in the antisense strand are 2'-O-methyl purine nucleotides. In a further embodiment the sense strand comprises a 3'-end and a 5'-end, a terminal cap moiety (e.g., an inverted deoxy abasic moiety) is present at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the sense strand. In another embodiment, the antisense strand comprises a phosphorothioate internucleotide linkage at the 3' end of the antisense strand. In another embodiment, the antisense strand comprises a glyceryl modification at the 3' end. In another embodiment, the 5'-end of the antisense strand optionally includes a phosphate group.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a XIAP gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of XIAP RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein each of the two strands of the siNA molecule comprises about 21 nucleotides. In one embodiment, about 21 nucleotides of

each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule. In another embodiment, about 19 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule, wherein at least two 3' terminal nucleotides of  
5 each strand of the siNA molecule are not base-paired to the nucleotides of the other strand of the siNA molecule. In another embodiment, each of the two 3' terminal nucleotides of each fragment of the siNA molecule are 2'-deoxy-pyrimidines, such as 2'-deoxy-thymidine. In another embodiment, each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule. In  
10 another embodiment, about 19 nucleotides of the antisense strand are base-paired to the nucleotide sequence of the XIAP RNA or a portion thereof. In another embodiment, about 21 nucleotides of the antisense strand are base-paired to the nucleotide sequence of the XIAP RNA or a portion thereof.

In one embodiment, the invention features a double-stranded short interfering  
15 nucleic acid (siNA) molecule that inhibits expression of a XIAP gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of XIAP RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a  
20 majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein the 5'-end of the antisense strand optionally includes a phosphate group.

In one embodiment, the invention features a double-stranded short interfering  
nucleic acid (siNA) molecule that inhibits expression of a XIAP gene, wherein one of the  
25 strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of XIAP RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule  
30 comprises a sugar modification, and wherein the nucleotide sequence or a portion thereof of the antisense strand is complementary to a nucleotide sequence of a untranslated region or a portion thereof of the XIAP RNA.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits expression of a XIAP gene, wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to nucleotide sequence of XIAP RNA or a portion thereof, the other strand is a sense strand which comprises nucleotide sequence that is complementary to a nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification, and wherein the nucleotide sequence or a portion thereof of the antisense strand is complementary to a nucleotide sequence of the XIAP RNA or a portion thereof that is present in the XIAP RNA.

In one embodiment, the invention features a composition comprising a siNA molecule of the invention in a pharmaceutically acceptable carrier or diluent.


In a non-limiting example, the introduction of chemically-modified nucleotides into nucleic acid molecules provides a powerful tool in overcoming potential limitations of *in vivo* stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically-modified nucleic acid molecules can enable a lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically-modified nucleic acid molecules tend to have a longer half-life in serum. Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving cellular uptake of the nucleic acid molecule. Therefore, even if the activity of a chemically-modified nucleic acid molecule is reduced as compared to a native nucleic acid molecule, for example, when compared to an all-RNA nucleic acid molecule, the overall activity of the modified nucleic acid molecule can be greater than that of the native molecule due to improved stability and/or delivery of the molecule. Unlike native unmodified siNA, chemically-modified siNA can also minimize the possibility of activating interferon activity in humans.

In any of the embodiments of siNA molecules described herein, the antisense region of a siNA molecule of the invention can comprise a phosphorothioate internucleotide linkage at the 3'-end of said antisense region. In any of the embodiments of siNA molecules described herein, the antisense region can comprise about one to

about five phosphorothioate internucleotide linkages at the 5'-end of said antisense region. In any of the embodiments of siNA molecules described herein, the 3'-terminal nucleotide overhangs of a siNA molecule of the invention can comprise ribonucleotides or deoxyribonucleotides that are chemically-modified at a nucleic acid sugar, base, or backbone. In any of the embodiments of siNA molecules described herein, the 3'-terminal nucleotide overhangs can comprise one or more universal base ribonucleotides. In any of the embodiments of siNA molecules described herein, the 3'-terminal nucleotide overhangs can comprise one or more acyclic nucleotides.

One embodiment of the invention provides an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention in a manner that allows expression of the nucleic acid molecule. Another embodiment of the invention provides a mammalian cell comprising such an expression vector. The mammalian cell can be a human cell. The siNA molecule of the expression vector can comprise a sense region and an antisense region. The antisense region can comprise sequence complementary to a RNA or DNA sequence encoding XIAP and the sense region can comprise sequence complementary to the antisense region. The siNA molecule can comprise two distinct strands having complementary sense and antisense regions. The siNA molecule can comprise a single strand having complementary sense and antisense regions.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against XIAP inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides comprising a backbone modified internucleotide linkage having Formula I:




wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or polynucleotide which can be naturally-occurring or chemically-modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O, S,

N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl, and wherein W, X, Y, and Z are optionally not all O.

The chemically-modified internucleotide linkages having Formula I, for example, wherein any Z, W, X, and/or Y independently comprises a sulphur atom, can be present  
5 in one or both oligonucleotide strands of the siNA duplex, for example, in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) chemically-modified internucleotide linkages having Formula I at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example,  
10 an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (*e.g.*, about 1, 2, 3, 4, 5, or more) chemically-modified internucleotide linkages having Formula I at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine  
15 nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or  
20 both strands. In another embodiment, a siNA molecule of the invention having internucleotide linkage(s) of Formula I also comprises a chemically-modified nucleotide or non-nucleotide having any of Formulae I-VII.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against  
25 XIAP inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula II:






wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S=O, CHF, or CF2, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA.

The chemically-modified nucleotide or non-nucleotide of Formula II can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula II at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (*e.g.*, about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (*e.g.*, about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 3'-end of the sense strand, the antisense strand, or both strands.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against XIAP inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or

5 non-nucleotides having Formula III:



wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S=O, CHF, or CF2, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be employed to be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA.

10

15


20 The chemically-modified nucleotide or non-nucleotide of Formula III can be present in one or both oligonucleotide strands of the siNA duplex, for example, in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula III at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-

25

modified nucleotide(s) or non-nucleotide(s) of Formula III at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotide or non-nucleotide of  
 5 Formula III at the 3'-end of the sense strand, the antisense strand, or both strands.

In another embodiment, a siNA molecule of the invention comprises a nucleotide having Formula II or III, wherein the nucleotide having Formula II or III is in an inverted configuration. For example, the nucleotide having Formula II or III is connected to the siNA construct in a 3'-3', 3'-2', 2'-3', or 5'-5' configuration, such as at the 3'-end, the 5'-  
 10 end, or both of the 3' and 5'-ends of one or both siNA strands.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against XIAP inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises a 5'-terminal phosphate group having Formula IV:



15

wherein each X and Y is independently O, S, N, alkyl, substituted alkyl, or alkylhalo; wherein each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, or alkylhalo; and wherein W, X, Y and Z are not all O.

In one embodiment, the invention features a siNA molecule having a 5'-terminal  
 20 phosphate group having Formula IV on the target-complementary strand, for example, a strand complementary to a target RNA, wherein the siNA molecule comprises an all RNA siNA molecule. In another embodiment, the invention features a siNA molecule having a 5'-terminal phosphate group having Formula IV on the target-complementary strand wherein the siNA molecule also comprises about 1 to about 3 (e.g., about 1, 2, or  
 25 3) nucleotide 3'-terminal nucleotide overhangs having about 1 to about 4 (e.g., about 1, 2, 3, or 4) deoxyribonucleotides on the 3'-end of one or both strands. In another embodiment, a 5'-terminal phosphate group having Formula IV is present on the target-

complementary strand of a siNA molecule of the invention, for example a siNA molecule having chemical modifications having any of Formulae I-VII.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against XIAP inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises one or more phosphorothioate internucleotide linkages. For example, in a non-limiting example, the invention features a chemically-modified short interfering nucleic acid (siNA) having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in one siNA strand. In yet another embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) individually having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in both siNA strands. The phosphorothioate internucleotide linkages can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more phosphorothioate internucleotide linkages at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (*e.g.*, about 1, 2, 3, 4, 5, or more) consecutive phosphorothioate internucleotide linkages at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands.

In one embodiment, the invention features a siNA molecule, wherein the sense strand comprises one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or about one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 10 or

more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a  
 5 terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more,  
 10 phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

In another embodiment, the invention features a siNA molecule, wherein the sense strand comprises about 1 to about 5, specifically about 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages, and/or one or more (*e.g.*, about 1, 2, 3, 4, 5, or more) 2'-deoxy,  
 15 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (*e.g.*, about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages, and/or one or more (*e.g.*, about 1, 2, 3, 4, 5, 6,  
 20 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA  
 25 strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without about 1 to about 5 or more, for example about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

30 In one embodiment, the invention features a siNA molecule, wherein the antisense strand comprises one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or about one or more (*e.g.*, about 1, 2, 3,

4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 10 or more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3' and 5'-ends, being present in the same or different strand.

In another embodiment, the invention features a siNA molecule, wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without about 1 to about 5, for example about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule having about 1 to about 5, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages in each strand of the siNA molecule.

In another embodiment, the invention features a siNA molecule comprising 2'-5' internucleotide linkages. The 2'-5' internucleotide linkage(s) can be at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of one or both siNA sequence strands. In addition, the 2'-5' internucleotide linkage(s) can be present at various other positions within one or both siNA sequence strands, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a pyrimidine nucleotide in one or both strands of the siNA molecule can comprise a 2'-5' internucleotide linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a purine nucleotide in one or both strands of the siNA molecule can comprise a 2'-5' internucleotide linkage.

In another embodiment, a chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified, wherein each strand is about 18 to about 27 (*e.g.*, about 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27) nucleotides in length, wherein the duplex has about 18 to about 23 (*e.g.*, about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the chemical modification comprises a structure having any of Formulae I-VII. For example, an exemplary chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein each strand consists of about 21 nucleotides, each having a 2-nucleotide 3'-terminal nucleotide overhang, and wherein the duplex has about 19 base pairs. In another embodiment, a siNA molecule of the invention comprises a single stranded hairpin structure, wherein the siNA is about 36 to about 70 (*e.g.*, about 36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (*e.g.*, about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having about 42 to about 50 (*e.g.*, about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms a hairpin structure having



about 19 base pairs and a 2-nucleotide 3'-terminal nucleotide overhang. In another embodiment, a linear hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. For example, a linear hairpin siNA molecule of the invention is designed such that degradation of the loop  
5 portion of the siNA molecule *in vivo* can generate a double-stranded siNA molecule with 3'-terminal overhangs, such as 3'-terminal nucleotide overhangs comprising about 2 nucleotides.

In another embodiment, a siNA molecule of the invention comprises a hairpin structure, wherein the siNA is about 25 to about 50 (*e.g.*, about 25, 26, 27, 28, 29, 30, 31,  
10 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides in length having about 3 to about 25 (*e.g.*, about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) base pairs, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of  
15 the invention comprises a linear oligonucleotide having about 25 to about 35 (*e.g.*, about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) nucleotides that is chemically-modified with one or more chemical modifications having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms a hairpin structure having about 3 to  
20 about 23 (*e.g.*, about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) base pairs and a 5'-terminal phosphate group that can be chemically modified as described herein (for example a 5'-terminal phosphate group having Formula IV). In another embodiment, a linear hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. In another embodiment, a linear hairpin siNA molecule of the invention comprises a loop portion  
25 comprising a non-nucleotide linker.

In another embodiment, a siNA molecule of the invention comprises an asymmetric hairpin structure, wherein the siNA is about 25 to about 50 (*e.g.*, about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,  
30 or 50) nucleotides in length having about 3 to about 20 (*e.g.*, about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) base pairs, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA

molecule of the invention comprises a linear oligonucleotide having about 25 to about 35 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35) nucleotides that is chemically-modified with one or more chemical modifications having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms an asymmetric hairpin structure having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18) base pairs and a 5'-terminal phosphate group that can be chemically modified as described herein (for example a 5'-terminal phosphate group having Formula IV). In another embodiment, an asymmetric hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. In another embodiment, an asymmetric hairpin siNA molecule of the invention comprises a loop portion comprising a non-nucleotide linker.


In another embodiment, a siNA molecule of the invention comprises an asymmetric double stranded structure having separate polynucleotide strands comprising sense and antisense regions, wherein the antisense region is about 16 to about 25 (e.g., about 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length, wherein the sense region is about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides in length, wherein the sense region the antisense region have at least 3 complementary nucleotides, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises an asymmetric double stranded structure having separate polynucleotide strands comprising sense and antisense regions, wherein the antisense region is about 18 to about 22 (e.g., about 18, 19, 20, 21, or 22) nucleotides in length and wherein the sense region is about 3 to about 15 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) nucleotides in length, wherein the sense region the antisense region have at least 3 complementary nucleotides, and wherein the siNA can include one or more chemical modifications comprising a structure having any of Formulae I-VII or any combination thereof. In another embodiment, the asymmetric double stranded siNA molecule can also have a 5'-terminal phosphate group that can be chemically modified as described herein (for example a 5'-terminal phosphate group having Formula IV).

In another embodiment, a siNA molecule of the invention comprises a circular nucleic acid molecule, wherein the siNA is about 38 to about 70 (e.g., about 38, 40, 45,

50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification, which comprises a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a circular oligonucleotide having about 42 to about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the circular oligonucleotide forms a dumbbell shaped structure having about 19 base pairs and 2 loops.


10 In another embodiment, a circular siNA molecule of the invention contains two loop motifs, wherein one or both loop portions of the siNA molecule is biodegradable. For example, a circular siNA molecule of the invention is designed such that degradation of the loop portions of the siNA molecule *in vivo* can generate a double-stranded siNA molecule with 3'-terminal overhangs, such as 3'-terminal nucleotide overhangs comprising about 2 nucleotides.

In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) abasic moiety, for example a compound having Formula V:




20 wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S=O, CHF, or CF2.

In one embodiment, a siNA molecule of the invention comprises at least one (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) inverted abasic moiety, for example a compound having Formula VI:



- 5 wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S=O, CHF, or CF2, and either R2, R3, R8 or R13 serve as points of attachment to the siNA molecule of the invention.
- 10

- In another embodiment, a siNA molecule of the invention comprises at least one (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) substituted polyalkyl moieties, for example a compound having Formula VII:
- 15



- wherein each n is independently an integer from 1 to 12, each R1, R2 and R3 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl,
- 20

aminoalkylamino, polyalkylamino, substituted silyl, or a group having Formula I, and R1, R2 or R3 serves as points of attachment to the siNA molecule of the invention.

In another embodiment, the invention features a compound having Formula VII, wherein R1 and R2 are hydroxyl (OH) groups,  $n = 1$ , and R3 comprises O and is the point of attachment to the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both strands of a double-stranded siNA molecule of the invention or to a single-stranded siNA molecule of the invention. This modification is referred to herein as "glyceryl" (for example modification 6 in Figure 10).

In another embodiment, a moiety having any of Formula V, VI or VII of the invention is at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of a siNA molecule of the invention. For example, a moiety having Formula V, VI or VII can be present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense strand, the sense strand, or both antisense and sense strands of the siNA molecule. In addition, a moiety having Formula VII can be present at the 3'-end or the 5'-end of a hairpin siNA molecule as described herein.

In another embodiment, a siNA molecule of the invention comprises an abasic residue having Formula V or VI, wherein the abasic residue having Formula VI or VI is connected to the siNA construct in a 3'-3', 3'-2', 2'-3', or 5'-5' configuration, such as at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both siNA strands.

In one embodiment, a siNA molecule of the invention comprises one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) locked nucleic acid (LNA) nucleotides, for example at the 5'-end, the 3'-end, both of the 5' and 3'-ends, or any combination thereof, of the siNA molecule.

In another embodiment, a siNA molecule of the invention comprises one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) acyclic nucleotides, for example at the 5'-end, the 3'-end, both of the 5' and 3'-ends, or any combination thereof, of the siNA molecule.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises a sense region, where any (*e.g.*, one or more or all) pyrimidine nucleotides

present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where any (*e.g.*, one or more or all) purine nucleotides present in the sense region are 2'-  
5 deoxy purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA  
10 comprises a sense region, where any (*e.g.*, one or more or all) pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where any (*e.g.*, one or more or all) purine nucleotides present in the sense region are 2'-  
15 deoxy purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides), wherein any nucleotides comprising a 3'-terminal nucleotide overhang that are present in said sense region are 2'-deoxy nucleotides.

In one embodiment, the invention features a chemically-modified short interfering  
20 nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises a sense region, where any (*e.g.*, one or more or all) pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and  
25 where any (*e.g.*, one or more or all) purine nucleotides present in the sense region are 2'-O-methyl purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering  
30 nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises a sense region, where any (*e.g.*, one or more or all) pyrimidine nucleotides

present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where any (*e.g.*, one or more or all) purine nucleotides present in the sense region are 2'-

5 O-methyl purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides), wherein any nucleotides comprising a 3'-terminal nucleotide overhang that are present in said sense region are 2'-deoxy nucleotides.

In one embodiment, the invention features a chemically-modified short interfering

10 nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (*e.g.*, one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine

15 nucleotides), and wherein any (*e.g.*, one or more or all) purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering

20 nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (*e.g.*, one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine

25 nucleotides), and wherein any (*e.g.*, one or more or all) purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides), wherein any nucleotides comprising a 3'-terminal nucleotide overhang that are present in said antisense region are 2'-deoxy nucleotides.

30 In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA

comprises an antisense region, where any (*e.g.*, one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where any (*e.g.*, one or more or all) purine nucleotides present in the antisense region are 2'-deoxy purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (*e.g.*, one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where any (*e.g.*, one or more or all) purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) against XIAP inside a cell or reconstituted *in vitro* system, wherein the chemically-modified siNA comprises a sense region, where one or more pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where one or more purine nucleotides present in the sense region are 2'-deoxy purine nucleotides (*e.g.*, wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides), and an antisense region, where one or more pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (*e.g.*, wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and



where one or more purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides). The sense region and/or the antisense region can have a terminal cap  
5 modification, such as any modification described herein or shown in **Figure 10**, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense and/or antisense sequence. The sense and/or antisense region can optionally further comprise a 3'-terminal nucleotide overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxynucleotides. The overhang nucleotides can further comprise one or more  
10 (e.g., about 1, 2, 3, 4 or more) phosphorothioate internucleotide linkages. Non-limiting examples of these chemically-modified siNAs are shown in **Figures 4 and 5** and **Tables III and IV** herein. In any of these described embodiments, the purine nucleotides present in the sense region are alternatively 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides) and one or more purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides). Also, in any of these  
15 embodiments, one or more purine nucleotides present in the sense region are alternatively purine ribonucleotides (e.g., wherein all purine nucleotides are purine ribonucleotides or alternately a plurality of purine nucleotides are purine ribonucleotides) and any purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides).  
20 Additionally, in any of these embodiments, one or more purine nucleotides present in the sense region and/or present in the antisense region are alternatively selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides (e.g., wherein all purine nucleotides are selected from the group consisting of 2'-deoxy  
25 nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides or alternately a plurality of purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-

O-methyl nucleotides). In another embodiment, any modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, *Principles of Nucleic Acid Structure*, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, are resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi. Non-limiting examples of nucleotides having a northern configuration include locked nucleic acid (LNA) nucleotides (e.g., 2'-O, 4'-C-methylene-(D-ribofuranosyl) nucleotides); 2'-methoxyethoxy (MOE) nucleotides; 2'-methyl-thio-ethyl, 2'-deoxy-2'-fluoro nucleotides, 2'-deoxy-2'-chloro nucleotides, 2'-azido nucleotides, and 2'-O-methyl nucleotides.

In one embodiment, the sense strand of a double stranded siNA molecule of the invention comprises a terminal cap moiety, (see for example Figure 10) such as an inverted deoxyabaisc moiety, at the 3'-end, 5'-end, or both 3' and 5'-ends of the sense strand.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid molecule (siNA) capable of mediating RNA interference (RNAi) against XIAP inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises a conjugate covalently attached to the chemically-modified siNA molecule. Non-limiting examples of conjugates contemplated by the invention include conjugates and ligands described in Vargeese *et al.*, USSN 10/427,160, filed April 30, 2003, incorporated by reference herein in its entirety, including the drawings. In another embodiment, the conjugate is covalently attached to the chemically-modified siNA molecule via a biodegradable linker. In one embodiment, the conjugate molecule is attached at the 3'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In another embodiment, the conjugate molecule is attached at the 5'-end of either the sense strand, the antisense strand, or both

strands of the chemically-modified siNA molecule. In yet another embodiment, the conjugate molecule is attached both the 3'-end and 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule, or any combination thereof. In one embodiment, a conjugate molecule of the invention  
5 comprises a molecule that facilitates delivery of a chemically-modified siNA molecule into a biological system, such as a cell. In another embodiment, the conjugate molecule attached to the chemically-modified siNA molecule is a poly ethylene glycol, human serum albumin, or a ligand for a cellular receptor that can mediate cellular uptake. Examples of specific conjugate molecules contemplated by the instant invention that can  
10 be attached to chemically-modified siNA molecules are described in Vargeese *et al.*, U.S. Serial No. 10/201,394, incorporated by reference herein. The type of conjugates used and the extent of conjugation of siNA molecules of the invention can be evaluated for improved pharmacokinetic profiles, bioavailability, and/or stability of siNA constructs while at the same time maintaining the ability of the siNA to mediate RNAi  
15 activity. As such, one skilled in the art can screen siNA constructs that are modified with various conjugates to determine whether the siNA conjugate complex possesses improved properties while maintaining the ability to mediate RNAi, for example in animal models as are generally known in the art.

In one embodiment, the invention features a short interfering nucleic acid (siNA)  
20 molecule of the invention, wherein the siNA further comprises a nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker that joins the sense region of the siNA to the antisense region of the siNA. In one embodiment, a nucleotide linker of the invention can be a linker of  $\geq 2$  nucleotides in length, for example about 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In another embodiment, the nucleotide linker can be a  
25 nucleic acid aptamer. By "aptamer" or "nucleic acid aptamer" as used herein is meant a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that comprises a sequence recognized by the target molecule in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule where the target molecule does not naturally bind to a nucleic acid.  
30 The target molecule can be any molecule of interest. For example, the aptamer can be used to bind to a ligand-binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. This is a non-limiting example and those in the art will recognize that other embodiments can be readily generated using

techniques generally known in the art. (See, for example, Gold *et al.*, 1995, *Annu. Rev. Biochem.*, 64, 763; Brody and Gold, 2000, *J. Biotechnol.*, 74, 5; Sun, 2000, *Curr. Opin. Mol. Ther.*, 2, 100; Kusser, 2000, *J. Biotechnol.*, 74, 27; Hermann and Patel, 2000, *Science*, 287, 820; and Jayasena, 1999, *Clinical Chemistry*, 45, 1628.)

5 In yet another embodiment, a non-nucleotide linker of the invention comprises abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds (e.g. polyethylene glycols such as those having between 2 and 100 ethylene glycol units). Specific examples include those described by Seela and Kaiser, *Nucleic Acids Res.* 1990, 18:6353 and *Nucleic Acids Res.* 10 1987, 15:3113; Cload and Schepartz, *J. Am. Chem. Soc.* 1991, 113:6324; Richardson and Schepartz, *J. Am. Chem. Soc.* 1991, 113:5109; Ma *et al.*, *Nucleic Acids Res.* 1993, 21:2585 and *Biochemistry* 1993, 32:1751; Durand *et al.*, *Nucleic Acids Res.* 1990, 18:6353; McCurdy *et al.*, *Nucleosides & Nucleotides* 1991, 10:287; Jsche *et al.*, *Tetrahedron Lett.* 1993, 34:301; Ono *et al.*, *Biochemistry* 1991, 30:9914; Arnold *et al.*, 15 International Publication No. WO 89/02439; Usman *et al.*, International Publication No. WO 95/06731; Dudycz *et al.*, International Publication No. WO 95/11910 and Ferentz and Verdine, *J. Am. Chem. Soc.* 1991, 113:4000, all hereby incorporated by reference herein. A "non-nucleotide" further means any group or compound that can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, 20 including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine, for example at the C1 position of the sugar.

In one embodiment, the invention features a short interfering nucleic acid (siNA) 25 molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein one or both strands of the siNA molecule that are assembled from two separate oligonucleotides do not comprise any ribonucleotides. For example, a siNA molecule can be assembled from a single oligonucleotide where the sense and antisense regions of the siNA comprise separate oligonucleotides not having any ribonucleotides 30 (e.g., nucleotides having a 2'-OH group) present in the oligonucleotides. In another example, a siNA molecule can be assembled from a single oligonucleotide where the sense and antisense regions of the siNA are linked or circularized by a nucleotide or non-

nucleotide linker as described herein, wherein the oligonucleotide does not have any ribonucleotides (e.g., nucleotides having a 2'-OH group) present in the oligonucleotide. Applicant has surprisingly found that the presence of ribonucleotides (e.g., nucleotides having a 2'-hydroxyl group) within the siNA molecule is not required or essential to support RNAi activity. As such, in one embodiment, all positions within the siNA can include chemically modified nucleotides and/or non-nucleotides such as nucleotides and or non-nucleotides having Formula I, II, III, IV, V, VI, or VII or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.

10 In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded polynucleotide having complementarity to a target nucleic acid sequence. In another embodiment, the single stranded siNA molecule of the invention comprises a 5'-terminal phosphate group. In another  
15 embodiment, the single stranded siNA molecule of the invention comprises a 5'-terminal phosphate group and a 3'-terminal phosphate group (e.g., a 2',3'-cyclic phosphate). In another embodiment, the single stranded siNA molecule of the invention comprises about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides. In yet another embodiment, the single stranded siNA molecule of the invention  
20 comprises one or more chemically modified nucleotides or non-nucleotides described herein. For example, all the positions within the siNA molecule can include chemically-modified nucleotides such as nucleotides having any of Formulae I-VII, or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.

25 In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded polynucleotide having complementarity to a target nucleic acid sequence, wherein one or more pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine  
30 nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides

(e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein or shown in Figure 10, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense sequence. The siNA optionally further comprises about 1 to about 4 or more (e.g., about 1, 2, 3, 4 or more) terminal 2'-deoxynucleotides at the 3'-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, 4 or more) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5'-terminal phosphate group. In any of these embodiments, any purine nucleotides present in the antisense region are alternatively 2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides). Also, in any of these embodiments, any purine nucleotides present in the siNA (i.e., purine nucleotides present in the sense and/or antisense region) can alternatively be locked nucleic acid (LNA) nucleotides (e.g., wherein all purine nucleotides are LNA nucleotides or alternately a plurality of purine nucleotides are LNA nucleotides). Also, in any of these embodiments, any purine nucleotides present in the siNA are alternatively 2'-methoxyethyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-methoxyethyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-methoxyethyl purine nucleotides). In another embodiment, any modified nucleotides present in the single stranded siNA molecules of the invention comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, *Principles of Nucleic Acid Structure*, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the single stranded siNA molecules of the invention are preferably resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi.

In one embodiment, the invention features a method for modulating the expression of a XIAP gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP gene; and (b) introducing the

siNA molecule into a cell under conditions suitable to modulate the expression of the XIAP gene in the cell.

5 In one embodiment, the invention features a method for modulating the expression of a XIAP gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP gene and wherein the sense strand sequence of the siNA comprises a sequence identical to the sequence of the target RNA; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the XIAP gene in the cell.

10 In another embodiment, the invention features a method for modulating the expression of more than one XIAP gene within a cell comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP genes; and (b) introducing the siNA molecules into a cell under conditions suitable to modulate the  
15 expression of the XIAP genes in the cell.

In another embodiment, the invention features a method for modulating the expression of two or more XIAP genes within a cell comprising: (a) synthesizing two or more siNA molecules of the invention, which can be chemically-modified, wherein the siNA strands comprise sequences complementary to RNA of the XIAP genes and  
20 wherein the sense strand sequences of the siNAs comprise sequences identical or substantially similar to the sequences of the target RNAs; and (b) introducing the siNA molecules into a cell under conditions suitable to modulate the expression of the XIAP genes in the cell.

25 In another embodiment, the invention features a method for modulating the expression of more than one XIAP gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP gene and wherein the sense strand sequence of the siNA comprises a sequence identical or substantially similar to the sequences of the target RNAs; and (b) introducing the siNA  
30 molecules into a cell under conditions suitable to modulate the expression of the XIAP genes in the cell.

In one embodiment, siNA molecules of the invention are used as reagents in ex vivo applications. For example, siNA reagents are introduced into tissue or cells that are transplanted into a subject for therapeutic effect. The cells and/or tissue can be derived from an organism or subject that later receives the explant, or can be derived from  
5 another organism or subject prior to transplantation. The siNA molecules can be used to modulate the expression of one or more genes in the cells or tissue, such that the cells or tissue obtain a desired phenotype or are able to perform a function when transplanted in vivo. In one embodiment, certain target cells from a patient are extracted. These extracted cells are contacted with siNAs targeting a specific nucleotide sequence within  
10 the cells under conditions suitable for uptake of the siNAs by these cells (e.g. using delivery reagents such as cationic lipids, liposomes and the like or using techniques such as electroporation to facilitate the delivery of siNAs into cells). The cells are then reintroduced back into the same patient or other patients. In one embodiment, the invention features a method of modulating the expression of a XIAP gene in a tissue  
15 explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP gene; and (b) introducing the siNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the XIAP gene in the tissue explant. In another embodiment,  
20 the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the XIAP gene in that organism.

In one embodiment, the invention features a method of modulating the expression of a XIAP gene in a tissue explant comprising: (a) synthesizing a siNA molecule of the  
25 invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP gene and wherein the sense strand sequence of the siNA comprises a sequence identical to the sequence of the target RNA; and (b) introducing the siNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the  
30 XIAP gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the XIAP gene in that organism.



In another embodiment, the invention features a method of modulating the expression of more than one XIAP gene in a tissue explant comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP genes; and (b) introducing the siNA molecules into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the XIAP genes in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the XIAP genes in that organism.

In one embodiment, the invention features a method of modulating the expression of a XIAP gene in an organism comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP gene; and (b) introducing the siNA molecule into the organism under conditions suitable to modulate the expression of the XIAP gene in the organism.

In another embodiment, the invention features a method of modulating the expression of more than one XIAP gene in an organism comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the XIAP genes; and (b) introducing the siNA molecules into the organism under conditions suitable to modulate the expression of the XIAP genes in the organism.

In one embodiment, the invention features a method for modulating the expression of a XIAP gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the XIAP gene; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the XIAP gene in the cell.

In another embodiment, the invention features a method for modulating the expression of more than one XIAP gene within a cell comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA

comprises a single stranded sequence having complementarity to RNA of the XIAP gene; and (b) contacting the siNA molecule with a cell in vitro or in vivo under conditions suitable to modulate the expression of the XIAP genes in the cell.

5 In one embodiment, the invention features a method of modulating the expression of a XIAP gene in a tissue explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the XIAP gene; and (b) contacting the siNA molecule with a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the XIAP gene in the tissue  
10 explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the XIAP gene in that organism.

In another embodiment, the invention features a method of modulating the expression of more than one XIAP gene in a tissue explant comprising: (a) synthesizing  
15 siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the XIAP gene; and (b) introducing the siNA molecules into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the XIAP genes in the tissue explant. In another embodiment, the method further comprises  
20 introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the XIAP genes in that organism.

In one embodiment, the invention features a method of modulating the expression of a XIAP gene in an organism comprising: (a) synthesizing a siNA molecule of the  
25 invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the XIAP gene; and (b) introducing the siNA molecule into the organism under conditions suitable to modulate the expression of the XIAP gene in the organism.

In another embodiment, the invention features a method of modulating the  
30 expression of more than one XIAP gene in an organism comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA

comprises a single stranded sequence having complementarity to RNA of the XIAP gene; and (b) introducing the siNA molecules into the organism under conditions suitable to modulate the expression of the XIAP genes in the organism.

5 In one embodiment, the invention features a method of modulating the expression of a XIAP gene in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the XIAP gene in the organism.

10 In another embodiment, the invention features a method of modulating the expression of more than one XIAP gene in an organism comprising contacting the organism with one or more siNA molecules of the invention under conditions suitable to modulate the expression of the XIAP genes in the organism.

The siNA molecules of the invention can be designed to down regulate or inhibit target (XIAP) gene expression through RNAi targeting of a variety of RNA molecules. In one embodiment, the siNA molecules of the invention are used to target various RNAs  
15 corresponding to a target gene. Non-limiting examples of such RNAs include messenger RNA (mRNA), alternate RNA splice variants of target gene(s), post-transcriptionally modified RNA of target gene(s), pre-mRNA of target gene(s), and/or RNA templates. If alternate splicing produces a family of transcripts that are distinguished by usage of appropriate exons, the instant invention can be used to inhibit gene expression through  
20 the appropriate exons to specifically inhibit or to distinguish among the functions of gene family members. For example, a protein that contains an alternatively spliced transmembrane domain can be expressed in both membrane bound and secreted forms. Use of the invention to target the exon containing the transmembrane domain can be used to determine the functional consequences of pharmaceutical targeting of membrane  
25 bound as opposed to the secreted form of the protein. Non-limiting examples of applications of the invention relating to targeting these RNA molecules include therapeutic pharmaceutical applications, pharmaceutical discovery applications, molecular diagnostic and gene function applications, and gene mapping, for example using single nucleotide polymorphism mapping with siNA molecules of the invention.  
30 Such applications can be implemented using known gene sequences or from partial sequences available from an expressed sequence tag (EST).

In another embodiment, the siNA molecules of the invention are used to target conserved sequences corresponding to a gene family or gene families such as XIAP family genes. As such, siNA molecules targeting multiple XIAP targets can provide increased therapeutic effect. In addition, siNA can be used to characterize pathways of gene function in a variety of applications. For example, the present invention can be used to inhibit the activity of target gene(s) in a pathway to determine the function of uncharacterized gene(s) in gene function analysis, mRNA function analysis, or translational analysis. The invention can be used to determine potential target gene pathways involved in various diseases and conditions toward pharmaceutical development. The invention can be used to understand pathways of gene expression involved in, for example, the progression and/or maintenance of cancer.

In one embodiment, siNA molecule(s) and/or methods of the invention are used to down regulate the expression of gene(s) that encode RNA referred to by Genbank Accession, for example XIAP genes encoding RNA sequence(s) referred to herein by Genbank Accession number, for example, Genbank Accession Nos. shown in Table I.

In one embodiment, the invention features a method comprising: (a) generating a library of siNA constructs having a predetermined complexity; and (b) assaying the siNA constructs of (a) above, under conditions suitable to determine RNAi target sites within the target RNA sequence. In one embodiment, the siNA molecules of (a) have strands of a fixed length, for example, about 23 nucleotides in length. In another embodiment, the siNA molecules of (a) are of differing length, for example having strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted *in vitro* siNA assay as described herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. In another embodiment, fragments of target RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNase protection assays, to determine the most suitable target site(s) within the target RNA sequence. The target RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for *in vitro* systems, and by cellular expression in *in vivo* systems.

In one embodiment, the invention features a method comprising: (a) generating a randomized library of siNA constructs having a predetermined complexity, such as of  $4^N$ , where N represents the number of base paired nucleotides in each of the siNA construct strands (eg. for a siNA construct having 21 nucleotide sense and antisense strands with 5 19 base pairs, the complexity would be  $4^{19}$ ); and (b) assaying the siNA constructs of (a) above, under conditions suitable to determine RNAi target sites within the target XIAP RNA sequence. In another embodiment, the siNA molecules of (a) have strands of a fixed length, for example about 23 nucleotides in length. In yet another embodiment, the siNA molecules of (a) are of differing length, for example having strands of about 19 to 10 about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted *in vitro* siNA assay as described in Example 7 herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. In another embodiment, fragments of XIAP RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern 15 blot analysis, or RNase protection assays, to determine the most suitable target site(s) within the target XIAP RNA sequence. The target XIAP RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for *in vitro* systems, and by cellular expression in *in vivo* systems.

In another embodiment, the invention features a method comprising: (a) analyzing 20 the sequence of a RNA target encoded by a target gene; (b) synthesizing one or more sets of siNA molecules having sequence complementary to one or more regions of the RNA of (a); and (c) assaying the siNA molecules of (b) under conditions suitable to determine RNAi targets within the target RNA sequence. In one embodiment, the siNA molecules of (b) have strands of a fixed length, for example about 23 nucleotides in length. In 25 another embodiment, the siNA molecules of (b) are of differing length, for example having strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted *in vitro* siNA assay as described herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. Fragments of target RNA are 30 analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNase protection assays, to determine the most suitable target site(s) within the target RNA sequence. The target RNA sequence can be obtained as is known

in the art, for example, by cloning and/or transcription for *in vitro* systems, and by expression in *in vivo* systems.

By "target site" is meant a sequence within a target RNA that is "targeted" for cleavage mediated by a siNA construct which contains sequences within its antisense  
5 region that are complementary to the target sequence.

By "detectable level of cleavage" is meant cleavage of target RNA (and formation of cleaved product RNAs) to an extent sufficient to discern cleavage products above the background of RNAs produced by random degradation of the target RNA. Production of cleavage products from 1-5% of the target RNA is sufficient to detect above the  
10 background for most methods of detection.

In one embodiment, the invention features a composition comprising a siNA molecule of the invention, which can be chemically-modified, in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a pharmaceutical composition comprising siNA molecules of the invention, which can be  
15 chemically-modified, targeting one or more genes in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a method for diagnosing a disease or condition in a subject comprising administering to the subject a composition of the invention under conditions suitable for the diagnosis of the disease or condition in the subject. In another embodiment, the invention features a method for  
20 treating or preventing a disease or condition in a subject, comprising administering to the subject a composition of the invention under conditions suitable for the treatment or prevention of the disease or condition in the subject, alone or in conjunction with one or more other therapeutic compounds. In yet another embodiment, the invention features a method for reducing or preventing tissue rejection in a subject comprising administering  
25 to the subject a composition of the invention under conditions suitable for the reduction or prevention of tissue rejection in the subject.

In another embodiment, the invention features a method for validating a XIAP gene target, comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands includes a sequence  
30 complementary to RNA of a XIAP target gene; (b) introducing the siNA molecule into a cell, tissue, or organism under conditions suitable for modulating expression of the XIAP

target gene in the cell, tissue, or organism; and (c) determining the function of the gene by assaying for any phenotypic change in the cell, tissue, or organism.

In another embodiment, the invention features a method for validating a XIAP target comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands includes a sequence complementary to RNA of a XIAP target gene; (b) introducing the siNA molecule into a biological system under conditions suitable for modulating expression of the XIAP target gene in the biological system; and (c) determining the function of the gene by assaying for any phenotypic change in the biological system.

By "biological system" is meant, material, in a purified or unpurified form, from biological sources, including but not limited to human, animal, plant, insect, bacterial, viral or other sources, wherein the system comprises the components required for RNAi activity. The term "biological system" includes, for example, a cell, tissue, or organism, or extract thereof. The term biological system also includes reconstituted RNAi systems that can be used in an *in vitro* setting.

By "phenotypic change" is meant any detectable change to a cell that occurs in response to contact or treatment with a nucleic acid molecule of the invention (e.g., siNA). Such detectable changes include, but are not limited to, changes in shape, size, proliferation, motility, protein expression or RNA expression or other physical or chemical changes as can be assayed by methods known in the art. The detectable change can also include expression of reporter genes/molecules such as Green Florescent Protein (GFP) or various tags that are used to identify an expressed protein or any other cellular component that can be assayed.

In one embodiment, the invention features a kit containing a siNA molecule of the invention, which can be chemically-modified, that can be used to modulate the expression of a XIAP target gene in a biological system, including, for example, in a cell, tissue, or organism. In another embodiment, the invention features a kit containing more than one siNA molecule of the invention, which can be chemically-modified, that can be used to modulate the expression of more than one XIAP target gene in a biological system, including, for example, in a cell, tissue, or organism.

In one embodiment, the invention features a cell containing one or more siNA molecules of the invention, which can be chemically-modified. In another embodiment, the cell containing a siNA molecule of the invention is a mammalian cell. In yet another embodiment, the cell containing a siNA molecule of the invention is a human cell.

5 In one embodiment, the synthesis of a siNA molecule of the invention, which can be chemically-modified, comprises: (a) synthesis of two complementary strands of the siNA molecule; (b) annealing the two complementary strands together under conditions suitable to obtain a double-stranded siNA molecule. In another embodiment, synthesis of the two complementary strands of the siNA molecule is by solid phase oligonucleotide  
10 synthesis. In yet another embodiment, synthesis of the two complementary strands of the siNA molecule is by solid phase tandem oligonucleotide synthesis.

In one embodiment, the invention features a method for synthesizing a siNA duplex molecule comprising: (a) synthesizing a first oligonucleotide sequence strand of the siNA molecule, wherein the first oligonucleotide sequence strand comprises a  
15 cleavable linker molecule that can be used as a scaffold for the synthesis of the second oligonucleotide sequence strand of the siNA; (b) synthesizing the second oligonucleotide sequence strand of siNA on the scaffold of the first oligonucleotide sequence strand, wherein the second oligonucleotide sequence strand further comprises a chemical moiety than can be used to purify the siNA duplex; (c) cleaving the linker molecule of (a) under  
20 conditions suitable for the two siNA oligonucleotide strands to hybridize and form a stable duplex; and (d) purifying the siNA duplex utilizing the chemical moiety of the second oligonucleotide sequence strand. In one embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example under hydrolysis conditions using an alkylamine base such as methylamine. In one  
25 embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity as the solid support derivatized linker, such that cleavage  
30 of the solid support derivatized linker and the cleavable linker of (a) takes place concomitantly. In another embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a



dimethoxytrityl group, which can be employed in a trityl-on synthesis strategy as described herein. In yet another embodiment, the chemical moiety, such as a dimethoxytrityl group, is removed during purification, for example, using acidic conditions.

5        In a further embodiment, the method for siNA synthesis is a solution phase synthesis or hybrid phase synthesis wherein both strands of the siNA duplex are synthesized in tandem using a cleavable linker attached to the first sequence which acts a scaffold for synthesis of the second sequence. Cleavage of the linker under conditions suitable for hybridization of the separate siNA sequence strands results in formation of  
10    the double-stranded siNA molecule.

      In another embodiment, the invention features a method for synthesizing a siNA duplex molecule comprising: (a) synthesizing one oligonucleotide sequence strand of the siNA molecule, wherein the sequence comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of another oligonucleotide sequence; (b)  
15    synthesizing a second oligonucleotide sequence having complementarity to the first sequence strand on the scaffold of (a), wherein the second sequence comprises the other strand of the double-stranded siNA molecule and wherein the second sequence further comprises a chemical moiety than can be used to isolate the attached oligonucleotide sequence; (c) purifying the product of (b) utilizing the chemical moiety of the second  
20    oligonucleotide sequence strand under conditions suitable for isolating the full-length sequence comprising both siNA oligonucleotide strands connected by the cleavable linker and under conditions suitable for the two siNA oligonucleotide strands to hybridize and form a stable duplex. In one embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example under  
25    hydrolysis conditions. In another embodiment, cleavage of the linker molecule in (c) above takes place after deprotection of the oligonucleotide. In another embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The  
30    cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity or differing reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place

either concomitantly or sequentially. In one embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group.

5 In another embodiment, the invention features a method for making a double-stranded siNA molecule in a single synthetic process comprising: (a) synthesizing an oligonucleotide having a first and a second sequence, wherein the first sequence is complementary to the second sequence, and the first oligonucleotide sequence is linked to the second sequence via a cleavable linker, and wherein a terminal 5'-protecting group, for example, a 5'-O-dimethoxytrityl group (5'-O-DMT) remains on the oligonucleotide  
10 having the second sequence; (b) deprotecting the oligonucleotide whereby the deprotection results in the cleavage of the linker joining the two oligonucleotide sequences; and (c) purifying the product of (b) under conditions suitable for isolating the double-stranded siNA molecule, for example using a trityl-on synthesis strategy as described herein.

15 In another embodiment, the method of synthesis of siNA molecules of the invention comprises the teachings of Scaringe *et al.*, US Patent Nos. 5,889,136; 6,008,400; and 6,111,086, incorporated by reference herein in their entirety.

In one embodiment, the invention features siNA constructs that mediate RNAi against XIAP, wherein the siNA construct comprises one or more chemical  
20 modifications, for example, one or more chemical modifications having any of Formulae I-VII or any combination thereof that increases the nuclease resistance of the siNA construct.

In another embodiment, the invention features a method for generating siNA molecules with increased nuclease resistance comprising (a) introducing nucleotides  
25 having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased nuclease resistance.

In one embodiment, the invention features siNA constructs that mediate RNAi against XIAP, wherein the siNA construct comprises one or more chemical

modifications described herein that modulates the binding affinity between the sense and antisense strands of the siNA construct.

In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the sense and antisense strands of the siNA molecule comprising (a) introducing nucleotides having any of Formula I-VII or  
5 any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the sense and antisense strands of the siNA molecule.

In one embodiment, the invention features siNA constructs that mediate RNAi  
10 against XIAP, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the antisense strand of the siNA construct and a complementary target RNA sequence within a cell.

In one embodiment, the invention features siNA constructs that mediate RNAi  
15 against XIAP, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the antisense strand of the siNA construct and a complementary target DNA sequence within a cell.

In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the antisense strand of the siNA molecule and a complementary target RNA sequence comprising (a) introducing  
20 nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the antisense strand of the siNA molecule and a complementary target RNA sequence.

In another embodiment, the invention features a method for generating siNA  
25 molecules with increased binding affinity between the antisense strand of the siNA molecule and a complementary target DNA sequence comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the antisense strand  
30 of the siNA molecule and a complementary target DNA sequence.

In one embodiment, the invention features siNA constructs that mediate RNAi against XIAP, wherein the siNA construct comprises one or more chemical modifications described herein that modulate the polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to the chemically-modified siNA construct.

In another embodiment, the invention features a method for generating siNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to a chemically-modified siNA molecule comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to the chemically-modified siNA molecule.

In one embodiment, the invention features chemically-modified siNA constructs that mediate RNAi against XIAP in a cell, wherein the chemical modifications do not significantly effect the interaction of siNA with a target RNA molecule, DNA molecule and/or proteins or other factors that are essential for RNAi in a manner that would decrease the efficacy of RNAi mediated by such siNA constructs.

In another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against XIAP comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity.

In yet another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against a XIAP target RNA comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity against the target RNA.

In yet another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against a XIAP target DNA comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity against the target DNA.

In one embodiment, the invention features siNA constructs that mediate RNAi against XIAP, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the cellular uptake of the siNA construct.

In another embodiment, the invention features a method for generating siNA molecules against XIAP with improved cellular uptake comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved cellular uptake.

In one embodiment, the invention features siNA constructs that mediate RNAi against XIAP, wherein the siNA construct comprises one or more chemical modifications described herein that increases the bioavailability of the siNA construct, for example, by attaching polymeric conjugates such as polyethyleneglycol or equivalent conjugates that improve the pharmacokinetics of the siNA construct, or by attaching conjugates that target specific tissue types or cell types *in vivo*. Non-limiting examples of such conjugates are described in Vargeese *et al.*, U.S. Serial No. 10/201,394 incorporated by reference herein.

In one embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability, comprising (a) introducing a conjugate into the structure of a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability. Such conjugates can include ligands for cellular receptors, such as peptides derived from naturally occurring protein ligands; protein localization sequences, including cellular ZIP code sequences; antibodies; nucleic acid aptamers; vitamins and other co-factors, such as folate and N-acetylgalactosamine; polymers, such as polyethyleneglycol (PEG); phospholipids; cholesterol; polyamines, such as spermine or spermidine; and others.

The term "ligand" refers to any compound or molecule, such as a drug, peptide, hormone, or neurotransmitter, that is capable of interacting with another compound, such as a receptor, either directly or indirectly. The receptor that interacts with a ligand can be present on the surface of a cell or can alternately be an intercellular receptor. Interaction  
5 of the ligand with the receptor can result in a biochemical reaction, or can simply be a physical interaction or association.

In another embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing an excipient formulation to a siNA molecule, and (b) assaying the siNA molecule of step (a)  
10 under conditions suitable for isolating siNA molecules having improved bioavailability. Such excipients include polymers such as cyclodextrins, lipids, cationic lipids, polyamines, phospholipids, and others.

In another embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing  
15 nucleotides having any of Formulae I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability.

In another embodiment, polyethylene glycol (PEG) can be covalently attached to siNA compounds of the present invention. The attached PEG can be any molecular  
20 weight, preferably from about 2,000 to about 50,000 daltons (Da).

The present invention can be used alone or as a component of a kit having at least one of the reagents necessary to carry out the *in vitro* or *in vivo* introduction of RNA to test samples and/or subjects. For example, preferred components of the kit include a siNA molecule of the invention and a vehicle that promotes introduction of the siNA into  
25 cells of interest as described herein (e.g., using lipids and other methods of transfection known in the art, see for example Beigelman *et al.*, US 6,395,713). The kit can be used for target validation, such as in determining gene function and/or activity, or in drug optimization, and in drug discovery (see for example Usman *et al.*, USSN 60/402,996). Such a kit can also include instructions to allow a user of the kit to practice the invention.

The term "short interfering nucleic acid", "siNA", "short interfering RNA", "siRNA", "short interfering nucleic acid molecule", "short interfering oligonucleotide molecule", or "chemically-modified short interfering nucleic acid molecule" as used herein refers to any nucleic acid molecule capable of inhibiting or down regulating gene expression or viral replication, for example by mediating RNA interference "RNAi" or gene silencing in a sequence-specific manner; see for example Bass, 2001, *Nature*, 411, 428-429; Elbashir *et al.*, 2001, *Nature*, 411, 494-498; and Kreutzer *et al.*, International PCT Publication No. WO 00/44895; Zernicka-Goetz *et al.*, International PCT Publication No. WO 01/36646; Fire, International PCT Publication No. WO 99/32619; Plaetinck *et al.*, International PCT Publication No. WO 00/01846; Mello and Fire, International PCT Publication No. WO 01/29058; Deschamps-Depaillette, International PCT Publication No. WO 99/07409; and Li *et al.*, International PCT Publication No. WO 00/44914; Allshire, 2002, *Science*, 297, 1818-1819; Volpe *et al.*, 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall *et al.*, 2002, *Science*, 297, 2232-2237; Hutvagner and Zamore, 2002, *Science*, 297, 2056-60; McManus *et al.*, 2002, *RNA*, 8, 842-850; Reinhart *et al.*, 2002, *Gene & Dev.*, 16, 1616-1626; and Reinhart & Bartel, 2002, *Science*, 297, 1831). Non limiting examples of siNA molecules of the invention are shown in **Figures 4-6**, and **Tables II, III, and IV** herein. For example the siNA can be a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (i.e. each strand comprises nucleotide sequence that is complementary to nucleotide sequence in the other strand; such as where the antisense strand and sense strand form a duplex or double stranded structure, for example wherein the double stranded region is about 19 base pairs); the antisense strand comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense strand comprises nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. Alternatively, the siNA is assembled from a single oligonucleotide, where the self-complementary sense and antisense regions of the siNA are linked by

means of a nucleic acid based or non-nucleic acid-based linker(s). The siNA can be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide  
5 sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is  
10 complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either *in vivo* or *in vitro* to generate an active siNA molecule capable of mediating RNAi. The siNA can also comprise a single stranded polynucleotide having  
15 nucleotide sequence complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof (for example, where such siNA molecule does not require the presence within the siNA molecule of nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof), wherein the single stranded polynucleotide can further comprise a terminal phosphate group, such as a 5'-phosphate  
20 (see for example Martinez *et al.*, 2002, *Cell.*, 110, 563-574 and Schwarz *et al.*, 2002, *Molecular Cell*, 10, 537-568), or 5',3'-diphosphate. In certain embodiment, the siNA molecule of the invention comprises separate sense and antisense sequences or regions, wherein the sense and antisense regions are covalently linked by nucleotide or non-nucleotide linkers molecules as is known in the art, or are alternately non-covalently  
25 linked by ionic interactions, hydrogen bonding, van der waals interactions, hydrophobic interactions, and/or stacking interactions. In certain embodiments, the siNA molecules of the invention comprise nucleotide sequence that is complementary to nucleotide sequence of a target gene. In another embodiment, the siNA molecule of the invention interacts with nucleotide sequence of a target gene in a manner that causes inhibition of  
30 expression of the target gene. As used herein, siNA molecules need not be limited to those molecules containing only RNA, but further encompasses chemically-modified nucleotides and non-nucleotides. In certain embodiments, the short interfering nucleic acid molecules of the invention lack 2'-hydroxy (2'-OH) containing nucleotides.



Applicant describes in certain embodiments short interfering nucleic acids that do not require the presence of nucleotides having a 2'-hydroxy group for mediating RNAi and as such, short interfering nucleic acid molecules of the invention optionally do not include any ribonucleotides (e.g., nucleotides having a 2'-OH group). Such siNA molecules that do not require the presence of ribonucleotides within the siNA molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups. Optionally, siNA molecules can comprise ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleotide positions. The modified short interfering nucleic acid molecules of the invention can also be referred to as short interfering modified oligonucleotides "siMON." As used herein, the term siNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically-modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term RNAi is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics. For example, siNA molecules of the invention can be used to epigenetically silence genes at both the post-transcriptional level or the pre-transcriptional level. In a non-limiting example, epigenetic regulation of gene expression by siNA molecules of the invention can result from siNA mediated modification of chromatin structure to alter gene expression (see, for example, Allshire, 2002, *Science*, 297, 1818-1819; Volpe *et al.*, 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall *et al.*, 2002, *Science*, 297, 2232-2237).

By "asymmetric hairpin" as used herein is meant a linear siNA molecule comprising an antisense region, a loop portion that can comprise nucleotides or non-nucleotides, and a sense region that comprises fewer nucleotides than the antisense region to the extent that the sense region has enough complimentary nucleotides to base pair with the antisense region and form a duplex with loop. For example, an asymmetric hairpin siNA molecule of the invention can comprise an antisense region having length sufficient to mediate RNAi in a cell or in vitro system (e.g. about 19 to about 22, such as about 19, 20, 21, or 22 nucleotides) and a loop region comprising about 4 to about 8

(e.g., about 4, 5, 6, 7, or 8) nucleotides, and a sense region having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides that are complementary to the antisense region. The asymmetric hairpin siNA molecule can also comprise a 5'-terminal phosphate group that can be chemically modified. The loop  
5 portion of the asymmetric hairpin siNA molecule can comprise nucleotides, non-nucleotides, linker molecules, or conjugate molecules as described herein.

By "asymmetric duplex" as used herein is meant a siNA molecule having two separate strands comprising a sense region and an antisense region, wherein the sense region comprises fewer nucleotides than the antisense region to the extent that the sense  
10 region has enough complimentary nucleotides to base pair with the antisense region and form a duplex. For example, an asymmetric duplex siNA molecule of the invention can comprise an antisense region having length sufficient to mediate RNAi in a cell or in vitro system (e.g. about 19 to about 22, such as. about 19, 20, 21, or 22 nucleotides) and a sense region having about 3 to about 18 (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,  
15 14, 15, 16, 17, or 18) nucleotides that are complementary to the antisense region.

By "modulate" is meant that the expression of the gene, or level of RNA molecule or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits is up regulated or down regulated, such that expression, level, or activity is greater than or less than that observed in the  
20 absence of the modulator. For example, the term "modulate" can mean "inhibit," but the use of the word "modulate" is not limited to this definition.

By "inhibit", "down-regulate", or "reduce", it is meant that the expression of the gene, or level of RNA molecules or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits, is  
25 reduced below that observed in the absence of the nucleic acid molecules (e.g., siNA) of the invention. In one embodiment, inhibition, down-regulation or reduction with an siNA molecule is below that level observed in the presence of an inactive or attenuated molecule. In another embodiment, inhibition, down-regulation, or reduction with siNA molecules is below that level observed in the presence of, for example, an siNA  
30 molecule with scrambled sequence or with mismatches. In another embodiment, inhibition, down-regulation, or reduction of gene expression with a nucleic acid molecule

of the instant invention is greater in the presence of the nucleic acid molecule than in its absence.

By "cancer" is meant a group of diseases characterized by uncontrolled growth and spread of abnormal cells.

5 By "gene" or "target gene" is meant, a nucleic acid that encodes an RNA, for example, nucleic acid sequences including, but not limited to, structural genes encoding a polypeptide. The target gene can be a gene derived from a cell, an endogenous gene, a transgene, or exogenous genes such as genes of a pathogen, for example a virus, which is present in the cell after infection thereof. The cell containing the target gene can be  
10 derived from or contained in any organism, for example a plant, animal, protozoan, virus, bacterium, or fungus. Non-limiting examples of plants include monocots, dicots, or gymnosperms. Non-limiting examples of animals include vertebrates or invertebrates. Non-limiting examples of fungi include molds or yeasts.

By "XIAP" as used herein is meant, any X-linked inhibitor of apoptosis (XIAP)  
15 protein, peptide, or polypeptide having XIAP activity, such as encoded by XIAP Genbank Accession Nos. shown in Table I. The term XIAP also refers to nucleic acid sequences encoding any XIAP protein, peptide, or polypeptide having XIAP activity. The term XIAP as used herein also refers to other inhibitor of apoptosis genes (IAP) encoding inhibitor of apoptosis proteins, such as HIAP1, HIAP2, and/or NAIP.

20 By "highly conserved sequence region" is meant, a nucleotide sequence of one or more regions in a target gene does not vary significantly from one generation to the other or from one biological system to the other.

By "sense region" is meant a nucleotide sequence of a siNA molecule having complementarity to an antisense region of the siNA molecule. In addition, the sense  
25 region of a siNA molecule can comprise a nucleic acid sequence having homology with a target nucleic acid sequence.

By "antisense region" is meant a nucleotide sequence of a siNA molecule having complementarity to a target nucleic acid sequence. In addition, the antisense region of a siNA molecule can optionally comprise a nucleic acid sequence having complementarity  
30 to a sense region of the siNA molecule.

By "target nucleic acid" is meant any nucleic acid sequence whose expression or activity is to be modulated. The target nucleic acid can be DNA or RNA.

By "complementarity" is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner *et al.*, 1987, *CSH Symp. Quant. Biol.* LII pp.123-133; Frier *et al.*, 1986, *Proc. Nat. Acad. Sci. USA* 83:9373-9377; Turner *et al.*, 1987, *J. Am. Chem. Soc.* 109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out of a total of 10 nucleotides in the first oligonucleotide being base paired to a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.

The siRNA molecules of the invention represent a novel therapeutic approach to treat a variety of pathologic indications or other conditions, such as cancers and proliferative conditions including ovarian cancer; cancers of non-lymphoid parenchymal organs including the heart, placenta, skeletal muscle and lung; breast cancer, cancers of the head and neck including various lymphomas such as mantle cell lymphoma, non-Hodgkins lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma, cancers of the retina, cancers of the esophagus, multiple myeloma, melanoma, colorectal cancer, lung cancer, bladder cancer, prostate cancer, testicular cancer glioblastoma; and proliferative diseases and conditions such as restenosis and polycystic kidney disease; and any other diseases or conditions that are related to or will respond to the levels of XIAP in a cell or tissue, alone or in combination with other therapies. The reduction of XIAP expression (specifically XIAP gene RNA levels) and thus reduction in the level of the respective protein relieves, to some extent, the symptoms of the disease or condition.

In one embodiment of the present invention, each sequence of a siNA molecule of the invention is independently about 18 to about 24 nucleotides in length, in specific embodiments about 18, 19, 20, 21, 22, 23, or 24 nucleotides in length. In another embodiment, the siNA duplexes of the invention independently comprise about 17 to about 23 base pairs (e.g., about 17, 18, 19, 20, 21, 22 or 23). In yet another embodiment, siNA molecules of the invention comprising hairpin or circular structures are about 35 to about 55 (e.g., about 35, 40, 45, 50 or 55) nucleotides in length, or about 38 to about 44 (e.g., 38, 39, 40, 41, 42, 43 or 44) nucleotides in length and comprising about 16 to about 22 (e.g., about 16, 17, 18, 19, 20, 21 or 22) base pairs. Exemplary siNA molecules of the invention are shown in **Table II**. Exemplary synthetic siNA molecules of the invention are shown in **Tables III and IV** and/or **Figures 4-5**.

As used herein "cell" is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell can be present in an organism, e.g., birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell). The cell can be of somatic or germ line origin, totipotent or pluripotent, dividing or non-dividing. The cell can also be derived from or can comprise a gamete or embryo, a stem cell, or a fully differentiated cell.

The siNA molecules of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues *ex vivo*, or *in vivo* through injection, infusion pump or stent, with or without their incorporation in biopolymers. In particular embodiments, the nucleic acid molecules of the invention comprise sequences shown in **Tables II-III** and/or **Figures 4-5**. Examples of such nucleic acid molecules consist essentially of sequences defined in these tables and figures. Furthermore, the chemically modified constructs described in **Table IV** can be applied to any siNA sequence of the invention.

In another aspect, the invention provides mammalian cells containing one or more siNA molecules of this invention. The one or more siNA molecules can independently be targeted to the same or different sites.

By "RNA" is meant a molecule comprising at least one ribonucleotide residue. By "ribonucleotide" is meant a nucleotide with a hydroxyl group at the 2' position of a  $\beta$ -D-ribo-furanose moiety. The terms include double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siRNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in the RNA molecules of the instant invention can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of naturally-occurring RNA.

By "subject" is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. "Subject" also refers to an organism to which the nucleic acid molecules of the invention can be administered. A subject can be a mammal or mammalian cells, including a human or human cells.

The term "phosphorothioate" as used herein refers to an internucleotide linkage having Formula I, wherein Z and/or W comprise a sulfur atom. Hence, the term phosphorothioate refers to both phosphorothioate and phosphorodithioate internucleotide linkages.

The term "universal base" as used herein refers to nucleotide base analogs that form base pairs with each of the natural DNA/RNA bases with little discrimination between them. Non-limiting examples of universal bases include C-phenyl, C-naphthyl and other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole as known in the art (see for example Loakes, 2001, *Nucleic Acids Research*, 29, 2437-2447).

The term "acyclic nucleotide" as used herein refers to any nucleotide having an acyclic ribose sugar, for example where any of the ribose carbons (C1, C2, C3, C4, or C5), are independently or in combination absent from the nucleotide.

The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed herein (e.g., cancers and othe proliferative conditions). For example, to treat a particular disease or condition, the siNA molecules can be administered to a subject or can be  
5 administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.

In a further embodiment, the siNA molecules can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described molecules could be used in combination with one or more known therapeutic  
10 agents to treat a disease or condition. Non-limiting examples of other therapeutic agents that can be readily combined with a siNA molecule of the invention are enzymatic nucleic acid molecules, allosteric nucleic acid molecules, antisense, decoy, or aptamer nucleic acid molecules, antibodies such as monoclonal antibodies, small molecules, and other organic and/or inorganic compounds including metals, salts and ions.

15 In one embodiment, the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention, in a manner which allows expression of the siNA molecule. For example, the vector can contain sequence(s) encoding both strands of a siNA molecule comprising a duplex. The vector can also contain sequence(s) encoding a single nucleic acid molecule that is self-  
20 complementary and thus forms a siNA molecule. Non-limiting examples of such expression vectors are described in Paul *et al.*, 2002, *Nature Biotechnology*, 19, 505; Miyagishi and Taira, 2002, *Nature Biotechnology*, 19, 497; Lee *et al.*, 2002, *Nature Biotechnology*, 19, 500; and Novina *et al.*, 2002, *Nature Medicine*, advance online publication doi:10.1038/nm725.

25 In another embodiment, the invention features a mammalian cell, for example, a human cell, including an expression vector of the invention.

In yet another embodiment, the expression vector of the invention comprises a sequence for a siNA molecule having complementarity to a RNA molecule referred to by a Genbank Accession numbers, for example Genbank Accession Nos. shown in Table I.

In one embodiment, an expression vector of the invention comprises a nucleic acid sequence encoding two or more siNA molecules, which can be the same or different.

In another aspect of the invention, siNA molecules that interact with target RNA molecules and down-regulate gene encoding target RNA molecules (for example target  
5 RNA molecules referred to by Genbank Accession numbers herein) are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siNA molecules can be delivered as  
10 described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the siNA molecules bind and down-regulate gene function or expression via RNA interference (RNAi). Delivery of siNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by  
15 administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell.

By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.

20 Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a non-limiting example of a scheme for the synthesis of siNA molecules. The complementary siNA sequence strands, strand 1 and strand 2, are  
25 synthesized in tandem and are connected by a cleavable linkage, such as a nucleotide succinate or abasic succinate, which can be the same or different from the cleavable linker used for solid phase synthesis on a solid support. The synthesis can be either solid phase or solution phase, in the example shown, the synthesis is a solid phase synthesis. The synthesis is performed such that a protecting group, such as a dimethoxytrityl group,  
30 remains intact on the terminal nucleotide of the tandem oligonucleotide. Upon cleavage



and deprotection of the oligonucleotide, the two siNA strands spontaneously hybridize to form a siNA duplex, which allows the purification of the duplex by utilizing the properties of the terminal protecting group, for example by applying a trityl on purification method wherein only duplexes/oligonucleotides with the terminal protecting  
 5 group are isolated.

**Figure 2** shows a MALDI-TOF mass spectrum of a purified siNA duplex synthesized by a method of the invention. The two peaks shown correspond to the predicted mass of the separate siNA sequence strands. This result demonstrates that the siNA duplex generated from tandem synthesis can be purified as a single entity using a  
 10 simple trityl-on purification methodology.

**Figure 3** shows a non-limiting proposed mechanistic representation of target RNA degradation involved in RNAi. Double-stranded RNA (dsRNA), which is generated by RNA-dependent RNA polymerase (RdRP) from foreign single-stranded RNA, for example viral, transposon, or other exogenous RNA, activates the DICER enzyme that in  
 15 turn generates siNA duplexes. Alternately, synthetic or expressed siNA can be introduced directly into a cell by appropriate means. An active siNA complex forms which recognizes a target RNA, resulting in degradation of the target RNA by the RISC endonuclease complex or in the synthesis of additional RNA by RNA-dependent RNA polymerase (RdRP), which can activate DICER and result in additional siNA molecules,  
 20 thereby amplifying the RNAi response.

**Figure 4A-F** shows non-limiting examples of chemically-modified siNA constructs of the present invention. In the figure, N stands for any nucleotide (adenosine, guanosine, cytosine, uridine, or optionally thymidine, for example thymidine can be substituted in the overhanging regions designated by parenthesis (N N). Various  
 25 modifications are shown for the sense and antisense strands of the siNA constructs.

**Figure 4A:** The sense strand comprises 21 nucleotides wherein the two terminal 3'-nucleotides are optionally base paired and wherein all nucleotides present are ribonucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.  
 30 The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the

target RNA sequence, and wherein all nucleotides present are ribonucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s” connects the (N N) nucleotides in the antisense strand.

**Figure 4B:** The sense strand comprises 21 nucleotides wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s” connects the (N N) nucleotides in the sense and antisense strand.

**Figure 4C:** The sense strand comprises 21 nucleotides having 5'- and 3'- terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl or 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a

phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s” connects the (N N) nucleotides in the antisense strand.

**Figure 4D:** The sense strand comprises 21 nucleotides having 5'- and 3'- terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein and wherein all purine nucleotides that may be present are 2'-deoxy nucleotides. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s” connects the (N N) nucleotides in the antisense strand.

**Figure 4E:** The sense strand comprises 21 nucleotides having 5'- and 3'- terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as “s” connects the (N N) nucleotides in the antisense strand.

**Figure 4F:** The sense strand comprises 21 nucleotides having 5'- and 3'- terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein and wherein all purine nucleotides that may be present are 2'-deoxy nucleotides. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and having one 3'-terminal phosphorothioate internucleotide linkage and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-deoxy nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. A modified internucleotide linkage, such as a phosphorothioate, phosphorodithioate or other modified internucleotide linkage as described herein, shown as "s" connects the (N N) nucleotides in the antisense strand. The antisense strand of constructs A-F comprise sequence complementary to any target nucleic acid sequence of the invention. Furthermore, when a glyceryl moiety (L) is present at the 3'-end of the antisense strand for any construct shown in Figure 4 A-F, the modified internucleotide linkage is optional.

**Figure 5A-F** shows non-limiting examples of specific chemically-modified siNA sequences of the invention. A-F applies the chemical modifications described in **Figure 4A-F** to an XIAP siNA sequence. Such chemical modifications can be applied to any sequence herein, such as any XIAP sequence.

**Figure 6** shows non-limiting examples of different siNA constructs of the invention. The examples shown (constructs 1, 2, and 3) have 19 representative base pairs; however, different embodiments of the invention include any number of base pairs described herein. Bracketed regions represent nucleotide overhangs, for example comprising about 1, 2, 3, or 4 nucleotides in length, preferably about 2 nucleotides. Constructs 1 and 2 can be used independently for RNAi activity. Construct 2 can comprise a polynucleotide or non-nucleotide linker, which can optionally be designed as a biodegradable linker. In one embodiment, the loop structure shown in construct 2 can

comprise a biodegradable linker that results in the formation of construct 1 *in vivo* and/or *in vitro*. In another example, construct 3 can be used to generate construct 2 under the same principle wherein a linker is used to generate the active siNA construct 2 *in vivo* and/or *in vitro*, which can optionally utilize another biodegradable linker to generate the active siNA construct 1 *in vivo* and/or *in vitro*. As such, the stability and/or activity of the siNA constructs can be modulated based on the design of the siNA construct for use *in vivo* or *in vitro* and/or *in vitro*.

Figure 7A-C is a diagrammatic representation of a scheme utilized in generating an expression cassette to generate siNA hairpin constructs.

Figure 7A: A DNA oligomer is synthesized with a 5'-restriction site (R1) sequence followed by a region having sequence identical (sense region of siNA) to a predetermined XIAP target sequence, wherein the sense region comprises, for example, about 19, 20, 21, or 22 nucleotides (N) in length, which is followed by a loop sequence of defined sequence (X), comprising, for example, about 3 to about 10 nucleotides.

Figure 7B: The synthetic construct is then extended by DNA polymerase to generate a hairpin structure having self-complementary sequence that will result in a siNA transcript having specificity for a XIAP target sequence and having self-complementary sense and antisense regions.

Figure 7C: The construct is heated (for example to about 95°C) to linearize the sequence, thus allowing extension of a complementary second DNA strand using a primer to the 3'-restriction sequence of the first strand. The double-stranded DNA is then inserted into an appropriate vector for expression in cells. The construct can be designed such that a 3'-terminal nucleotide overhang results from the transcription, for example by engineering restriction sites and/or utilizing a poly-U termination region as described in Paul *et al.*, 2002, *Nature Biotechnology*, 29, 505-508.

Figure 8A-C is a diagrammatic representation of a scheme utilized in generating an expression cassette to generate double-stranded siNA constructs.

Figure 8A: A DNA oligomer is synthesized with a 5'-restriction (R1) site sequence followed by a region having sequence identical (sense region of siNA) to a predetermined XIAP target sequence, wherein the sense region comprises, for example,

about 19, 20, 21, or 22 nucleotides (N) in length, and which is followed by a 3'-restriction site (R2) which is adjacent to a loop sequence of defined sequence (X).

**Figure 8B:** The synthetic construct is then extended by DNA polymerase to generate a hairpin structure having self-complementary sequence.

5       **Figure 8C:** The construct is processed by restriction enzymes specific to R1 and R2 to generate a double-stranded DNA which is then inserted into an appropriate vector for expression in cells. The transcription cassette is designed such that a U6 promoter region flanks each side of the dsDNA which generates the separate sense and antisense strands of the siNA. Poly T termination sequences can be added to the constructs to  
10      generate U overhangs in the resulting transcript.

**Figure 9A-E** is a diagrammatic representation of a method used to determine target sites for siNA mediated RNAi within a particular target nucleic acid sequence, such as messenger RNA.

15       **Figure 9A:** A pool of siNA oligonucleotides are synthesized wherein the antisense region of the siNA constructs has complementarity to target sites across the target nucleic acid sequence, and wherein the sense region comprises sequence complementary to the antisense region of the siNA.

20       **Figure 9B&C:** (**Figure 9B**) The sequences are pooled and are inserted into vectors such that (**Figure 9C**) transfection of a vector into cells results in the expression of the siNA.

**Figure 9D:** Cells are sorted based on phenotypic change that is associated with modulation of the target nucleic acid sequence.

**Figure 9E:** The siNA is isolated from the sorted cells and is sequenced to identify efficacious target sites within the target nucleic acid sequence.

25       **Figure 10** shows non-limiting examples of different stabilization chemistries (1-10) that can be used, for example, to stabilize the 3'-end of siNA sequences of the invention, including (1) [3'-3']-inverted deoxyribose; (2) deoxyribonucleotide; (3) [5'-3']-3'-deoxyribonucleotide; (4) [5'-3']-ribonucleotide; (5) [5'-3']-3'-O-methyl ribonucleotide; (6) 3'-glyceryl; (7) [3'-5']-3'-deoxyribonucleotide; (8) [3'-3']-deoxyribonucleotide; (9) [5'-

2']-deoxyribonucleotide; and (10) [5-3']-dideoxyribonucleotide. In addition to modified and unmodified backbone chemistries indicated in the figure, these chemistries can be combined with different backbone modifications as described herein, for example, backbone modifications having Formula I. In addition, the 2'-deoxy nucleotide shown 5' to the terminal modifications shown can be another modified or unmodified nucleotide or non-nucleotide described herein, for example modifications having any of Formulae I-VII or any combination thereof.

Figure 11 shows a non-limiting example of a strategy used to identify chemically modified siNA constructs of the invention that are nuclease resistance while preserving the ability to mediate RNAi activity. Chemical modifications are introduced into the siNA construct based on educated design parameters (e.g. introducing 2'-modifications, base modifications, backbone modifications, terminal cap modifications etc). The modified construct is tested in an appropriate system (e.g. human serum for nuclease resistance, shown, or an animal model for PK/delivery parameters). In parallel, the siNA construct is tested for RNAi activity, for example in a cell culture system such as a luciferase reporter assay). Lead siNA constructs are then identified which possess a particular characteristic while maintaining RNAi activity, and can be further modified and assayed once again. This same approach can be used to identify siNA-conjugate molecules with improved pharmacokinetic profiles, delivery, and RNAi activity.

## DETAILED DESCRIPTION OF THE INVENTION

### Mechanism of action of Nucleic Acid Molecules of the Invention

The discussion that follows discusses the proposed mechanism of RNA interference mediated by short interfering RNA as is presently known, and is not meant to be limiting and is not an admission of prior art. Applicant demonstrates herein that chemically-modified short interfering nucleic acids possess similar or improved capacity to mediate RNAi as do siRNA molecules and are expected to possess improved stability and activity *in vivo*; therefore, this discussion is not meant to be limiting only to siRNA and can be applied to siNA as a whole. By "improved capacity to mediate RNAi" or "improved RNAi activity" is meant to include RNAi activity measured *in vitro* and/or *in vivo* where the RNAi activity is a reflection of both the ability of the siNA to mediate RNAi and the stability of the siNAs of the invention. In this invention, the product of

these activities can be increased *in vitro* and/or *in vivo* compared to an all RNA siRNA or a siNA containing a plurality of ribonucleotides. In some cases, the activity or stability of the siNA molecule can be decreased (i.e., less than ten-fold), but the overall activity of the siNA molecule is enhanced *in vitro* and/or *in vivo*.

5 RNA interference refers to the process of sequence specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire *et al.*, 1998, *Nature*, 391, 806). The corresponding process in plants is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an  
10 evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes which is commonly shared by diverse flora and phyla (Fire *et al.*, 1999, *Trends Genet.*, 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or the random integration of transposon elements into a host genome via a  
15 cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response though a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2', 5'-oligoadenylate synthetase resulting in non-specific  
20 cleavage of mRNA by ribonuclease L.

The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as Dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Berstein *et al.*, 2001, *Nature*, 409, 363). Short interfering RNAs derived from Dicer activity are typically  
25 about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner *et al.*, 2001, *Science*, 293, 834). The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an  
30 RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence homologous to the siRNA. Cleavage of the target RNA takes place in the middle of the region complementary to the guide sequence of the siRNA



duplex (Elbashir *et al.*, 2001, *Genes Dev.*, 15, 188). In addition, RNA interference can also involve small RNA (e.g., micro-RNA or miRNA) mediated gene silencing, presumably through cellular mechanisms that regulate chromatin structure and thereby prevent transcription of target gene sequences (see for example Allshire, 2002, *Science*, 297, 1818-1819; Volpe *et al.*, 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall *et al.*, 2002, *Science*, 297, 2232-2237). As such, siRNA molecules of the invention can be used to mediate gene silencing via interaction with RNA transcripts or alternately by interaction with particular gene sequences, wherein such interaction results in gene silencing either at the transcriptional level or post-transcriptional level.

RNAi has been studied in a variety of systems. Fire *et al.*, 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. elegans*. Wianny and Goetz, 1999, *Nature Cell Biol.*, 2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond *et al.*, 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells transfected with dsRNA. Elbashir *et al.*, 2001, *Nature*, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21 nucleotide siRNA duplexes are most active when containing two 2-nucleotide 3'-terminal nucleotide overhangs. Furthermore, substitution of one or both siRNA strands with 2'-deoxy or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of 3'-terminal siRNA nucleotides with deoxy nucleotides was shown to be tolerated. Mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen *et al.*, 2001, *Cell*, 107, 309); however, siRNA molecules lacking a 5'-phosphate are active when introduced exogenously, suggesting that 5'-phosphorylation of siRNA constructs may occur *in vivo*.

### Synthesis of Nucleic acid Molecules

Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small" refers to nucleic acid motifs no more than 5 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., individual siNA oligonucleotide sequences or siNA sequences synthesized in tandem) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of protein and/or RNA structure. Exemplary molecules of the 10 instant invention are chemically synthesized, and others can similarly be synthesized.

Oligonucleotides (e.g., certain modified oligonucleotides or portions of oligonucleotides lacking ribonucleotides) are synthesized using protocols known in the art, for example as described in Caruthers *et al.*, 1992, *Methods in Enzymology* 211, 3-19, Thompson *et al.*, International PCT Publication No. WO 99/54459, Wincott *et al.*, 15 1995, *Nucleic Acids Res.* 23, 2677-2684, Wincott *et al.*, 1997, *Methods Mol. Bio.*, 74, 59, Brennan *et al.*, 1998, *Biotechnol Bioeng.*, 61, 33-45, and Brennan, U.S. Pat. No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non- 20 limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2  $\mu$ mol scale protocol with a 2.5 min coupling step for 2'-O-methylated nucleotides and a 45 second coupling step for 2'-deoxy nucleotides or 2'-deoxy-2'-fluoro nucleotides. Table V outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2  $\mu$ mol scale can 25 be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60  $\mu$ L of 0.11 M = 6.6  $\mu$ mol) of 2'-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60  $\mu$ L of 0.25 M = 15  $\mu$ mol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 22-fold excess (40  $\mu$ L of 0.11 30 M = 4.4  $\mu$ mol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40  $\mu$ L of 0.25 M = 10  $\mu$ mol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems,

Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% *N*-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM I<sub>2</sub>, 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.

Deprotection of the DNA-based oligonucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aqueous methylamine (1 mL) at 65 °C for 10 minutes. After cooling to -20 °C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H<sub>2</sub>O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder.

The method of synthesis used for RNA including certain siNA molecules of the invention follows the procedure as described in Usman *et al.*, 1987, *J. Am. Chem. Soc.*, 109, 7845; Scaringe *et al.*, 1990, *Nucleic Acids Res.*, 18, 5433; and Wincott *et al.*, 1995, *Nucleic Acids Res.* 23, 2677-2684 Wincott *et al.*, 1997, *Methods Mol. Bio.*, 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2'-O-methylated nucleotides. Table V outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μmol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M = 6.6 μmol) of 2'-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 μL of 0.25 M = 15

5  $\mu\text{mol}$ ) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 66-fold excess (120  $\mu\text{L}$  of 0.11 M = 13.2  $\mu\text{mol}$ ) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120  $\mu\text{L}$  of 0.25 M = 30  $\mu\text{mol}$ ) can be used in each coupling cycle of ribo residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% *N*-methyl imidazole in THF (ABI) and  
 10 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM  $\text{I}_2$ , 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage  
 15 reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide 0.05 M in acetonitrile) is used.

Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 °C for 10 min. After cooling to -20 °C, the supernatant is removed from the  
 20 polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H<sub>2</sub>O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300  $\mu\text{L}$  of a solution of 1.5 mL *N*-methylpyrrolidinone, 750  $\mu\text{L}$   
 25 TEA and 1 mL TEA•3HF to provide a 1.4 M HF concentration) and heated to 65 °C. After 1.5 h, the oligomer is quenched with 1.5 M  $\text{NH}_4\text{HCO}_3$ .

Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65 °C for 15 minutes.  
 30 The vial is brought to room temperature TEA•3HF (0.1 mL) is added and the vial is heated at 65 °C for 15 minutes. The sample is cooled at -20 °C and then quenched with 1.5 M  $\text{NH}_4\text{HCO}_3$ .

For purification of the trityl-on oligomers, the quenched  $\text{NH}_4\text{HCO}_3$  solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 minutes. The cartridge is then washed again with  
5 water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile.

The average stepwise coupling yields are typically >98% (Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described  
10 above including but not limited to 96-well format.

Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore *et al.*, 1992, *Science* 256, 9923; Draper *et al.*, International PCT publication No. WO 93/23569; Shabarova *et al.*, 1991, *Nucleic Acids Research* 19, 4247; Bellon *et al.*,  
15 1997, *Nucleosides & Nucleotides*, 16, 951; Bellon *et al.*, 1997, *Bioconjugate Chem.* 8, 204), or by hybridization following synthesis and/or deprotection.

The siNA molecules of the invention can also be synthesized via a tandem synthesis methodology as described in Example 1 herein, wherein both siNA strands are synthesized as a single contiguous oligonucleotide fragment or strand separated by a  
20 cleavable linker which is subsequently cleaved to provide separate siNA fragments or strands that hybridize and permit purification of the siNA duplex. The linker can be a polynucleotide linker or a non-nucleotide linker. The tandem synthesis of siNA as described herein can be readily adapted to both multiwell/multiplate synthesis platforms such as 96 well or similarly larger multi-well platforms. The tandem synthesis of siNA as  
25 described herein can also be readily adapted to large scale synthesis platforms employing batch reactors, synthesis columns and the like.

A siNA molecule can also be assembled from two distinct nucleic acid strands or fragments wherein one fragment includes the sense region and the second fragment includes the antisense region of the RNA molecule.

The nucleic acid molecules of the present invention can be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren, 1992, *TIBS* 17, 34; Usman *et al.*, 1994, *Nucleic Acids Symp. Ser.* 31, 163). siNA constructs can  
5 be purified by gel electrophoresis using general methods or can be purified by high pressure liquid chromatography (HPLC; see Wincott *et al.*, *supra*, the totality of which is hereby incorporated herein by reference) and re-suspended in water.

In another aspect of the invention, siNA molecules of the invention are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can  
10 be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules.

15 Optimizing Activity of the nucleic acid molecule of the invention.

Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) can prevent their degradation by serum ribonucleases, which can increase their potency (see *e.g.*, Eckstein *et al.*, International Publication No. WO 92/07065; Perrault *et al.*, 1990 *Nature* 344, 565; Pieken *et al.*, 1991, *Science* 253, 314;  
20 Usman and Cedergren, 1992, *Trends in Biochem. Sci.* 17, 334; Usman *et al.*, International Publication No. WO 93/15187; and Rossi *et al.*, International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; Gold *et al.*, U.S. Pat. No. 6,300,074; and Burgin *et al.*, *supra*; all of which are incorporated by reference herein). All of the above references describe various chemical modifications that can be made to the base,  
25 phosphate and/or sugar moieties of the nucleic acid molecules described herein. Modifications that enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired.

There are several examples in the art describing sugar, base and phosphate  
30 modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are

modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-O-allyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, *TIBS*, 17, 34; Usman *et al.*, 1994, *Nucleic Acids Symp. Ser.* 31, 163; Burgin *et al.*, 1996, *Biochemistry*, 35, 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein *et al.*, *International Publication* PCT No. WO 92/07065; Perrault *et al.* *Nature*, 1990, 344, 565-568; Pieken *et al.* *Science*, 1991, 253, 314-317; Usman and Cedergren, *Trends in Biochem. Sci.*, 1992, 17, 334-339; Usman *et al.* *International Publication* PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman *et al.*, 1995, *J. Biol. Chem.*, 270, 25702; Beigelman *et al.*, *International PCT publication* No. WO 97/26270; Beigelman *et al.*, U.S. Pat. No. 5,716,824; Usman *et al.*, U.S. Pat. No. 5,627,053; Woolf *et al.*, *International PCT Publication* No. WO 98/13526; Thompson *et al.*, *USSN* 60/082,404 which was filed on April 20, 1998; Karpeisky *et al.*, 1998, *Tetrahedron Lett.*, 39, 1131; Earnshaw and Gait, 1998, *Biopolymers (Nucleic Acid Sciences)*, 48, 39-55; Verma and Eckstein, 1998, *Annu. Rev. Biochem.*, 67, 99-134; and Burlina *et al.*, 1997, *Bioorg. Med. Chem.*, 5, 1999-2010; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into nucleic acid molecules without modulating catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the siNA nucleic acid molecules of the instant invention so long as the ability of siNA to promote RNAi in cells is not significantly inhibited.

While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorodithioate, and/or 5'-methylphosphonate linkages improves stability, excessive modifications can cause some toxicity or decreased activity. Therefore, when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity, resulting in increased efficacy and higher specificity of these molecules.

Short interfering nucleic acid (siNA) molecules having chemical modifications that maintain or enhance activity are provided. Such a nucleic acid is also generally more

resistant to nucleases than an unmodified nucleic acid. Accordingly, the *in vitro* and/or *in vivo* activity should not be significantly lowered. In cases in which modulation is the goal, therapeutic nucleic acid molecules delivered exogenously should optimally be stable within cells until translation of the target RNA has been modulated long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Improvements in the chemical synthesis of RNA and DNA (Wincott *et al.*, 1995, *Nucleic Acids Res.* 23, 2677; Caruthers *et al.*, 1992, *Methods in Enzymology* 211,3-19 (incorporated by reference herein)) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability, as described above.

In one embodiment, nucleic acid molecules of the invention include one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) G-clamp nucleotides. A G-clamp nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998, *J. Am. Chem. Soc.*, 120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when hybridized to complementary oligonucleotides. The inclusion of such nucleotides in nucleic acid molecules of the invention results in both enhanced affinity and specificity to nucleic acid targets, complementary sequences, or template strands. In another embodiment, nucleic acid molecules of the invention include one or more (*e.g.*, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) LNA "locked nucleic acid" nucleotides such as a 2', 4'-C methylene bicyclo nucleotide (see for example Wengel *et al.*, International PCT Publication No. WO 00/66604 and WO 99/14226).

In another embodiment, the invention features conjugates and/or complexes of siNA molecules of the invention. Such conjugates and/or complexes can be used to facilitate delivery of siNA molecules into a biological system, such as a cell. The conjugates and complexes provided by the instant invention can impart therapeutic activity by transferring therapeutic compounds across cellular membranes, altering the pharmacokinetics, and/or modulating the localization of nucleic acid molecules of the invention. The present invention encompasses the design and synthesis of novel conjugates and complexes for the delivery of molecules, including, but not limited to,



small molecules, lipids, cholesterol, phospholipids, nucleosides, nucleotides, nucleic acids, antibodies, toxins, negatively charged polymers and other polymers, for example proteins, peptides, hormones, carbohydrates, polyethylene glycols, or polyamines, across cellular membranes. In general, the transporters described are designed to be used either  
5 individually or as part of a multi-component system, with or without degradable linkers. These compounds are expected to improve delivery and/or localization of nucleic acid molecules of the invention into a number of cell types originating from different tissues, in the presence or absence of serum (see Sullenger and Cech, U.S. Pat. No. 5,854,038). Conjugates of the molecules described herein can be attached to biologically active  
10 molecules via linkers that are biodegradable, such as biodegradable nucleic acid linker molecules.

The term "biodegradable linker" as used herein, refers to a nucleic acid or non-nucleic acid linker molecule that is designed as a biodegradable linker to connect one molecule to another molecule, for example, a biologically active molecule to a siNA  
15 molecule of the invention or the sense and antisense strands of a siNA molecule of the invention. The biodegradable linker is designed such that its stability can be modulated for a particular purpose, such as delivery to a particular tissue or cell type. The stability of a nucleic acid-based biodegradable linker molecule can be modulated by using various chemistries, for example combinations of ribonucleotides, deoxyribonucleotides, and  
20 chemically-modified nucleotides, such as 2'-O-methyl, 2'-fluoro, 2'-amino, 2'-O-amino, 2'-C-allyl, 2'-O-allyl, and other 2'-modified or base modified nucleotides. The biodegradable nucleic acid linker molecule can be a dimer, trimer, tetramer or longer nucleic acid molecule, for example, an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or can comprise a single  
25 nucleotide with a phosphorus-based linkage, for example, a phosphoramidate or phosphodiester linkage. The biodegradable nucleic acid linker molecule can also comprise nucleic acid backbone, nucleic acid sugar, or nucleic acid base modifications.

The term "biodegradable" as used herein, refers to degradation in a biological system, for example enzymatic degradation or chemical degradation.

30 The term "biologically active molecule" as used herein, refers to compounds or molecules that are capable of eliciting or modifying a biological response in a system.

Non-limiting examples of biologically active siNA molecules either alone or in combination with other molecules contemplated by the instant invention include therapeutically active molecules such as antibodies, cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, siNA, dsRNA, allozymes, aptamers, decoys and analogs thereof. Biologically active molecules of the invention also include molecules capable of modulating the pharmacokinetics and/or pharmacodynamics of other biologically active molecules, for example, lipids and polymers such as polyamines, polyamides, polyethylene glycol and other polyethers.

The term "phospholipid" as used herein, refers to a hydrophobic molecule comprising at least one phosphorus group. For example, a phospholipid can comprise a phosphorus-containing group and saturated or unsaturated alkyl group, optionally substituted with OH, COOH, oxo, amine, or substituted or unsubstituted aryl groups.

Therapeutic nucleic acid molecules (*e.g.*, siNA molecules) delivered exogenously optimally are stable within cells until reverse transcription of the RNA has been modulated long enough to reduce the levels of the RNA transcript. The nucleic acid molecules are resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.

In yet another embodiment, siNA molecules having chemical modifications that maintain or enhance enzymatic activity of proteins involved in RNAi are provided. Such nucleic acids are also generally more resistant to nucleases than unmodified nucleic acids. Thus, *in vitro* and/or *in vivo* the activity should not be significantly lowered.

Use of the nucleic acid-based molecules of the invention will lead to better treatment of the disease progression by affording the possibility of combination therapies (*e.g.*, multiple siNA molecules targeted to different genes; nucleic acid molecules coupled with known small molecule modulators; or intermittent treatment with combinations of molecules, including different motifs and/or other chemical or

biological molecules). The treatment of subjects with siNA molecules can also include combinations of different types of nucleic acid molecules, such as enzymatic nucleic acid molecules (ribozymes), allozymes, antisense, 2,5-A oligoadenylate, decoys, and aptamers.

- 5 In another aspect a siNA molecule of the invention comprises one or more 5' and/or a 3'-cap structure, for example on only the sense siNA strand, the antisense siNA strand, or both siNA strands.

By "cap structure" is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Adamic *et al.*, U.S. Pat. No. 10 5,998,203, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5'-terminus (5'-cap) or at the 3'-terminal (3'-cap) or may be present on both termini. In non-limiting examples, of the 5'-cap includes, but are not limited to, glyceryl, inverted deoxy abasic residue (moiety); 15 4',5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide, 4'-thio nucleotide; carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; *threo*-pentofuransyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic 20 moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety.

Non-limiting examples of the 3'-cap includes, but are not limited to, glyceryl, 25 inverted deoxy abasic residue (moiety), 4', 5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminoethyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; 30 phosphorodithioate; *threo*-pentofuransyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide

moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details see Beaucage and Iyer, 5 1993, *Tetrahedron* 49, 1925; incorporated by reference herein).

By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not 10 contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine and therefore lacks a base at the 1'-position.

An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 15 4 carbons. The alkyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub> or N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH. The term also includes alkenyl groups that are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. 20 More preferably, it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub>, halogen, N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH. The term "alkyl" also includes alkynyl groups that have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, 25 including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably, it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub> or N(CH<sub>3</sub>)<sub>2</sub>, amino or SH.

30 Such alkyl groups can also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An "aryl" group refers to an aromatic group that has at

least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to  
 5 an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen,  
 10 sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An "amide" refers to an -C(O)-NH-R, where R is either alkyl, aryl, alkylaryl or hydrogen. An "ester" refers to an -C(O)-OR', where R is either alkyl, aryl, alkylaryl or hydrogen.

By "nucleotide" as used herein is as recognized in the art to include natural bases  
 15 (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and  
 20 other; see, for example, Usman and McSwiggen, *supra*; Eckstein *et al.*, International PCT Publication No. WO 92/07065; Usman *et al.*, International PCT Publication No. WO 93/15187; Uhlman & Peyman, *supra*, all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach *et al.*, 1994, *Nucleic Acids Res.* 22, 2183. Some of the non-  
 25 limiting examples of base modifications that can be introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (*e.g.*, 5-methylcytidine), 5-alkyluridines (*e.g.*, ribothymidine), 5-halouridine (*e.g.*, 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (*e.g.* 6-  
 30 methyluridine), propyne, and others (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090; Uhlman & Peyman, *supra*). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents.

In one embodiment, the invention features modified siNA molecules, with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, 1995, *Nucleic Acid Analogues: Synthesis and Properties*, in *Modern Synthetic Methods*, VCH, 331-417, and Mesmaeker *et al.*, 1994, *Novel Backbone Replacements for Oligonucleotides*, in *Carbohydrate Modifications in Antisense Research*, ACS, 24-39.

By "abasic" is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position, see for example Adamic *et al.*, U.S. Pat. No. 5,998,203.

By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, thymine, or uracil joined to the 1' carbon of  $\beta$ -D-ribo-furanose.

By "modified nucleoside" is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate. Non-limiting examples of modified nucleotides are shown by Formulae I-VII and/or other modifications described herein.

In connection with 2'-modified nucleotides as described for the present invention, by "amino" is meant 2'-NH<sub>2</sub> or 2'-O- NH<sub>2</sub>, which can be modified or unmodified. Such modified groups are described, for example, in Eckstein *et al.*, U.S. Pat. No. 5,672,695 and Matulic-Adamic *et al.*, U.S. Pat. No. 6,248,878, which are both incorporated by reference in their entireties.

Various modifications to nucleic acid siNA structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life *in vitro*, stability, and ease of introduction of such oligonucleotides to the target site, *e.g.*, to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.

#### Administration of Nucleic Acid Molecules

A siNA molecule of the invention can be adapted for use to treat, for example, ovarian cancer; cancers of non-lymphoid parenchymal organs including the heart, placenta, skeletal muscle and lung; breast cancer, cancers of the head and neck including various lymphomas such as mantle cell lymphoma, non-Hodgkins lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma, cancers of the retina, cancers of the esophagus, multiple myeloma, melanoma, colorectal cancer, lung cancer, bladder cancer, prostate cancer, testicular cancer, glioblastoma; and proliferative diseases and conditions such as restenosis and polycystic kidney disease; and any other diseases or conditions that are related to or will respond to the levels of XIAP in a cell or tissue, alone or in combination with other therapies. For example, a siNA molecule can comprise a delivery vehicle, including liposomes, for administration to a subject, carriers and diluents and their salts, and/or can be present in pharmaceutically acceptable formulations. Methods for the delivery of nucleic acid molecules are described in Akhtar *et al.*, 1992, *Trends Cell Bio.*, 2, 139; *Delivery Strategies for Antisense Oligonucleotide Therapeutics*, ed. Akhtar, 1995, Maurer *et al.*, 1999, *Mol. Membr. Biol.*, 16, 129-140; Hofland and Huang, 1999, *Handb. Exp. Pharmacol.*, 137, 165-192; and Lee *et al.*, 2000, *ACS Symp. Ser.*, 752, 184-192, all of which are incorporated herein by reference. Beigelman *et al.*, U.S. Pat. No. 6,395,713 and Sullivan *et al.*, PCT WO 94/02595 further describe the general methods for delivery of nucleic acid molecules. These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as biodegradable polymers, hydrogels, cyclodextrins (see for example Gonzalez *et al.*, 1999, *Bioconjugate Chem.*, 10, 1068-1074; Wang *et al.*, International PCT publication Nos. WO 03/47518 and WO 03/46185), poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (see for example US Patent 6,447,796 and US Patent Application Publication No. US 2002130430), biodegradable nanocapsules, and bioadhesive microspheres, or by proteinaceous vectors (O'Hare and Normand, International PCT Publication No. WO 00/53722). Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of an infusion pump. Direct injection of the nucleic acid molecules of the invention, whether subcutaneous, intramuscular, or intradermal, can take place using standard needle and syringe methodologies, or by needle-free

technologies such as those described in Conry *et al.*, 1999, *Clin. Cancer Res.*, 5, 2330-2337 and Barry *et al.*, International PCT Publication No. WO 99/31262. The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, modulate the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a subject.

In one embodiment, a siNA molecule of the invention is complexed with membrane disruptive agents such as those described in U.S. Patent Application Publication No. 20010007666, incorporated by reference herein in its entirety including the drawings. In another embodiment, the membrane disruptive agent or agents and the siNA molecule are also complexed with a cationic lipid or helper lipid molecule, such as those lipids described in U.S. Patent No. 6,235,310, incorporated by reference herein in its entirety including the drawings.

Thus, the invention features a pharmaceutical composition comprising one or more nucleic acid(s) of the invention in an acceptable carrier, such as a stabilizer, buffer, and the like. The polynucleotides of the invention can be administered (*e.g.*, RNA, DNA or protein) and introduced into a subject by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention can also be formulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions, suspensions for injectable administration, and the other compositions known in the art.

The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, *e.g.*, acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.

A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, *e.g.*, systemic administration, into a cell or subject, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (*i.e.*, a cell



to which the negatively charged nucleic acid is desirable for delivery). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms that prevent the composition or formulation from exerting its effect.

5 By "systemic administration" is meant *in vivo* systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes that lead to systemic absorption include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes exposes the siNA molecules of the  
 10 invention to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the  
 15 association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach can provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cells producing excess XIAP.

By "pharmaceutically acceptable formulation" is meant, a composition or  
 20 formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85), which can enhance entry of drugs into the CNS (Joliet-Riant and Tillement, 1999, *Fundam. Clin.*  
 25 *Pharmacol.*, 13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich, DF *et al*, 1999, *Cell Transplant*, 8, 47-58) (Alkermes, Inc. Cambridge, MA); and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (*Prog*  
 30 *Neuropsychopharmacol Biol Psychiatry*, 23, 941-949, 1999). Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado *et al.*, 1998, *J. Pharm. Sci.*, 87, 1308-1315; Tyler *et*

*al.*, 1999, *FEBS Lett.*, 421, 280-284; Pardridge *et al.*, 1995, *PNAS USA.*, 92, 5592-5596; Boado, 1995, *Adv. Drug Delivery Rev.*, 15, 73-107; Aldrian-Herrada *et al.*, 1998, *Nucleic Acids Res.*, 26, 4910-4916; and Tyler *et al.*, 1999, *PNAS USA.*, 96, 7053-7058.

The invention also features the use of the composition comprising surface-  
 5 modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the  
 10 encapsulated drug (Lasic *et al.* *Chem. Rev.* 1995, 95, 2601-2627; Ishiwata *et al.*, *Chem. Pharm. Bull.* 1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic *et al.*, *Science* 1995, 267, 1275-1276; Oku *et al.*, 1995, *Biochim. Biophys. Acta*, 1238, 86-90). The long-circulating liposomes enhance the  
 15 pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu *et al.*, *J. Biol. Chem.* 1995, 42, 24864-24870; Choi *et al.*, International PCT Publication No. WO 96/10391; Ansell *et al.*, International PCT Publication No. WO 96/10390; Holland *et al.*, International PCT Publication No. WO 96/10392). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a  
 20 greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.

The present invention also includes compositions prepared for storage or administration that include a pharmaceutically effective amount of the desired  
 25 compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co. (A.R. Gennaro edit. 1985), hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents can be provided. These include  
 30 sodium benzoate, sorbic acid and esters of *p*-hydroxybenzoic acid. In addition, antioxidants and suspending agents can be used.

A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.

The nucleic acid molecules of the invention and formulations thereof can be administered orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising a nucleic acid molecule of the invention and a pharmaceutically acceptable carrier. One or more nucleic acid molecules of the invention can be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing nucleic acid molecules of the invention can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium

stearate, stearic acid or talc. The tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.

Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

10       Aqueous suspensions contain the active materials in a mixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occurring phosphatide, for example, 15       lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with 20       partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

25       Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be 30       preserved by the addition of an anti-oxidant such as ascorbic acid

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already  
5 mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.

Pharmaceutical compositions of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents can be naturally-occurring gums, for example gum  
10 acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening and flavoring agents.

Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable  
20 dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils  
25 are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The nucleic acid molecules of the invention can also be administered in the form of suppositories, *e.g.*, for rectal administration of the drug. These compositions can be  
30 prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the

rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.

Nucleic acid molecules of the invention can be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either  
5 be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per subject per day). The amount of active ingredient that can be  
10 combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms generally contain between from about 1 mg to about 500 mg of an active ingredient.

It is understood that the specific dose level for any particular subject depends upon a variety of factors including the activity of the specific compound employed, the age,  
15 body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

For administration to non-human animals, the composition can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and  
20 drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It can also be convenient to present the composition as a premix for addition to the feed or drinking water.

The nucleic acid molecules of the present invention can also be administered to a subject in combination with other therapeutic compounds to increase the overall  
25 therapeutic effect. The use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects.

In one embodiment, the invention comprises compositions suitable for administering nucleic acid molecules of the invention to specific cell types. For example, the asialoglycoprotein receptor (ASGPr) (Wu and Wu, 1987, *J. Biol. Chem.*  
30 262, 4429-4432) is unique to hepatocytes and binds branched galactose-terminal

glycoproteins, such as asialoorosomucoid (ASOR). In another example, the folate receptor is overexpressed in many cancer cells. Binding of such glycoproteins, synthetic glycoconjugates, or folates to the receptor takes place with an affinity that strongly depends on the degree of branching of the oligosaccharide chain, for example, triantennary structures are bound with greater affinity than biantennary or monoantennary chains (Baenziger and Fiete, 1980, *Cell*, 22, 611-620; Connolly *et al.*, 1982, *J. Biol. Chem.*, 257, 939-945). Lee and Lee, 1987, *Glycoconjugate J.*, 4, 317-328, obtained this high specificity through the use of N-acetyl-D-galactosamine as the carbohydrate moiety, which has higher affinity for the receptor, compared to galactose. This "clustering effect" has also been described for the binding and uptake of mannosyl-terminating glycoproteins or glycoconjugates (Ponpipom *et al.*, 1981, *J. Med. Chem.*, 24, 1388-1395). The use of galactose, galactosamine, or folate based conjugates to transport exogenous compounds across cell membranes can provide a targeted delivery approach to, for example, the treatment of liver disease, cancers of the liver, or other cancers. The use of bioconjugates can also provide a reduction in the required dose of therapeutic compounds required for treatment. Furthermore, therapeutic bioavailability, pharmacodynamics, and pharmacokinetic parameters can be modulated through the use of nucleic acid bioconjugates of the invention. Non-limiting examples of such bioconjugates are described in Vargeese *et al.*, USSN 10/201,394, filed August 13, 2001; and Matulic-Adamic *et al.*, USSN 60/362,016, filed March 6, 2002.

Alternatively, certain siNA molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985, *Science*, 229, 345; McGarry and Lindquist, 1986, *Proc. Natl. Acad. Sci. USA* 83, 399; Scanlon *et al.*, 1991, *Proc. Natl. Acad. Sci. USA*, 88, 10591-5; Kashani-Sabet *et al.*, 1992, *Antisense Res. Dev.*, 2, 3-15; Dropulic *et al.*, 1992, *J. Virol.*, 66, 1432-41; Weerasinghe *et al.*, 1991, *J. Virol.*, 65, 5531-4; Ojwang *et al.*, 1992, *Proc. Natl. Acad. Sci. USA*, 89, 10802-6; Chen *et al.*, 1992, *Nucleic Acids Res.*, 20, 4581-9; Sarver *et al.*, 1990 *Science*, 247, 1222-1225; Thompson *et al.*, 1995, *Nucleic Acids Res.*, 23, 2259; Good *et al.*, 1997, *Gene Therapy*, 4, 45. Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper *et al.*, PCT WO 93/23569, and Sullivan *et al.*, PCT WO 94/02595; Ohkawa *et al.*, 1992, *Nucleic Acids Symp. Ser.*, 27, 15-6; Taira *et al.*, 1991,

*Nucleic Acids Res.*, 19, 5125-30; Ventura *et al.*, 1993, *Nucleic Acids Res.*, 21, 3249-55; Chowrira *et al.*, 1994, *J. Biol. Chem.*, 269, 25856.

In another aspect of the invention, RNA molecules of the present invention can be expressed from transcription units (see for example Couture *et al.*, 1996, *TIG.*, 12, 510) inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. In another embodiment, pol III based constructs are used to express nucleic acid molecules of the invention (see for example Thompson, U.S. Pats. Nos. 5,902,880 and 6,146,886). The recombinant vectors capable of expressing the siNA molecules can be delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the siNA molecule interacts with the target mRNA and generates an RNAi response. Delivery of siNA molecule expressing vectors can be systemic, such as by intravenous or intra-muscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell (for a review see Couture *et al.*, 1996, *TIG.*, 12, 510).

In one aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the instant invention. The expression vector can encode one or both strands of a siNA duplex, or a single self-complementary strand that self hybridizes into a siNA duplex. The nucleic acid sequences encoding the siNA molecules of the instant invention can be operably linked in a manner that allows expression of the siNA molecule (see for example Paul *et al.*, 2002, *Nature Biotechnology*, 19, 505; Miyagishi and Taira, 2002, *Nature Biotechnology*, 19, 497; Lee *et al.*, 2002, *Nature Biotechnology*, 19, 500; and Novina *et al.*, 2002, *Nature Medicine*, advance online publication doi:10.1038/nm725).

In another aspect, the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); and c) a nucleic acid sequence encoding at least one of the siNA molecules of the instant



invention, wherein said sequence is operably linked to said initiation region and said termination region in a manner that allows expression and/or delivery of the siNA molecule. The vector can optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the sequence encoding the siNA of the invention; and/or an intron (intervening sequences).

Transcription of the siNA molecule sequences can be driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters are expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type depends on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990, *Proc. Natl. Acad. Sci. U S A*, 87, 6743-7; Gao and Huang 1993, *Nucleic Acids Res.*, 21, 2867-72; Lieber *et al.*, 1993, *Methods Enzymol.*, 217, 47-66; Zhou *et al.*, 1990, *Mol. Cell. Biol.*, 10, 4529-37). Several investigators have demonstrated that nucleic acid molecules expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet *et al.*, 1992, *Antisense Res. Dev.*, 2, 3-15; Ojwang *et al.*, 1992, *Proc. Natl. Acad. Sci. U S A*, 89, 10802-6; Chen *et al.*, 1992, *Nucleic Acids Res.*, 20, 4581-9; Yu *et al.*, 1993, *Proc. Natl. Acad. Sci. U S A*, 90, 6340-4; L'Huillier *et al.*, 1992, *EMBO J.*, 11, 4411-8; Lisiewicz *et al.*, 1993, *Proc. Natl. Acad. Sci. U. S. A*, 90, 8000-4; Thompson *et al.*, 1995, *Nucleic Acids Res.*, 23, 2259; Sullenger & Cech, 1993, *Science*, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as siNA in cells (Thompson *et al.*, *supra*; Couture and Stinchcomb, 1996, *supra*; Noonberg *et al.*, 1994, *Nucleic Acid Res.*, 22, 2830; Noonberg *et al.*, U.S. Pat. No. 5,624,803; Good *et al.*, 1997, *Gene Ther.*, 4, 45; Beigelman *et al.*, International PCT Publication No. WO 96/18736. The above siNA transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, *supra*).

In another aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the siNA molecules of the invention in a manner that allows expression of that siNA molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; and c) a nucleic acid sequence encoding at least one strand of the siNA molecule, wherein the sequence is operably linked to the initiation region and the termination region in a manner that allows expression and/or delivery of the siNA molecule.

In another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; and d) a nucleic acid sequence encoding at least one strand of a siNA molecule, wherein the sequence is operably linked to the 3'-end of the open reading frame and wherein the sequence is operably linked to the initiation region, the open reading frame and the termination region in a manner that allows expression and/or delivery of the siNA molecule. In yet another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; and d) a nucleic acid sequence encoding at least one siNA molecule, wherein the sequence is operably linked to the initiation region, the intron and the termination region in a manner which allows expression and/or delivery of the nucleic acid molecule.

In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; and e) a nucleic acid sequence encoding at least one strand of a siNA molecule, wherein the sequence is operably linked to the 3'-end of the open reading frame and wherein the sequence is operably linked to the initiation region, the intron, the open reading frame and the termination region in a manner which allows expression and/or delivery of the siNA molecule.

#### XIAP biology and biochemistry

Apoptosis is a physiological cell death process that is important in the development, homeostasis, and immune defense of multicellular animals. The inhibitor of apoptosis (IAP) gene family encodes a group of structurally related proteins that have the ability to suppress apoptotic cell death by binding to and inhibiting caspases (Lotocki *et al.*, 2002, *IUBMB Life*, 54(5), 231 and Salvesen *et al.*, 2002, *Nature Reviews*

*Molecular Cell Biology*, 3, 401). Caspases are cysteine proteases with a substrate preference for aspartic acid and are the key effectors of apoptosis (Verhagen *et al.*, 2001 *Genome Biology*, 2). All IAP's are BIR (baculovirus IAP repeat) containing proteins and BIRs are essential for the anti-apoptotic properties of the IAP's because they have been  
5 attributed to the binding and inhibition of caspases (Salvesen *et al.*, supra). IAP's can be induced by the transcription factor NF-KB or v-Rel, and HIAP1 and HIAP2 can activate NF-KB (LaCasse *et al.*, 1998, *Oncogene*, 17(25), 3247).

XIAP (X-linked inhibitor of apoptosis protein) is a 57-kDA protein (Salvesen *et al.*, supra). XIAP is also a mammalian inhibitor of apoptosis protein and is a suppressor  
10 of apoptotic cell death. XIAP blocks the mitochondrial death pathway by binding directly to certain initiator and effector caspases. (Li *et al.*, 2003 *Hebei Daxue Xuebao, Ziran Kexueban* 23, 100). However, XIAP mutants that cannot bind caspases can still inhibit apoptosis (Salvesen *et al.*, supra). When cells are infected by a virus, such as cancer, XIAP inhibits the apoptosis that would occur and the cancer cells continue  
15 inappropriate proliferation. Other IAPs (inhibitor of apoptosis proteins) including HIAP1, HIAP2 (human inhibitor of apoptosis 1 and 2), and NAIP (neuronal apoptosis inhibitor protein) can also suppress apoptosis.

Because XIAP and other IAP's, including HIAP1, HIAP2, and NAIP, are inhibitors of apoptosis, modulation of IAP gene expression using RNA  
20 interference mediated by short interfering nucleic acids represents a novel treatment approach for cancer and other proliferative diseases and conditions where the regulation of apoptosis is lost.

#### Examples:

The following are non-limiting examples showing the selection, isolation,  
25 synthesis and activity of nucleic acids of the instant invention.

#### Example 1: Tandem synthesis of siNA constructs

Exemplary siNA molecules of the invention are synthesized in tandem using a cleavable linker, for example, a succinyl-based linker. Tandem synthesis as described herein is followed by a one-step purification process that provides RNAi molecules in

high yield. This approach is highly amenable to siNA synthesis in support of high throughput RNAi screening, and can be readily adapted to multi-column or multi-well synthesis platforms.

After completing a tandem synthesis of a siNA oligo and its complement in which the 5'-terminal dimethoxytrityl (5'-O-DMT) group remains intact (trityl on synthesis), the oligonucleotides are deprotected as described above. Following deprotection, the siNA sequence strands are allowed to spontaneously hybridize. This hybridization yields a duplex in which one strand has retained the 5'-O-DMT group while the complementary strand comprises a terminal 5'-hydroxyl. The newly formed duplex behaves as a single molecule during routine solid-phase extraction purification (Trityl-On purification) even though only one molecule has a dimethoxytrityl group. Because the strands form a stable duplex, this dimethoxytrityl group (or an equivalent group, such as other trityl groups or other hydrophobic moieties) is all that is required to purify the pair of oligos, for example, by using a C18 cartridge.

Standard phosphoramidite synthesis chemistry is used up to the point of introducing a tandem linker, such as an inverted deoxy abasic succinate or glyceryl succinate linker (see Figure 1) or an equivalent cleavable linker. A non-limiting example of linker coupling conditions that can be used includes a hindered base such as diisopropylethylamine (DIPA) and/or DMAP in the presence of a activator reagent such as Bromotripyrrolidinophosphoniumhexafluorophosphate (PyBrOP). After the linker is coupled, standard synthesis chemistry is utilized to complete synthesis of the second sequence leaving the terminal the 5'-O-DMT intact. Following synthesis, the resulting oligonucleotide is deprotected according to the procedures described herein and quenched with a suitable buffer, for example with 50mM NaOAc or 1.5M  $\text{NH}_4\text{H}_2\text{CO}_3$ .

Purification of the siNA duplex can be readily accomplished using solid phase extraction, for example using a Waters C18 SepPak 1g cartridge conditioned with 1 column volume (CV) of acetonitrile, 2 CV  $\text{H}_2\text{O}$ , and 2 CV 50mM NaOAc. The sample is loaded and then washed with 1 CV  $\text{H}_2\text{O}$  or 50mM NaOAc. Failure sequences are eluted with 1 CV 14% ACN (Aqueous with 50mM NaOAc and 50mM NaCl). The column is then washed, for example with 1 CV  $\text{H}_2\text{O}$  followed by on-column detritylation, for example by passing 1 CV of 1% aqueous trifluoroacetic acid (TFA)

(400/124)

over the column, then adding a second CV of 1% aqueous TFA to the column and allowing to stand for approximately 10 minutes. The remaining TFA solution is removed and the column washed with H<sub>2</sub>O followed by 1 CV 1M NaCl and additional H<sub>2</sub>O. The siNA duplex product is then eluted, for example, using 1 CV 20% aqueous  
5 CAN.

Figure 2 provides an example of MALDI-TOF mass spectrometry analysis of a purified siNA construct in which each peak corresponds to the calculated mass of a individual siNA strand of the siNA duplex. The same purified siNA provides three peaks when analyzed by capillary gel electrophoresis (CGE), one peak presumably  
10 corresponding to the duplex siNA, and two peaks presumably corresponding to the separate siNA sequence strands. Ion exchange HPLC analysis of the same siNA contract only shows a single peak. Testing of the purified siNA construct using a luciferase reporter assay described below demonstrated the same RNAi activity compared to siNA constructs generated from separately synthesized oligonucleotide sequence strands.

15 Example 2: Identification of potential siNA target sites in any RNA sequence

The sequence of a RNA target of interest, such as a viral or human mRNA transcript, is screened for target sites, for example by using a computer folding algorithm. In a non-limiting example, the sequence of a gene or RNA gene transcript derived from a database, such as Genbank, is used to generate siNA targets having  
20 complementarity to the target. Such sequences can be obtained from a database, or can be determined experimentally as known in the art. Target sites that are known, for example, those target sites determined to be effective target sites based on studies with other nucleic acid molecules, for example ribozymes or antisense, or those targets known to be associated with a disease or condition such as those sites containing mutations or  
25 deletions, can be used to design siNA molecules targeting those sites. Various parameters can be used to determine which sites are the most suitable target sites within the target RNA sequence. These parameters include but are not limited to secondary or tertiary RNA structure, the nucleotide base composition of the target sequence, the degree of homology between various regions of the target sequence, or the relative  
30 position of the target sequence within the RNA transcript. Based on these determinations, any number of target sites within the RNA transcript can be chosen to

screen siNA molecules for efficacy, for example by using *in vitro* RNA cleavage assays, cell culture, or animal models. In a non-limiting example, anywhere from 1 to 1000 target sites are chosen within the transcript based on the size of the siNA construct to be used. High throughput screening assays can be developed for screening siNA molecules using methods known in the art, such as with multi-well or multi-plate assays to determine efficient reduction in target gene expression.

### Example 3: Selection of siNA molecule target sites in a RNA

The following non-limiting steps can be used to carry out the selection of siNAs targeting a given gene sequence or transcript.

- 10 1. The target sequence is parsed *in silico* into a list of all fragments or subsequences of a particular length, for example 23 nucleotide fragments, contained within the target sequence. This step is typically carried out using a custom Perl script, but commercial sequence analysis programs such as Oligo, MacVector, or the GCG Wisconsin Package can be employed as well.
- 15 2. In some instances the siNAs correspond to more than one target sequence; such would be the case for example in targeting different transcripts of the same gene, targeting different transcripts of more than one gene, or for targeting both the human gene and an animal homolog. In this case, a subsequence list of a particular length is generated for each of the targets, and then the lists are compared to find matching  
20 sequences in each list. The subsequences are then ranked according to the number of target sequences that contain the given subsequence; the goal is to find subsequences that are present in most or all of the target sequences. Alternately, the ranking can identify subsequences that are unique to a target sequence, such as a mutant target  
25 sequence. Such an approach would enable the use of siNA to target specifically the mutant sequence and not effect the expression of the normal sequence.
3. In some instances the siNA subsequences are absent in one or more sequences while present in the desired target sequence; such would be the case if the siNA targets a gene with a paralogous family member that is to remain untargeted. As in case 2 above, a subsequence list of a particular length is generated for each of the targets,

and then the lists are compared to find sequences that are present in the target gene but are absent in the untargeted paralog.

4. The ranked siNA subsequences can be further analyzed and ranked according to GC content. A preference can be given to sites containing 30-70% GC, with a further  
5 preference to sites containing 40-60% GC.
5. The ranked siNA subsequences can be further analyzed and ranked according to self-folding and internal hairpins. Weaker internal folds are preferred; strong hairpin structures are to be avoided.
6. The ranked siNA subsequences can be further analyzed and ranked according to  
10 whether they have runs of GGG or CCC in the sequence. GGG (or even more Gs) in either strand can make oligonucleotide synthesis problematic and can potentially interfere with RNAi activity, so it is avoided whenever better sequences are available. CCC is searched in the target strand because that will place GGG in the antisense strand.
- 15 7. The ranked siNA subsequences can be further analyzed and ranked according to whether they have the dinucleotide UU (uridine dinucleotide) on the 3'-end of the sequence, and/or AA on the 5'-end of the sequence (to yield 3' UU on the antisense sequence). These sequences allow one to design siNA molecules with terminal TT thymidine dinucleotides.
- 20 8. Four or five target sites are chosen from the ranked list of subsequences as described above. For example, in subsequences having 23 nucleotides, the right 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the upper (sense) strand of the siNA duplex, while the reverse complement of the left 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized  
25 for the lower (antisense) strand of the siNA duplex (see **Tables II and III**). If terminal TT residues are desired for the sequence (as described in paragraph 7), then the two 3' terminal nucleotides of both the sense and antisense strands are replaced by TT prior to synthesizing the oligos.

9. The siNA molecules are screened in an *in vitro*, cell culture or animal model system to identify the most active siNA molecule or the most preferred target site within the target RNA sequence.

In an alternate approach, a pool of siNA constructs specific to an XIAP target sequence is used to screen for target sites in cells expressing XIAP RNA, such as human T cells. The general strategy used in this approach is shown in Figure 9. A non-limiting example of such is a pool comprising sequences having any of SEQ ID NOS 1-996. Cells expressing XIAP (e.g., T cells) are transfected with the pool of siNA constructs and cells that demonstrate a phenotype associated with XIAP inhibition are sorted. The pool of siNA constructs can be expressed from transcription cassettes inserted into appropriate vectors (see for example Figure 7 and Figure 8). The siNA from cells demonstrating a positive phenotypic change (e.g., decreased fatty acid synthesis, decreased XIAP mRNA levels or decreased XIAP protein expression), are sequenced to determine the most suitable target site(s) within the target XIAP RNA sequence.

15 Example 4: XIAP targeted siNA design

siNA target sites were chosen by analyzing sequences of the XIAP RNA target and optionally prioritizing the target sites on the basis of folding (structure of any given sequence analyzed to determine siNA accessibility to the target), by using a library of siNA molecules as described in Example 3, or alternately by using an *in vitro* siNA system as described in Example 6 herein. siNA molecules were designed that could bind each target and are optionally individually analyzed by computer folding to assess whether the siNA molecule can interact with the target sequence. Varying the length of the siNA molecules can be chosen to optimize activity. Generally, a sufficient number of complementary nucleotide bases are chosen to bind to, or otherwise interact with, the target RNA, but the degree of complementarity can be modulated to accommodate siNA duplexes or varying length or base composition. By using such methodologies, siNA molecules can be designed to target sites within any known RNA sequence, for example those RNA sequences corresponding to the any gene transcript.

Chemically modified siNA constructs are designed to provide nuclease stability for systemic administration *in vivo* and/or improved pharmacokinetic, localization, and delivery properties while preserving the ability to mediate RNAi activity. Chemical



modifications as described herein are introduced synthetically using synthetic methods described herein and those generally known in the art. The synthetic siNA constructs are then assayed for nuclease stability in serum and/or cellular/tissue extracts (e.g. liver extracts). The synthetic siNA constructs are also tested in parallel for RNAi activity  
 5 using an appropriate assay, such as a luciferase reporter assay as described herein or another suitable assay that can quantify RNAi activity. Synthetic siNA constructs that possess both nuclease stability and RNAi activity can be further modified and re-evaluated in stability and activity assays. The chemical modifications of the stabilized active siNA constructs can then be applied to any siNA sequence targeting any chosen  
 10 RNA and used, for example, in target screening assays to pick lead siNA compounds for therapeutic development (see for example Figure 11).

#### Example 5: Chemical Synthesis and Purification of siNA

siNA molecules can be designed to interact with various sites in the RNA message, for example, target sequences within the RNA sequences described herein. The  
 15 sequence of one strand of the siNA molecule(s) is complementary to the target site sequences described above. The siNA molecules can be chemically synthesized using methods described herein. Inactive siNA molecules that are used as control sequences can be synthesized by scrambling the sequence of the siNA molecules such that it is not complementary to the target sequence. Generally, siNA constructs can be synthesized  
 20 using solid phase oligonucleotide synthesis methods as described herein (see for example Usman *et al.*, US Patent Nos. 5,804,683; 5,831,071; 5,998,203; 6,117,657; 6,353,098; 6,362,323; 6,437,117; 6,469,158; Scaringe *et al.*, US Patent Nos. 6,111,086; 6,008,400; 6,111,086 all incorporated by reference herein in their entirety).

In a non-limiting example, RNA oligonucleotides are synthesized in a stepwise  
 25 fashion using the phosphoramidite chemistry as is known in the art. Standard phosphoramidite chemistry involves the use of nucleosides comprising any of 5'-O-dimethoxytrityl, 2'-O-tert-butyldimethylsilyl, 3'-O-2-Cyanoethyl N,N-diisopropylphosphoroamidite groups, and exocyclic amine protecting groups (e.g. N6-benzoyl adenosine, N4 acetyl cytidine, and N2-isobutyryl guanosine). Alternately, 2'-O-Silyl Ethers can be  
 30 used in conjunction with acid-labile 2'-O-orthoester protecting groups in the synthesis of RNA as described by Scaringe *supra*. Differing 2' chemistries can require different protecting groups, for example 2'-deoxy-2'-amino nucleosides can utilize N-phthaloyl

protection as described by Usman *et al.*, US Patent 5,631,360, incorporated by reference herein in its entirety).

During solid phase synthesis, each nucleotide is added sequentially (3'- to 5'- direction) to the solid support-bound oligonucleotide. The first nucleoside at the 3'-end of the chain is covalently attached to a solid support (e.g., controlled pore glass or polystyrene) using various linkers. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are combined resulting in the coupling of the second nucleoside phosphoramidite onto the 5'-end of the first nucleoside. The support is then washed and any unreacted 5'-hydroxyl groups are capped with a capping reagent such as acetic anhydride to yield inactive 5'-acetyl moieties. The trivalent phosphorus linkage is then oxidized to a more stable phosphate linkage. At the end of the nucleotide addition cycle, the 5'-O-protecting group is cleaved under suitable conditions (e.g., acidic conditions for trityl-based groups and Fluoride for silyl-based groups). The cycle is repeated for each subsequent nucleotide.

Modification of synthesis conditions can be used to optimize coupling efficiency, for example by using differing coupling times, differing reagent/phosphoramidite concentrations, differing contact times, differing solid supports and solid support linker chemistries depending on the particular chemical composition of the siNA to be synthesized. Deprotection and purification of the siNA can be performed as is generally described in Deprotection and purification of the siNA can be performed as is generally described in Usman *et al.*, US 5,831,071, US 6,353,098, US 6,437,117, and Bellon *et al.*, US 6,054,576, US 6,162,909, US 6,303,773, or Scaringe *supra*, incorporated by reference herein in their entireties. Additionally, deprotection conditions can be modified to provide the best possible yield and purity of siNA constructs. For example, applicant has observed that oligonucleotides comprising 2'-deoxy-2'-fluoro nucleotides can degrade under inappropriate deprotection conditions. Such oligonucleotides are deprotected using aqueous methylamine at about 35°C for 30 minutes. If the 2'-deoxy-2'-fluoro containing oligonucleotide also comprises ribonucleotides, after deprotection with aqueous methylamine at about 35°C for 30 minutes, TEA-HF is added and the reaction maintained at about 65°C for an additional 15 minutes.

Example 6: RNAi *in vitro* assay to assess siNA activity

An *in vitro* assay that recapitulates RNAi in a cell-free system is used to evaluate siNA constructs targeting XIAP RNA targets. The assay comprises the system described by Tuschl *et al.*, 1999, *Genes and Development*, 13, 3191-3197 and Zamore *et al.*, 2000, *Cell*, 101, 25-33 adapted for use with XIAP target RNA. A *Drosophila* extract derived from syncytial blastoderm is used to reconstitute RNAi activity *in vitro*. Target RNA is generated via *in vitro* transcription from an appropriate XIAP expressing plasmid using T7 RNA polymerase or via chemical synthesis as described herein. Sense and antisense siNA strands (for example 20 uM each) are annealed by incubation in buffer (such as 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 min. at 90°C followed by 1 hour at 37°C, then diluted in lysis buffer (for example 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2mM magnesium acetate). Annealing can be monitored by gel electrophoresis on an agarose gel in TBE buffer and stained with ethidium bromide. The *Drosophila* lysate is prepared using zero to two-hour-old embryos from Oregon R flies collected on yeasted molasses agar that are dechorionated and lysed. The lysate is centrifuged and the supernatant isolated. The assay comprises a reaction mixture containing 50% lysate [vol/vol], RNA (10-50 pM final concentration), and 10% [vol/vol] lysis buffer containing siNA (10 nM final concentration). The reaction mixture also contains 10 mM creatine phosphate, 10 ug/ml creatine phosphokinase, 100 uM GTP, 100 uM UTP, 100 uM CTP, 500 uM ATP, 5 mM DTT, 0.1 U/uL RNasin (Promega), and 100 uM of each amino acid. The final concentration of potassium acetate is adjusted to 100 mM. The reactions are pre-assembled on ice and preincubated at 25° C for 10 minutes before adding RNA, then incubated at 25° C for an additional 60 minutes. Reactions are quenched with 4 volumes of 1.25 x Passive Lysis Buffer (Promega). Target RNA cleavage is assayed by RT-PCR analysis or other methods known in the art and are compared to control reactions in which siNA is omitted from the reaction.

Alternately, internally-labeled target RNA for the assay is prepared by *in vitro* transcription in the presence of [ $\alpha$ -<sup>32</sup>P] CTP, passed over a G 50 Sephadex column by spin chromatography and used as target RNA without further purification. Optionally, target RNA is 5'-<sup>32</sup>P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed as described above and target RNA and the specific RNA cleavage

products generated by RNAi are visualized on an autoradiograph of a gel. The percentage of cleavage is determined by Phosphor Imager<sup>®</sup> quantitation of bands representing intact control RNA or RNA from control reactions without siNA and the cleavage products generated by the assay.

- 5        In one embodiment, this assay is used to determine target sites the XIAP RNA target for siNA mediated RNAi cleavage, wherein a plurality of siNA constructs are screened for RNAi mediated cleavage of the XIAP RNA target, for example, by analyzing the assay reaction by electrophoresis of labeled target RNA, or by northern blotting, as well as by other methodology well known in the art.

10    Example 7: Nucleic acid inhibition of XIAP target RNA *in vivo*

siNA molecules targeted to the human XIAP RNA are designed and synthesized as described above. These nucleic acid molecules can be tested for cleavage activity *in vivo*, for example, using the following procedure. The target sequences and the nucleotide location within the XIAP RNA are given in Table II and III.

- 15        Two formats are used to test the efficacy of siNAs targeting XIAP. First, the reagents are tested in cell culture using, for example HELA cells, to determine the extent of RNA and protein inhibition. siNA reagents (*e.g.*; see Tables II and III) are selected against the XIAP target as described herein. RNA inhibition is measured after delivery of these reagents by a suitable transfection agent to, for example, HELA cells. Relative  
20    amounts of target RNA are measured versus actin using real-time PCR monitoring of amplification (*eg.*, ABI 7700 Taqman<sup>®</sup>). A comparison is made to a mixture of oligonucleotide sequences made to unrelated targets or to a randomized siNA control with the same overall length and chemistry, but randomly substituted at each position. Primary and secondary lead reagents are chosen for the target and optimization  
25    performed. After an optimal transfection agent concentration is chosen, a RNA time-course of inhibition is performed with the lead siNA molecule. In addition, a cell-plating format can be used to determine RNA inhibition.

Delivery of siNA to Cells

Cells (e.g., HELA cells) are seeded, for example, at  $1 \times 10^5$  cells per well of a six-well dish in EGM-2 (BioWhittaker) the day before transfection. siNA (final concentration, for example 20nM) and cationic lipid (e.g., final concentration  $2 \mu\text{g/ml}$ ) are complexed in EGM basal media (Biowhittaker) at  $37^\circ\text{C}$  for 30 mins in polystyrene  
 5 tubes. Following vortexing, the complexed siNA is added to each well and incubated for the times indicated. For initial optimization experiments, cells are seeded, for example, at  $1 \times 10^3$  in 96 well plates and siNA complex added as described. Efficiency of delivery of siNA to cells is determined using a fluorescent siNA complexed with lipid. Cells in 6-well dishes are incubated with siNA for 24 hours, rinsed with PBS and fixed in 2%  
 10 paraformaldehyde for 15 minutes at room temperature. Uptake of siNA is visualized using a fluorescent microscope.

#### Taqman and Lightcycler quantification of mRNA

Total RNA is prepared from cells following siNA delivery, for example, using Qiagen RNA purification kits for 6-well or Rneasy extraction kits for 96-well assays. For  
 15 Taqman analysis, dual-labeled probes are synthesized with the reporter dye, FAM or JOE, covalently linked at the 5'-end and the quencher dye TAMRA conjugated to the 3'-end. One-step RT-PCR amplifications are performed on, for example, an ABI PRISM 7700 Sequence Detector using 50  $\mu\text{l}$  reactions consisting of 10  $\mu\text{l}$  total RNA, 100 nM forward primer, 900 nM reverse primer, 100 nM probe, 1X TaqMan PCR reaction buffer  
 20 (PE-Applied Biosystems), 5.5 mM  $\text{MgCl}_2$ , 300  $\mu\text{M}$  each dATP, dCTP, dGTP, and dTTP, 10U RNase Inhibitor (Promega), 1.25U AmpliTaq Gold (PE-Applied Biosystems) and 10U M-MLV Reverse Transcriptase (Promega). The thermal cycling conditions can consist of 30 min at  $48^\circ\text{C}$ , 10 min at  $95^\circ\text{C}$ , followed by 40 cycles of 15 sec at  $95^\circ\text{C}$  and 1 min at  $60^\circ\text{C}$ . Quantitation of mRNA levels is determined relative to standards generated  
 25 from serially diluted total cellular RNA (300, 100, 33, 11 ng/rxn) and normalizing to  $\beta$ -actin or GAPDH mRNA in parallel TaqMan reactions. For each gene of interest an upper and lower primer and a fluorescently labeled probe are designed. Real time incorporation of SYBR Green I dye into a specific PCR product can be measured in glass capillary tubes using a lightcycler. A standard curve is generated for each primer pair  
 30 using control cRNA. Values are represented as relative expression to GAPDH in each sample.

### Western blotting

Nuclear extracts can be prepared using a standard micro preparation technique (see for example Andrews and Faller, 1991, *Nucleic Acids Research*, 19, 2499). Protein extracts from supernatants are prepared, for example using TCA precipitation. An equal  
5 volume of 20% TCA is added to the cell supernatant, incubated on ice for 1 hour and pelleted by centrifugation for 5 minutes. Pellets are washed in acetone, dried and resuspended in water. Cellular protein extracts are run on a 10% Bis-Tris NuPage (nuclear extracts) or 4-12% Tris-Glycine (supernatant extracts) polyacrylamide gel and transferred onto nitro-cellulose membranes. Non-specific binding can be blocked by  
10 incubation, for example, with 5% non-fat milk for 1 hour followed by primary antibody for 16 hour at 4°C. Following washes, the secondary antibody is applied, for example (1:10,000 dilution) for 1 hour at room temperature and the signal detected with SuperSignal reagent (Pierce).

### Example 8: Models useful to evaluate the down-regulation of XIAP gene expression

#### 15 *Cell Culture*

There are numerous cell culture systems that can be used to analyze reduction of XIAP levels either directly or indirectly by measuring downstream effects. For example, HELA cells can be used in cell culture experiments to assess the efficacy of nucleic acid molecules of the invention. As such, cells treated with nucleic acid molecules of the  
20 invention (e.g., siNA) targeting XIAP RNA would be expected to have decreased XIAP expression capacity compared to matched control nucleic acid molecules having a scrambled or inactive sequence. In a non-limiting example, HELA cells are cultured and XIAP expression is quantified, for example by time-resolved immuno fluorometric assay. XIAP messenger-RNA expression is quantitated with RT-PCR in cultured cells.  
25 Untreated cells are compared to cells treated with siNA molecules transfected with a suitable reagent, for example a cationic lipid such as lipofectamine, and XIAP protein and RNA levels are quantitated. Dose response assays are then performed to establish dose dependent inhibition of XIAP expression. In a non-limiting example, cell culture experiments are adapted to those experiments described in Korneluk et al., International  
30 PCT Publication No. WO 02/26968.

In several cell culture systems, cationic lipids have been shown to enhance the bioavailability of oligonucleotides to cells in culture (Bennet, *et al.*, 1992, *Mol. Pharmacology*, 41, 1023-1033). In one embodiment, siNA molecules of the invention are complexed with cationic lipids for cell culture experiments. siNA and cationic lipid mixtures are prepared in serum-free DMEM immediately prior to addition to the cells. DMEM plus additives are warmed to room temperature (about 20-25°C) and cationic lipid is added to the final desired concentration and the solution is vortexed briefly. siNA molecules are added to the final desired concentration and the solution is again vortexed briefly and incubated for 10 minutes at room temperature. In dose response experiments, the RNA/lipid complex is serially diluted into DMEM following the 10 minute incubation.

#### *Animal Models*

Evaluating the efficacy of anti-XIAP agents in animal models is an important prerequisite to human clinical trials. The role of XIAP has recently been investigated (Conte *et al.*, 2001, *Proc. Natl. Acad. Sci. USA*, 98, 5049) using engineered transgenic mice that over express a human XIAP transgene under the control of a T cell specific promoter, *lck*, to assess the effect of XIAP on T cell development. The investigators evaluated the ability of XIAP to rescue apoptotic-sensitive thymocytes from apoptotic triggers, such as C2 ceramide, UV radiation, and anti-Fas antibody. Investigators found that *lck*-XIAP thymocytes demonstrated reduced in vitro apoptosis, with only 20% cell death relative to untreated *lck*-xiap thymocytes over 18 hours when exposed to C2 ceramide exposure. The ability of XIAP to inhibit apoptotic pathways after exposure to UV radiation and a Fas death receptor (anti-Fas antibody) led to the finding that *lck*-XIAP thymocytes were resistant to apoptosis, with apoptosis being reduced compared with wild-type thymocytes (Conte *et al.*, *supra*).

In addition, thymocytes were treated with dexamethasone or anti-CD3 antibody in vitro which triggers apoptosis of thymocytes; however the *lck*-XIAP thymocytes demonstrated enhanced resistance to apoptosis. Thymocytes of control mice and *lck*-xiap mice were also injected with anti-Fas antibody to test levels of apoptosis in vivo. The control mice thymocytes had extensive apoptotic death while the thymocytes of *lck*-

XIAP mice had significantly less apoptosis. The resistance to apoptosis by lck-XIAP thymocytes was attributable to over expression of XIAP (Conte *et al.*, *supra*).

The animal model described by Conte *et al.*, *supra*, can be used to evaluate inhibition of XIAP expression and the increased regression of tumor growth after the transfer of conditioned T-cells in the presence of a XIAP blockade using siNA molecules of the invention. The improved clearance of tumors in mice can be associated with the XIAP blockade that improves apoptosis of disease infected cells. These results raise the possibility that manipulation of XIAP can be used toward therapeutic use in preventing and/or treating cancer and other proliferative conditions discussed herein in human subjects.

#### Example 9: RNAi mediated inhibition of XIAP RNA expression

siNA constructs (Table III) are tested for efficacy in reducing XIAP RNA expression in, for example, HELA cells. Cells are plated approximately 24h before transfection in 96-well plates at 5,000-7,500 cells/well, 100  $\mu$ l/well, such that at the time of transfection cells are 70-90% confluent. For transfection, annealed siNAs are mixed with the transfection reagent (Lipofectamine 2000, Invitrogen) in a volume of 50  $\mu$ l/well and incubated for 20 min. at room temperature. The siNA transfection mixtures are added to cells to give a final siNA concentration of 25 nM in a volume of 150  $\mu$ l. Each siNA transfection mixture is added to 3 wells for triplicate siNA treatments. Cells are incubated at 37° for 24 hours in the continued presence of the siNA transfection mixture. At 24 hours, RNA is prepared from each well of treated cells. The supernatants with the transfection mixtures are first removed and discarded, then the cells are lysed and RNA prepared from each well. Target gene expression following treatment is evaluated by RT-PCR for the target gene and for a control gene (36B4, an RNA polymerase subunit) for normalization. The triplicate data is averaged and the standard deviations determined for each treatment. Normalized data are graphed and the percent reduction of target mRNA by active siNAs in comparison to their respective inverted control siNAs is determined.

#### Example 10: Indications



The present body of knowledge in inhibitors of apoptosis research indicates the need for methods and compounds that can regulate XIAP, HIAP1, HIAP2, and/or NAIP gene expression for research, diagnostic, and therapeutic use. As described herein, the nucleic acid molecules of the present invention can be used to treat cancer and other proliferative conditions such as ovarian cancer; cancers of non-lymphoid parenchymal organs including the heart, placenta, skeletal muscle and lung; breast cancer, cancers of the head and neck including various lymphomas such as mantle cell lymphoma, non-Hodgkins lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma, cancers of the retina, cancers of the esophagus, multiple myeloma, melanoma, colorectal cancer, lung cancer, bladder cancer, prostate cancer, glioblastoma; and proliferative diseases and conditions such as restenosis and polycystic kidney disease; and any other indications that can respond to the level of a XIAP, HIAP1, HIAP2, and/or NAIP gene in a cell or tissue.

The use of radiation treatments and chemotherapeutics, such as Gemcytabine and cyclophosphamide, are non-limiting examples of chemotherapeutic agents that can be combined with or used in conjunction with the nucleic acid molecules (e.g. siNA molecules) of the instant invention. Those skilled in the art will recognize that other anti-cancer compounds and therapies can similarly be readily combined with the nucleic acid molecules of the instant invention (e.g. siNA molecules) and are hence within the scope of the instant invention. Such compounds and therapies are well known in the art (see for example *Cancer: Principles and Practice of Oncology*, Volumes 1 and 2, eds Devita, V.T., Hellman, S., and Rosenberg, S.A., J.B. Lippincott Company, Philadelphia, USA; incorporated herein by reference) and include, without limitation, folates, antifolates, pyrimidine analogs, fluoropyrimidines, purine analogs, adenosine analogs, topoisomerase I inhibitors, anthracyclins, platinum analogs, alkylating agents, nitrosoureas, plant derived compounds such as vinca alkaloids, epipodophyllotoxins, tyrosine kinase inhibitors, taxols, radiation therapy, surgery, nutritional supplements, gene therapy, radiotherapy, for example 3D-CRT, immunotoxin therapy, for example ricin, and monoclonal antibodies. Specific examples of chemotherapeutic compounds that can be combined with or used in conjunction with the nucleic acid molecules of the invention include, but are not limited to, Paclitaxel; Docetaxel; Methotrexate; Doxorubicin; Edatrexate; Vinorelbine; Tomaxifen; Leucovorin; 5-fluoro uridine (5-FU); Irinotecan; Cisplatin; Carboplatin; Amsacrine; Cytarabine;

Bleomycin; Mitomycin C; Dactinomycin; Mithramycin; Hexamethylmelamine; Dacarbazine; L-asparaginase; Nitrogen mustard; Melphalan, Chlorambucil; Busulfan; Ifosfamide; 4-hydroperoxycyclophosphamide; Thiotepa; Irinotecan (CAMPTOSAR®, CPT-11, Camptothecin-11, Campto) Tamoxifen; Herceptin; IMC C225; ABX-EGF; and combinations thereof. The above list of compounds are non-limiting examples of compounds and/or methods that can be combined with or used in conjunction with the nucleic acid molecules (e.g. siNA) of the instant invention. Those skilled in the art will recognize that other drug compounds and therapies can similarly be readily combined with the nucleic acid molecules of the instant invention (e.g., siNA molecules) are hence within the scope of the instant invention.

#### Example 11: Diagnostic uses

The siNA molecules of the invention can be used in a variety of diagnostic applications, such as in the identification of molecular targets (e.g., RNA) in a variety of applications, for example, in clinical, industrial, environmental, agricultural and/or research settings. Such diagnostic use of siNA molecules involves utilizing reconstituted RNAi systems, for example, using cellular lysates or partially purified cellular lysates. siNA molecules of this invention can be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of endogenous or exogenous, for example viral, RNA in a cell. The close relationship between siNA activity and the structure of the target RNA allows the detection of mutations in any region of the molecule, which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple siNA molecules described in this invention, one can map nucleotide changes, which are important to RNA structure and function *in vitro*, as well as in cells and tissues. Cleavage of target RNAs with siNA molecules can be used to inhibit gene expression and define the role of specified gene products in the progression of disease or infection. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple siNA molecules targeted to different genes, siNA molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations siNA molecules and/or other chemical or biological molecules). Other *in vitro* uses of siNA molecules of this invention are well known in the art, and include detection of the

presence of mRNAs associated with a disease, infection, or related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a siNA using standard methodologies, for example, fluorescence resonance emission transfer (FRET).

5 In a specific example, siNA molecules that cleave only wild-type or mutant forms of the target RNA are used for the assay. The first siNA molecules (*i.e.*, those that cleave only wild-type forms of target RNA) are used to identify wild-type RNA present in the sample and the second siNA molecules (*i.e.*, those that cleave only mutant forms of target RNA) are used to identify mutant RNA in the sample. As reaction controls,  
10 synthetic substrates of both wild-type and mutant RNA are cleaved by both siNA molecules to demonstrate the relative siNA efficiencies in the reactions and the absence of cleavage of the "non-targeted" RNA species. The cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus, each analysis requires two siNA  
15 molecules, two substrates and one unknown sample, which is combined into six reactions. The presence of cleavage products is determined using an RNase protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic  
20 changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (*i.e.*, disease related or infection related) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels is adequate and decreases the cost of the initial diagnosis. Higher mutant form to wild-type ratios are correlated with higher risk  
25 whether RNA levels are compared qualitatively or quantitatively.

All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

30 One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as

those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are  
5 defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims. The present invention teaches  
10 one skilled in the art to test various combinations and/or substitutions of chemical modifications described herein toward generating nucleic acid constructs with improved activity for mediating RNAi activity. Such improved activity can comprise improved stability, improved bioavailability, and/or improved activation of cellular responses mediating RNAi. Therefore, the specific embodiments described herein are not limiting  
15 and one skilled in the art can readily appreciate that specific combinations of the modifications described herein can be tested without undue experimentation toward identifying siNA molecules with improved RNAi activity.

The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically  
20 disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of", and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and  
25 described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be  
30 within the scope of this invention as defined by the description and the appended claims.

(400/124)

In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

**Table I: XIAP Accession Numbers**

<b>BIRC1</b>				
LOCUS	NM_004536	6133 bp	mRNA	linear
DEFINITION	Homo sapiens baculoviral IAP repeat-containing 1 (BIRC1), mRNA.			
ACCESSION	NM_004536			PRI 05-APR-2003
<b>BIRC2</b>				
LOCUS	NM_001166	3496 bp	mRNA	linear
DEFINITION	Homo sapiens baculoviral IAP repeat-containing 2 (BIRC2), mRNA.			
ACCESSION	NM_001166			PRI 03-APR-2003
<b>BIRC3</b>				
LOCUS	NM_001165	3165 bp	mRNA	linear
DEFINITION	Homo sapiens baculoviral IAP repeat-containing 3 (BIRC3), mRNA.			
ACCESSION	NM_001165			PRI 03-APR-2003
<b>BIRC4</b>				
LOCUS	NM_001167	8413 bp	mRNA	linear
DEFINITION	Homo sapiens baculoviral IAP repeat-containing 4 (BIRC4), mRNA.			
ACCESSION	NM_001167			PRI 11-JUL-2003
<b>BIRC5</b>				
LOCUS	NM_001168	1619 bp	mRNA	linear
DEFINITION	Homo sapiens baculoviral IAP repeat-containing 5 (survivin) (BIRC5), mRNA.			
				PRI 03-APR-2003

(400/124)

ACCESSION NM\_001168

### BIRC6

LOCUS NM\_016252 14490 bp mRNA linear PRI 06-APR-2003  
DEFINITION Homo sapiens baculoviral IAP repeat-containing 6 (apollon) (BIRC6),  
mRNA.

ACCESSION NM\_016252

### BIRC7-1

LOCUS NM\_139317 1322 bp mRNA linear PRI 06-APR-2003  
DEFINITION Homo sapiens baculoviral IAP repeat-containing 7 (livin) (BIRC7),  
transcript variant 1, mRNA.  
ACCESSION NM\_139317

### BIRC7-2

LOCUS NM\_022161 1268 bp mRNA linear PRI 06-APR-2003  
DEFINITION Homo sapiens baculoviral IAP repeat-containing 7 (livin) (BIRC7), transcript variant  
2, mRNA.  
ACCESSION NM\_022161

### BIRC8

LOCUS NM\_033341 2032 bp mRNA linear PRI 06-APR-2003  
DEFINITION Homo sapiens baculoviral IAP repeat-containing 8 (BIRC8), mRNA.  
ACCESSION NM\_033341  
VERSION NM\_033341.2 GI:16974127

Table II: XIAP siNA and Target Sequences

XIAP BIRC4|NM\_001167.2

Seq	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID
UCCAGAUUGGGGCUCCGGGC	1	3	UCCAGAUUGGGGCUCCGGGC	1	21	GCCCGAGCCCCAAUCUGGA	468
CCGCGCCUCCUCCGGGACC	2	21	CCGCGCCUCCUCCGGGACC	2	39	GGUCCGGAGGAGGCGCGG	469
CCUCCCCUUGGACCGAGCC	3	39	CCUCCCCUUGGACCGAGCC	3	57	GGCUCGGUCCAAAGGGAGG	470
CGAUCGCCGCGGGCAGUU	4	57	CGAUCGCCGCGGGCAGUU	4	75	AACUGCCCCGCGGGCGAUCG	471
UCGGGCCGCGUCCUGGC	5	75	UCGGGCCGCGUCCUGGC	5	93	GCCAGGACAGCCGCGCCCGA	472
CGCGAAAAGGUGGACAAGU	6	93	CGCGAAAAGGUGGACAAGU	6	111	ACUUGUCCACCUCUUGCGC	473
UCCAUUUUCAAGAGAAGA	7	111	UCCAUUUUCAAGAGAAGA	7	129	UCUUCUCUUGAAAAUAGGA	474
AUGACUUUUACAGUUUUG	8	129	AUGACUUUUACAGUUUUG	8	147	CAAAACUGUUAAAAAGUCAU	475
GAAGGAUCUAAAACUUUG	9	147	GAAGGAUCUAAAACUUUG	9	165	CACAAGUUUUAGAUCCUUC	476
GUACCGCAGACAUCAAUA	10	165	GUACCGCAGACAUCAAUA	10	183	UAUUGAUGUCUGCAGGUAC	477
AAGGAAGAAUUUUUGUAG	11	183	AAGGAAGAAUUUUUGUAG	11	201	CUACAAAUUUCUUCUCCUU	478
GAAGAGUUUAAUAGAUAA	12	201	GAAGAGUUUAAUAGAUAA	12	219	UUAAUCUAUUAAACUCUUC	479
AAAACUUUUGCUAAUUUUC	13	219	AAAACUUUUGCUAAUUUUC	13	237	GAAAAUUAGCAAAAGUUUU	480
CCAAGUGGUAGUCCUGUUU	14	237	CCAAGUGGUAGUCCUGUUU	14	255	AAACAGGACUACCACUUGG	481
UCAGCAUCAACACUGGCAC	15	255	UCAGCAUCAACACUGGCAC	15	273	GUGCCAGUUUGAUGCUGA	482
CGAGCAGGUUUUCUUUAUA	16	273	CGAGCAGGUUUUCUUUAUA	16	291	UAUAAAGAAACCCUCCUCG	483
ACUGGGUGAAGGAGAUACCG	17	291	ACUGGGUGAAGGAGAUACCG	17	309	CGGUAUCUCCUUCACCAGU	484
GUGCGGUGCUUUAGUUUGUC	18	309	GUGCGGUGCUUUAGUUUGUC	18	327	GACAACUAAAGCACCCGCAC	485
CAUGCAGCUGUAGAUAGAU	19	327	CAUGCAGCUGUAGAUAGAU	19	345	AUCUAUCUACAGCUGCAUG	486
UGGCAUAUUGGAGACUCAG	20	345	UGGCAUAUUGGAGACUCAG	20	363	CUGAGUCUCCAUUUUGCCA	487
GCAGUUGGAAGACACAGGA	21	363	GCAGUUGGAAGACACAGGA	21	381	UCCUGUGUCUUCCAAACUCG	488
AAAGUAUCCCCAAUUUGCA	22	381	AAAGUAUCCCCAAUUUGCA	22	399	UGCAAUUUUGGGGAUACUUU	489
AGAUUUUAUCAACGGCUUUU	23	399	AGAUUUUAUCAACGGCUUUU	23	417	AAAAGCCGUUGAUAAAUUCU	490
UAUCUUGAAAUAUGGCCA	24	417	UAUCUUGAAAUAUGGCCA	24	435	UGGCACUAUUUCAAAGAU	491
ACGCAGUCUACAAAUUCUG	25	435	ACGCAGUCUACAAAUUCUG	25	453	CAGAAUUUGUAGACUCCGU	492
GGUAUCCAGAAUGGUCAGU	26	453	GGUAUCCAGAAUGGUCAGU	26	471	ACUGACCAUUCUGGAUACC	493



UACAAAGUUUGAAACUAUC	27	471	UACAAAGUUUGAAACUAUC	27	489	GAUAGUUUUCACCUUUGUA	494
CUGGGAAGCAGAGAUCAUU	28	489	CUGGGAAGCAGAGAUCAUU	28	507	AAUGAUCUCUGCUUCCAG	495
UUUGCCUUAGACAGGCCAU	29	507	UUUGCCUUAGACAGGCCAU	29	525	AUGGCCUGUCUAGGCAAA	496
UCUGAGACACAUAGCAGCU	30	525	UCUGAGACACAUAGCAGCU	30	543	AGUCUGCAUGUGUCUCAGA	497
UAUCUUUGAGAACUGGGC	31	543	UAUCUUUGAGAACUGGGC	31	561	GCCCAGUUCUCAAAGAU	498
CAGGUUGUAGAUUAUCAG	32	561	CAGGUUGUAGAUUAUCAG	32	579	CUGAUUAUUCUACAACCCUG	499
GACACCAUAUACCCGAGGA	33	579	GACACCAUAUACCCGAGGA	33	597	UCCUCGGGUUAUUGGUGUC	500
AACCCUGCCAUUAUAGUG	34	597	AACCCUGCCAUUAUAGUG	34	615	CACUAUAUAGGCGGGUU	501
GAAGAAGCUAGAUUAAAGU	35	615	GAAGAAGCUAGAUUAAAGU	35	633	ACUUUAAUCUAGCUUCUUC	502
UCCUUUCAGAACUGGCCAG	36	633	UCCUUUCAGAACUGGCCAG	36	651	CUGGCCAGUUCUGAAAGGA	503
GACUAUGCUCACCUAACCC	37	651	GACUAUGCUCACCUAACCC	37	669	GGGUAGGUUGAGCAUAGUC	504
CCAAGAGAGUUAGCAAGUG	38	669	CCAAGAGAGUUAGCAAGUG	38	687	CACUUUGCUAACUCUCUUGG	505
GCUGGACUCUACACACAG	39	687	GCUGGACUCUACACACAG	39	705	CUGUGUAGUAGAGUCCAGC	506
GGUAUUGGUGACCAAGUGC	40	705	GGUAUUGGUGACCAAGUGC	40	723	GCACUUGGUCACCAAUACC	507
CAGUGCUUUUGUUGUGGUG	41	723	CAGUGCUUUUGUUGUGGUG	41	741	CACCACAACAAAAGCAGCUG	508
GGAAAACUGAAAAUUGGG	42	741	GGAAAACUGAAAAUUGGG	42	759	CCCAUUUUUUCAGUUUUC	509
GAACCUUGUGAUCGUGCCU	43	759	GAACCUUGUGAUCGUGCCU	43	777	AGGCACGAUCACAAAGGUUC	510
UGGUCAGAACACAGGCGAC	44	777	UGGUCAGAACACAGGCGAC	44	795	GUCGCCUGUGUUUCUGACCA	511
CACUUUCCUAAUUGCUUCU	45	795	CACUUUCCUAAUUGCUUCU	45	813	AGAAGCAUUAGGAAAGUG	512
UUUGUUUUGGGCGGAAUC	46	813	UUUGUUUUGGGCGGAAUC	46	831	GAUUCGGCGCCAAAACAAA	513
CUUAAUAUUCGAAGUGAAU	47	831	CUUAAUAUUCGAAGUGAAU	47	849	AUUCACUUCGAAUAUUAAG	514
UCUGAUGCUGUGAGUUCUG	48	849	UCUGAUGCUGUGAGUUCUG	48	867	CAGAACUCACAGCAUCAGA	515
GAUAGGAUUUCCCAAAU	49	867	GAUAGGAUUUCCCAAAU	49	885	AAUUUGGGAUUUCCUAUC	516
UCAACAAAUUCUCCAAAGAA	50	885	UCAACAAAUUCUCCAAAGAA	50	903	UUCUUUGGAAGAUUUUGUUGA	517
AAUCCAUCUUGGCAGAUU	51	903	AAUCCAUCUUGGCAGAUU	51	921	AAUCUGCCAUUGGAGGAUU	518
UAUGAAGCACGGAUCUUUA	52	921	UAUGAAGCACGGAUCUUUA	52	939	UAAAGAUCCGUGCUUCAUA	519
ACUUUUGGGACAUUGGAU	53	939	ACUUUUGGGACAUUGGAU	53	957	UAUCCAUGUCCCAAAAGU	520
UACUCAGUUAAACAAGGAGC	54	957	UACUCAGUUAAACAAGGAGC	54	975	GUCCUUUUUAACUCUGAUA	521
CAGCUUGCAAGAGCUGGAU	55	975	CAGCUUGCAAGAGCUGGAU	55	993	AUCCAGCUUUGCAAGCUG	522
UUUUAUGCUUUAGGUGAAG	56	993	UUUUAUGCUUUAGGUGAAG	56	1011	CUUACCCUAAAGCAUAAAA	523
GGUGAUAAAGUAAAGUGCU	57	1011	GGUGAUAAAGUAAAGUGCU	57	1029	AGCACUUUUAUUUAUCACC	524
UUUCACUGUGGAGGAGGGC	58	1029	UUUCACUGUGGAGGAGGGC	58	1047	GCCCUCUCCACAGUGAAA	525
CUAACUGAUUGGAAGCCCA	59	1047	CUAACUGAUUGGAAGCCCA	59	1065	UGGGCUUCCAUCAGUUG	526
AGUGAAGACCCUUGGGAAC	60	1065	AGUGAAGACCCUUGGGAAC	60	1083	GUUCCCAAGGGUCUUCACU	527

CAACAUGC	UAAUUG	UAUC	61	1083	CAACAUGC	UAAUUG	UAUC	61	1101	GAUACCAU	UUAG	CAUUG	528
CCAGGGUG	CAAAUAUC	UGU	62	1101	CCAGGGUG	CAAAUAUC	UGU	62	1119	ACAGAUAU	UUGC	ACCCUG	529
UUAGAAC	AGAGGACA	AG	63	1119	UUAGAAC	AGAGGACA	AG	63	1137	CUUGCCCU	UCUG	UUA	530
GAUAUAU	AAACAUAUC		64	1137	GAUAUAU	AAACAUAUC		64	1155	GAUAUUGU	UUUAU	UAUC	531
CAUUUAUC	UAUCACUUG		65	1155	CAUUUAUC	UAUCACUUG		65	1173	CAAGUAAU	GAGU	AAUUG	532
GAGGAGUG	UCUGUAAGAA		66	1173	GAGGAGUG	UCUGUAAGAA		66	1191	UUCUACCA	GACACUCC	UC	533
ACUACUG	GAGAAACACCAU		67	1191	ACUACUG	GAGAAACACCAU		67	1209	AUGGUGUU	UUCACAGUAGU		534
UCACUAAC	UAGAAAUUG		68	1209	UCACUAAC	UAGAAAUUG		68	1227	CAAUUCU	UUCUAGU	UAGUGA	535
GAUGAUAC	CAUCUCCAAA		69	1227	GAUGAUAC	CAUCUCCAAA		69	1245	UUUGGAU	GAGUUAUC	AUC	536
AAUCCUAU	GGUACAAGAG		70	1245	AAUCCUAU	GGUACAAGAG		70	1263	CUUCUUU	GUACCAU	AGGAU	537
GUUAUAC	GAUUGGUUA		71	1263	GUUAUAC	GAUUGGUUA		71	1281	UGAACCC	CAUUCGU	UAAGC	538
AGUUUAAG	GACAUUAAGA		72	1281	AGUUUAAG	GACAUUAAGA		72	1299	UCUUAU	GUCCUUG	AAACU	539
AAAAUAUG	GAGGAAAAA		73	1299	AAAAUAUG	GAGGAAAAA		73	1317	UUUUUCC	CUUUAUUU		540
AUUCAGAU	AUCUGGGAGCA		74	1317	AUUCAGAU	AUCUGGGAGCA		74	1335	UGCUC	CAGAU	AUCUGAAU	541
AACUAUAA	UACUUGAGG		75	1335	AACUAUAA	UACUUGAGG		75	1353	CCUCAAG	UGAUUUUAU	AGUU	542
GUUCUGGU	GCAGAUUCUAG		76	1353	GUUCUGGU	GCAGAUUCUAG		76	1371	CUAGAUCU	GCAACCAGAAC		543
GUGAAUGC	UCAGAAAGACA		77	1371	GUGAAUGC	UCAGAAAGACA		77	1389	UGUCUUU	CUGAGCAUUCAC		544
AGUAUGCA	GAUGAUCAA		78	1389	AGUAUGCA	GAUGAUCAA		78	1407	UUGACU	CAUCUUGCAU	UACU	545
AGUCAGACU	UAUUAACAGA		79	1407	AGUCAGACU	UAUUAACAGA		79	1425	UCUGUAU	GAGUUGCUGACU		546
AAAGAGAU	UAGUACUGAAG		80	1425	AAAGAGAU	UAGUACUGAAG		80	1443	CUUCAGU	ACUAUCUCU	UU	547
GAGCAGCU	AAGCGCCUJC		81	1443	GAGCAGCU	AAGCGCCUJC		81	1461	GCAGGCG	CUUAGCUGCUC		548
CAAGAGGA	AGCUUUGCA		82	1461	CAAGAGGA	AGCUUUGCA		82	1479	UGCAAAG	CUUCCUCUUG		549
AAAAUCUG	UAUGGAUAGAA		83	1479	AAAAUCUG	UAUGGAUAGAA		83	1497	UUCUAUCC	AUACAGAUUUU		550
AAUAUUGCU	AUCGUUUUUG		84	1497	AAUAUUGCU	AUCGUUUUUG		84	1515	CAAAAA	CGAUAGCAUUAU		551
GUUCCUUG	UGGACAUCUAG		85	1515	GUUCCUUG	UGGACAUCUAG		85	1533	CUAGAUG	UCCACAAGGAAC		552
GUACACUUG	UAACAUAUGUG		86	1533	GUACACUUG	UAACAUAUGUG		86	1551	CACAUUGU	UUACAAGUGAC		553
GCUGAAGC	AGUUGACAAGU		87	1551	GCUGAAGC	AGUUGACAAGU		87	1569	ACUUGU	CAACUGCUUCAGC		554
UGUCCCAUG	UGUACACAG		88	1569	UGUCCCAUG	UGUACACAG		88	1587	CUGUGU	AGCACAUGGGACA		555
GUCAUUAU	UUAAGCAAA		89	1587	GUCAUUAU	UUAAGCAAA		89	1605	UUUGCUU	GAAAGUAUAGAC		556
AAAAUUUU	AUGUCUUAU		90	1605	AAAAUUUU	AUGUCUUAU		90	1623	AUUAAG	ACAUAAAAUUUU		557
UCUAACUCU	AUAGUAGGCA		91	1623	UCUAACUCU	AUAGUAGGCA		91	1641	UGCCUA	CUAUAGAGU	UAGA	558
AUGUUUUGU	GUUCUUAU		92	1641	AUGUUUUGU	GUUCUUAU		92	1659	AAUAAGA	CAACAUAACAU		559
UACCCUGAU	UGAAUGUGUG		93	1659	UACCCUGAU	UGAAUGUGUG		93	1677	CACACAU	CAUACAGGGUA		560
GAUGUGAAC	UGACUUUAAG		94	1677	GAUGUGAAC	UGACUUUAAG		94	1695	CUUAAAG	UCAGUUCACAU	C	561

GUAAUCAGGAUUGAAUUC	95	1695	GUAAUCAGGAUUGAAUUC	95	1713	GGAAUUCAAUCCUGAUUAC	562
CAUUAGCAUUUUGCUACCAA	96	1713	CAUUAGCAUUUUGCUACCAA	96	1731	UUGGUAGCAAAUUGCUAAUUG	563
AGUAGGAAAAAAAUUGUAC	97	1731	AGUAGGAAAAAAAUUGUAC	97	1749	GUACAUUUUUUUUCCUACU	564
CAUGGCAGUGUUUUAGUUG	98	1749	CAUGGCAGUGUUUUAGUUG	98	1767	CAACUAAAAACACUGCCAUUG	565
GGCAUAUAUAUCUUUGAAU	99	1767	GGCAUAUAUAUCUUUGAAU	99	1785	AUUCAAAAGAUUAUAUUGCC	566
UUUCUUGAUUUUUCAGGGU	100	1785	UUUCUUGAUUUUUCAGGGU	100	1803	ACCCUGAAAAUUUUAAGAAA	567
UAUUAGCUGUAUAUCCAU	101	1803	UAUUAGCUGUAUAUCCAU	101	1821	AUGGAUAUAUACAGCUAAUA	568
UUUUUUUACUGUAUUUA	102	1821	UUUUUUUACUGUAUUUA	102	1839	UAAUAACAGUAAAAAA	569
AAUUGAAACCAUAGACUAA	103	1839	AAUUGAAACCAUAGACUAA	103	1857	UUAGUCUAUGGUUUUCAUU	570
AGAAUAAGAAGCAUCAUAC	104	1857	AGAAUAAGAAGCAUCAUAC	104	1875	GUAGUAGCUUCUUUAUUCU	571
CUAAACUGAACACAAUGU	105	1875	CUAAACUGAACACAAUGU	105	1893	ACAUUGUGUUCAGUUUAUG	572
UGUAUUCAUAGUAUACUGA	106	1893	UGUAUUCAUAGUAUACUGA	106	1911	UCAGUAUACUAUGAAUACA	573
AUUUAUUUCUAAGUGUAA	107	1911	AUUUAUUUCUAAGUGUAA	107	1929	UUACACUUAGAAAAUUAAU	574
AGUGAAUUAAUCAUCUGGA	108	1929	AGUGAAUUAAUCAUCUGGA	108	1947	UCCAGAUGAUUAAUUCACU	575
AUUUUUAUUUCUUUCAGA	109	1947	AUUUUUAUUUCUUUCAGA	109	1965	UCUGAAAAAGAAUAAAAAU	576
AUAGGCUUAACAAUUGGAG	110	1965	AUAGGCUUAACAAUUGGAG	110	1983	CUCCAUUUGUUUAAAGCCUUAU	577
GCUUUCUGUAUAUAAUUGU	111	1983	GCUUUCUGUAUAUAAUUGU	111	2001	ACAUUUUAUUAACAGAAAGC	578
UGGAGAUUAGAGUUAAUUCU	112	2001	UGGAGAUUAGAGUUAAUUCU	112	2019	AGAUUAACUCUAAUUCUCCA	579
UCCCCAAUCACAUAAUUG	113	2019	UCCCCAAUCACAUAAUUG	113	2037	CAAUUAUGUGAUUGGGGA	580
GUUUUGUGUGAAAAAGGAA	114	2037	GUUUUGUGUGAAAAAGGAA	114	2055	UUCUUUUUUCACACAAAAC	581
AUAAAUUGUCCAUUCUGG	115	2055	AUAAAUUGUCCAUUCUGG	115	2073	CCAGCAUGGGAACAAUUUAU	582
GUGGAAAGAUAGAGAUUGU	116	2073	GUGGAAAGAUAGAGAUUGU	116	2091	ACAUCUCUAUCUUUCCAC	583
UUUUUAGAGGUUGGUUGUU	117	2091	UUUUUAGAGGUUGGUUGUU	117	2109	AACAACCAACCUCUAAAA	584
UGUGUUUUAGGAUUCUGUC	118	2109	UGUGUUUUAGGAUUCUGUC	118	2127	GACAGAAUCCUAAAAACACA	585
CCAUUUUCUUUUAAAGUUA	119	2127	CCAUUUUCUUUUAAAGUUA	119	2145	UAACUUUAAAAAGAAAAUUG	586
AUAAACACGUAUUGUGCG	120	2145	AUAAACACGUAUUGUGCG	120	2163	CGCACAAAGUACGUGUUUAU	587
GAAUUAUUUUUUUAAAGUG	121	2163	GAAUUAUUUUUUUAAAGUG	121	2181	CACUUUAAAAAAAUAAUUC	588
GAUUUGCCAUUUUUUGAAAG	122	2181	GAUUUGCCAUUUUUUGAAAG	122	2199	CUUUCAAAAAUUGGCAAUUC	589
GCGUAUUUAAUGAUAGAAU	123	2199	GCGUAUUUAAUGAUAGAAU	123	2217	AUUCUAUCAUUAAAAUACGC	590
UACUAUCGAGCCCAACAUGU	124	2217	UACUAUCGAGCCCAACAUGU	124	2235	ACAUGUUGGCUCGUAUAGUA	591
UACUGACAUGGAAAGAUGU	125	2235	UACUGACAUGGAAAGAUGU	125	2253	ACAUCUUUCCAUUGUCAGUA	592
UCAAAGAUUAUGUUAAGUGU	126	2253	UCAAAGAUUAUGUUAAGUGU	126	2271	ACACUUAAACAUUUCUUUGA	593
UAAAAUGCAAGUGGCAAAA	127	2271	UAAAAUGCAAGUGGCAAAA	127	2289	UUUUGCCACUUGCAUUUUA	594
ACACUAUGUAUAGUCUGAG	128	2289	ACACUAUGUAUAGUCUGAG	128	2307	CUCAGACUAUACAUAGUGU	595

GCCAGAUCAAAGUAUGUAU	129	2307	GCCAGAUCAAAGUAUGUAU	129	2325	AUACAUACUUUGAUCUGGC	596
UGUUUUAAUAUGCAUAGA	130	2325	UGUUUUAAUAUGCAUAGA	130	2343	UCUAUGCAUUAUAAAAACA	597
AACAAAAGAUUUGGAAAGA	131	2343	AACAAAAGAUUUGGAAAGA	131	2361	UCUUUCCAAAUCUUUUUGUU	598
AUAUACACCAACUGUUA	132	2361	AUAUACACCAACUGUUA	132	2379	UUAACAGUUUGGUGUAUUA	599
AAUGUGGUUUCUCUUCGGG	133	2379	AAUGUGGUUUCUCUUCGGG	133	2397	CCCCGAAGAGAAAACCAUUA	600
GGAGGGGGGAUUGGGGA	134	2397	GGAGGGGGGAUUGGGGA	134	2415	UCCCCAAUCCCCCUCUC	601
AGGGGCCCCAGAGGGGUUU	135	2415	AGGGGCCCCAGAGGGGUUU	135	2433	AAACCCUCUCUGGGGCCCCU	602
UUUAAGGGGCCUUUUUCACU	136	2433	UUUAAGGGGCCUUUUUCACU	136	2451	AGUGAAAAGGCCCCUUAUAA	603
UUUCUACUUUUUUCAUUUU	137	2451	UUUCUACUUUUUUCAUUUU	137	2469	AAAAUGAAAAAGUAGAAA	604
UGUUCUGUUCGAAUUUUUU	138	2469	UGUUCUGUUCGAAUUUUUU	138	2487	AAAAAUUCGAACAGAAA	605
UAUAAGUAUAUAUAUUUU	139	2487	UAUAAGUAUAUAUAUUUU	139	2505	AAAGUAUAUAUAUAUAUA	606
UUUAUAUCAGAAUUUUUAG	140	2505	UUUAUAUCAGAAUUUUUAG	140	2523	CUAAAAUUUCUGAUUACAA	607
GAAAGUAUUUUGCUGAUUU	141	2523	GAAAGUAUUUUGCUGAUUU	141	2541	AAAUACAGCAAAAUACUUC	608
UAAAGGCUUAGGCAUGUUC	142	2541	UAAAGGCUUAGGCAUGUUC	142	2559	GAACAUGCCUAAGCCUUUA	609
CAAAAGCCUGCAAAACUAG	143	2559	CAAAAGCCUGCAAAACUAG	143	2577	GUAGUUUUUGCAGGCCUUUG	610
CUUAUCACUCAGCUUUUAGU	144	2577	CUUAUCACUCAGCUUUUAGU	144	2595	ACUAAAGCUGAGUGAUAG	611
UUUUUCUAAUCCAAGAGG	145	2595	UUUUUCUAAUCCAAGAGG	145	2613	CCUUCUUGGAUUUAGAAAA	612
GCAGGGCAGUUAACCUUUU	146	2613	GCAGGGCAGUUAACCUUUU	146	2631	AAAAGGUUAACUGCCUUG	613
UUGGUGCCAAUGUGAAUUG	147	2631	UUGGUGCCAAUGUGAAUUG	147	2649	CAUUUCACAUUUGGCACCAA	614
GUAAAUAGAUUUUAUGUUUU	148	2649	GUAAAUAGAUUUUAUGUUUU	148	2667	AAACAUAAAAUUAUUAUAC	615
UUCUGCCUUUGGGAUGAA	149	2667	UUCUGCCUUUGGGAUGAA	149	2685	UUCAUCCACAAAGCAGGAA	616
AAAAAUUUUCUGAGUGGUA	150	2685	AAAAAUUUUCUGAGUGGUA	150	2703	UACCACUCAGAAAAUUAUUU	617
AGUUUUUUGACAGGUAGAC	151	2703	AGUUUUUUGACAGGUAGAC	151	2721	GUUACCUUGUCAAACAAACU	618
CCAUGUCUUUAUCUUGUUUC	152	2721	CCAUGUCUUUAUCUUGUUUC	152	2739	GAAACAAGAUAAAGACAUGG	619
CAAAUAAGUAUUUCUGAU	153	2739	CAAAUAAGUAUUUCUGAU	153	2757	AUCAGAAAUACUUUUUUUG	620
UUUUUGUAAAAUGAAUAUA	154	2757	UUUUUGUAAAAUGAAUAUA	154	2775	UAUAUUUAUUUUUACAAAA	621
AAAAUUGUCUCAGAUUUU	155	2775	AAAAUUGUCUCAGAUUUU	155	2793	AAGAUUCUGAGACAUUUUU	622
UCCAAUUAAUUAAGUAAGGA	156	2793	UCCAAUUAAUUAAGUAAGGA	156	2811	UCCUUACUAAUUAAUUGGA	623
AUUCAUCCUUAAUCCUUGC	157	2811	AUUCAUCCUUAAUCCUUGC	157	2829	GCAAGGAUUAAAGGAUAAU	624
CUAGUUUAAGCCUGCCUAA	158	2829	CUAGUUUAAGCCUGCCUAA	158	2847	UUAGGCAGGCUUAAACUAG	625
AGUCACUUUAUUAAAGAU	159	2847	AGUCACUUUAUUAAAGAU	159	2865	AUCUUUUAGUAAAGUGACU	626
UCUUUGUUAAACUCAGUAUU	160	2865	UCUUUGUUAAACUCAGUAUU	160	2883	AAUACUGAGUUAAACAAAGA	627
UUUAAACAUUCUGUCAGCUU	161	2883	UUUAAACAUUCUGUCAGCUU	161	2901	AAGCUGACAGAUUUUUAAA	628
UAUGUAGGUAAAAAGUAGAA	162	2901	UAUGUAGGUAAAAAGUAGAA	162	2919	UUCUACUUUUUACCUACAUA	629

AGCAUGUUUUGUACACUGCU	163	2919	AGCAUGUUUUGUACACUGCU	163	2937	AGCAGUGUACAAACAUUGCU	630
UUGUAGUUUAUAGUGACAGC	164	2937	UUGUAGUUUAUAGUGACAGC	164	2955	GCUGUCACUUAACUACAA	631
CUUUCCAUGUUGAGAUUCU	165	2955	CUUUCCAUGUUGAGAUUCU	165	2973	AGAAUCUCAACAUUGGAAAG	632
UCAUAUCAUCUUGAUUCU	166	2973	UCAUAUCAUCUUGAUUCU	166	2991	AAGAUACAAGAUAGAUAGA	633
UAAAGUUUCAUGUGAGUUU	167	2991	UAAAGUUUCAUGUGAGUUU	167	3009	AAACUCACAUUGAAACUUUA	634
UUUACCGUUAAGGAUGAUUA	168	3009	UUUACCGUUAAGGAUGAUUA	168	3027	UAAUCAUCCUAACCGUAAA	635
AAGAUGUAUAUAGGACAAA	169	3027	AAGAUGUAUAUAGGACAAA	169	3045	UUUGUCCUUAUUAACAUUCU	636
AUGUUUAAGUCUUUCCUCU	170	3045	AUGUUUAAGUCUUUCCUCU	170	3063	AGAGGAAAGACUUUAACAU	637
UACCUACAUUUGUUUUCUU	171	3063	UACCUACAUUUGUUUUCUU	171	3081	AAGAAACAAAUUGUAGGUA	638
UGGCUAGUAUAUAGUAGUAG	172	3081	UGGCUAGUAUAUAGUAGUAG	172	3099	CUACUACUUAUUAUAGGCA	639
GAUACUUCUGAAUAAUAG	173	3099	GAUACUUCUGAAUAAUAG	173	3117	CAUUUAUUUCAGAGUAUC	640
GUUCUCUCAAGAUCCUUAA	174	3117	GUUCUCUCAAGAUCCUUAA	174	3135	UUAAGGAUCUUGAGAGAAC	641
AAACCUUCUUGGAAAUUAUA	175	3135	AAACCUUCUUGGAAAUUAUA	175	3153	UAUAUUUCCAAAGAGGUUU	642
AAAAAUUUUGGCAAGAAA	176	3153	AAAAAUUUUGGCAAGAAA	176	3171	UUUUCUUGGCCAAUAUUUU	643
AGAAGAAUAUGUUUUUAAA	177	3171	AGAAGAAUAUGUUUUUAAA	177	3189	UUUAAACAACUUAUUCUUCU	644
AUAUUUUUUAAAAACACU	178	3189	AUAUUUUUUAAAAACACU	178	3207	AGUGUUUUUUAAAAAUUAU	645
UUGAAUAAGAUAUCAGUAGG	179	3207	UUGAAUAAGAUAUCAGUAGG	179	3225	CCUACUGAUUCUUUAUUGAA	646
GGUAUAAACUAGAAGUUUA	180	3225	GGUAUAAACUAGAAGUUUA	180	3243	UAAACUUCUAGUUUAUACC	647
AAAAUUGCUUCAUAGAACG	181	3243	AAAAUUGCUUCAUAGAACG	181	3261	CGUUCUAUGAAGCAUJUUU	648
GUCCAGGGUUUACAUUACA	182	3261	GUCCAGGGUUUACAUUACA	182	3279	UGUAUUGUAAACCCUGGAC	649
AAGAUUCUCACAACAACCC	183	3279	AAGAUUCUCACAACAACCC	183	3297	GGUUUGUUGUGAGAAUCUU	650
CUAUUGUAGAGGUGAGUAA	184	3297	CUAUUGUAGAGGUGAGUAA	184	3315	UUACUCACCCUCUACAUAAG	651
AGGCAUGUUUACUACAGAGG	185	3315	AGGCAUGUUUACUACAGAGG	185	3333	CCUCUGUAGUAAACAUGCCU	652
GAAAGUUUGAGAGUAAAAAC	186	3333	GAAAGUUUGAGAGUAAAAAC	186	3351	GUUUUACUCUCAAACUUUC	653
CUGUAAAAAUUAUUAUUU	187	3351	CUGUAAAAAUUAUUAUUU	187	3369	AAAAUAUUUUUUUUAACAG	654
UUGUUUGUACUUUCUAAGAG	188	3369	UUGUUUGUACUUUCUAAGAG	188	3387	CUCUUAGAAAGUACAACAA	655
GAAAGAGUAUUUUAUGUU	189	3387	GAAAGAGUAUUUUAUGUU	189	3405	AACUAACAACUACUCUUUC	656
UCUCCUAACUUCUGUUGAU	190	3405	UCUCCUAACUUCUGUUGAU	190	3423	AUCAACAGAAAGUUGGAGA	657
UUACUACUUUAAGUGAUUA	191	3423	UUACUACUUUAAGUGAUUA	191	3441	AUAUGACUUAAAAAGUAGUA	658
UUCAUUUAAAACAUUGCAA	192	3441	UUCAUUUAAAACAUUGCAA	192	3459	UUGCAUUGUUUUUAAAAUGAA	659
AUUUUUUUUUAUUUAUUUA	193	3459	AUUUUUUUUUAUUUAUUUA	193	3477	UAAAAAUUAUUUAUUUUU	660
AUUUUUUUUUUUGAGUUGG	194	3477	AUUUUUUUUUUUGAGUUGG	194	3495	CCAUCUCAAAGAAAAUUU	661
GAGUCUUGCUUGUCACCCA	195	3495	GAGUCUUGCUUGUCACCCA	195	3513	UGGGUGACAAGCAAGACUC	662
AGGCUGGAGUGCAGUGGAG	196	3513	AGGCUGGAGUGCAGUGGAG	196	3531	CUCCACUGCACUCCAGCCU	663

GUGAUCUCUGCUCACUGCA	197	3531	GUGAUCUCUGCUCACUGCA	197	3549	UGCAGUGAGCAGAGAUAC	664
AACCCGCGCCUUCUGGGUU	198	3549	AACCCGCGCCUUCUGGGUU	198	3587	AACCCAGAGCGGGGUGU	665
UAGCGGCUUCUGGCGCU	199	3567	UCAGCGAUUCUGGUGCCU	199	3585	AGCCAGAGAUUCGCUUGA	666
UCAGCUUCCUGAGUAGCUG	200	3585	UCAGCUUCCUGAGUAGCUG	200	3603	CAGCUACUCAGGAAGCUGA	667
GGAUUACAGGCAGGUGCC	201	3603	GGAUUACAGGCAGGUGCC	201	3621	GGCACCUGCCUGUAUUCC	668
CACCAUGCCCGACUAUUU	202	3621	CACCAUGCCCGACUAUUU	202	3639	AAAUUAGUCGGCAUGGUG	669
UUUUUUUUUUUUUAGUAGA	203	3639	UUUUUUUUUUUUUAGUAGA	203	3657	UCUACUAAAAUAAAAAA	670
AGACGGGGUUUCACCAUGU	204	3657	AGACGGGGUUUCACCAUGU	204	3675	ACAUGGUGAAACCCCGUCU	671
UUGGCCAGGCGUGUAUCAA	205	3675	UUGGCCAGGCGUGUAUCAA	205	3693	UUUAUACCGCCUGGCCAA	672
AACUCCUGACCUCACAGAGA	206	3693	AACUCCUGACCUCACAGAGA	206	3711	UCUCUUUGAGGUCAGGAGUU	673
AUCCACUCGCGCUUGCCUC	207	3711	AUCCACUCGCGCUUGCCUC	207	3729	GAGGGCAAGGCGAGUGGAU	674
CCCAAAGUCUGGGAUUAC	208	3729	CCCAAAGUCUGGGAUUAC	208	3747	GUAAUCCAGCACUUUUGG	675
CAGGCUUGAGCCACCACGC	209	3747	CAGGCUUGAGCCACCACGC	209	3765	GCUGUGGUCUCAAGCCUG	676
CCCGGCUAAAAUUGCAA	210	3765	CCCGGCUAAAAUUGCAA	210	3783	UUGCAAUGUUUAGCCGGG	677
AAUUUAAUUGAGAGUUUA	211	3783	AAUUUAAUUGAGAGUUUA	211	3801	UAAAAUCUCAUUUAAAAU	678
AAAAUUAAAAUAGACUG	212	3801	AAAAUUAAAAUAGACUG	212	3819	CAGUCAUUUUUAAUUUUU	679
GCCCGUUUCUGUUUAGU	213	3819	GCCCGUUUCUGUUUAGU	213	3837	ACUAAAAACAGAAACAGGGC	680
UAUGUAAUCCUCAGUUCU	214	3837	UAUGUAAUCCUCAGUUCU	214	3855	AGAACUGAGGAUUUACAUA	681
UUCACCUUUGCACUGUCUG	215	3855	UUCACCUUUGCACUGUCUG	215	3873	CAGACAGUGCAAAGGUGAA	682
GCCACUUAGUUUGGUUAUA	216	3873	GCCACUUAGUUUGGUUAUA	216	3891	UAUAACCAACUAAGUGGC	683
AUAGUCAUUAAACUUGAAU	217	3891	AUAGUCAUUAAACUUGAAU	217	3909	AAUUCAGUUAAUUGACUUA	684
UUGGUCUGUAUAGUCUAGA	218	3909	UUGGUCUGUAUAGUCUAGA	218	3927	UCUAGACUAUACAGACCAA	685
ACUUUAAAAUUAAAGUUUU	219	3927	ACUUUAAAAUUAAAGUUUU	219	3945	AAAAUUUUAAAAUUAAGU	686
UCUACAAGGGAGAAAAAGU	220	3945	UCUACAAGGGAGAAAAAGU	220	3963	ACUUUUCUCCCCUUGUAGA	687
UGUUAAAAUUUUAAAAUA	221	3963	UGUUAAAAUUUUAAAAUA	221	3981	UAUUUUAAAAUUUUUAAACA	688
AUGUUUCCAGGACACUUC	222	3981	AUGUUUCCAGGACACUUC	222	3999	GAAUGUGCCUGGAAAAACAU	689
CACUCCCAAGUCAGGUAGG	223	3999	CACUCCCAAGUCAGGUAGG	223	4017	CCUACCCUGACUUGGAAGUG	690
GUAGUCAAUCUAGUUGUU	224	4017	GUAGUCAAUCUAGUUGUU	224	4035	AACAACUAGAUUGAACUAC	691
UAGCCAAGGACUCAAGGAC	225	4035	UAGCCAAGGACUCAAGGAC	225	4053	GUCCUUGAGUCCUUGGCUA	692
CUGAAUUUUUUUAACAUAA	226	4053	CUGAAUUUUUUUAACAUAA	226	4071	UUUAUGUUAAAAACAUAUCAG	693
AGGCUUUUCCUGUUCUGGG	227	4071	AGGCUUUUCCUGUUCUGGG	227	4089	CCCAGAACAGGAAAAAGCCU	694
GAGCCGCACUUCAUUAAAA	228	4089	GAGCCGCACUUCAUUAAAA	228	4107	UUUUUUAUGAAGUGCGGCUC	695
AUUCUUCUAAAAACUUGUUA	229	4107	AUUCUUCUAAAAACUUGUUA	229	4125	AUACAAGUUUUUAGAGAAU	696
UGUUUAGAGUUUAAAGCAAGA	230	4125	UGUUUAGAGUUUAAAGCAAGA	230	4143	UCUUGCUUAAACUCUAAACA	697





GUUUUUGAUUUUUUUUA	265	4755	GUUUUUGAUUUUUUUUA	265	4773	UACAAAAUUAUUAUAC	732
AUUUUUGUUUUUAUUUA	266	4773	AUUUUUGUUUUUAUUUA	266	4791	AUAAUUAACAACAAAAAU	733
UUUACAUUUCAGUAGUUG	267	4791	UUUACAUUUCAGUAGUUG	267	4809	ACAACUACUGAAAUUGUAAA	734
UUUUUUGUGUUUCCAUUU	268	4809	UUUUUUGUGUUUCCAUUU	268	4827	AAAAUGGAAACACAAAAA	735
UAGUGGAUAAAAUUUGUAU	269	4827	UAGUGGAUAAAAUUUGUAU	269	4845	AUACAAUUUUUAUCCACUA	736
UUUUGAACUAUAGAUUGGAG	270	4845	UUUUGAACUAUAGAUUGGAG	270	4863	CUCCAUUAUAGUUAUAAAA	737
GACUACCGCCCGCAUUA	271	4863	GACUACCGCCCGCAUUA	271	4881	UAUUGCUGGGCGGUAGUC	738
AGUUUCACAUAGUAUACCC	272	4881	AGUUUCACAUAGUAUACCC	272	4899	GGGUUAUUAUGUGAAAAAU	739
CUUUAAACCGGAUUAUUG	273	4899	CUUUAAACCGGAUUAUUG	273	4917	CAUUGAUUUCGGUUUUAAG	740
GUUUUAUUUCCUGAUUACA	274	4917	GUUUUAUUUCCUGAUUACA	274	4935	UGUAAUUCAGGAAUUAUAAAC	741
ACAGGUGUUGAAUUGGGAA	275	4935	ACAGGUGUUGAAUUGGGAA	275	4953	UUCGCCAUUAACACCCUGU	742
AAGGGCUAGUAUAUCAGU	276	4953	AAGGGCUAGUAUAUCAGU	276	4971	ACUGAUUAUACUAGCCCCUU	743
UAGGAUAUAUUGGGAUG	277	4971	UAGGAUAUAUUGGGAUG	277	4989	CAUCCCAUAGUAUAUCCUA	744
GUUAUAUAUAUUGCUGU	278	4989	GUUAUAUAUAUUGCUGU	278	5007	ACAGCAUAGUAUAUUAUAC	745
UUAGAGAAAUAGAAUAAAA	279	5007	UUAGAGAAAUAGAAUAAAA	279	5025	UUUUUUUAUUAUUCUCUAA	746
AUGGGCUGGGCUCAGUGG	280	5025	AUGGGCUGGGCUCAGUGG	280	5043	CCACUGAGCCCGCCCAU	747
GCUCACGCCUGUAAUCCCA	281	5043	GCUCACGCCUGUAAUCCCA	281	5061	UGGGAUUAACAGCGGUGAGC	748
AGCACUUUGGAGGCUGAG	282	5061	AGCACUUUGGAGGCUGAG	282	5079	CUCAGCCUCCCAAGUGCU	749
GGCAGGUGGAUCACGAGGU	283	5079	GGCAGGUGGAUCACGAGGU	283	5097	ACCUCGUAUCCACCUGCC	750
UCAGGAGAUCCAGACCAUC	284	5097	UCAGGAGAUCCAGACCAUC	284	5115	GAUGGUCUCGAUUCUCCUGA	751
CCUGGCUAACACGGUGAAA	285	5115	CCUGGCUAACACGGUGAAA	285	5133	UUUCACCGUGUUAGCCAGG	752
ACCCCGUCUCUACUAAAA	286	5133	ACCCCGUCUCUACUAAAA	286	5151	UUUUUAGUAGAGAGCGGGU	753
AACAGAAAAUUAGCCGGC	287	5151	AACAGAAAAUUAGCCGGC	287	5169	GCCCGCUAAUUUUUGUUU	754
CGUGGUGGGCGGCCUGU	288	5169	CGUGGUGGGCGGCCUGU	288	5187	ACAGCGCCCGCCACCACG	755
UAGUCCCGAGCUACUGGGA	289	5187	UAGUCCCGAGCUACUGGGA	289	5205	UCCCGAGUAGCUGGGACUA	756
AGGCUAGGCGAGGAGAUUG	290	5205	AGGCUAGGCGAGGAGAUUG	290	5223	CAUUCUCCUGCCUACAGCCU	757
GGUGUAGACCCGGGAGGCA	291	5223	GGUGUAGACCCGGGAGGCA	291	5241	UGCCUCCCGGGUUCACACC	758
AGAGCUUGCAGUAGGCCGA	292	5241	AGAGCUUGCAGUAGGCCGA	292	5259	UCGGCUACUCGCAAGCUCU	759
AGAUCUCGCCACUGCACUC	293	5259	AGAUCUCGCCACUGCACUC	293	5277	GAGUGCAGUGGCGGAGUCU	760
CCAGCCUGGGCAACAGAGC	294	5277	CCAGCCUGGGCAACAGAGC	294	5295	GCUCUGUUGCCCGGCGUGG	761
CAAGACUCUGUCUAAAAA	295	5295	CAAGACUCUGUCUAAAAA	295	5313	UUUUUGAGACAGAGUCUUG	762
AAAAAUAUAUAUAUAUAUA	296	5313	AAAAAUAUAUAUAUAUAUA	296	5331	UUUUUUUUUUUUUUUUUUU	763
AGAAAUUGGGAAGCAUAU	297	5331	AGAAAUUGGGAAGCAUAU	297	5349	AUAUUGCUUCCCAUUAUUCU	764
UUUGACAUAGUUUUUUUA	298	5349	UUUGACAUAGUUUUUUUA	298	5367	UAAAAAGAAUAUUGUAAAA	765



AGUCAAUUCUACUUGUAA	299	5367	AGUCAAUUCUACUUGUAA	299	5385	UUAACAAAGUAGAUUGACU	766
AAAAAGGGUAGCAGUUA	300	5385	AAAAAGGGUAGCAGUUA	300	5403	UAAACUGCUACCCUUIUUU	767
AUUCUUCUGUAGAAAGAA	301	5403	AUUCUUCUGUAGAAAGAA	301	5421	UUUCUUUUCACAGAUAU	768
AAUAAUACUUAUCUUA	302	5421	AAUAAUACUUAUCUUA	302	5439	UUUAAGAUAAAGUAUUAU	769
AGGUUGCAAGCUCUAGG	303	5439	AGGUUGCAAGCUCUAGG	303	5457	CCUUGAGCUCUUGCAACCU	770
GAGACCAUGUAUGUAAAGU	304	5457	GAGACCAUGUAUGUAAAGU	304	5475	ACUUUACAUACAUGGUCUC	771
UUCUUGCUGUAAAUAGAA	305	5475	UUCUUGCUGUAAAUAGAA	305	5493	UUCAUUAUUUACAGCAGAA	772
ACUCCCAUCCUAAUACCCU	306	5493	ACUCCCAUCCUAAUACCCU	306	5511	AGGUUAUUAGGAUGGGAGU	773
UUUUAACUCUCUGUGGGUU	307	5511	UUUUAACUCUCUGUGGGUU	307	5529	AACCCACAGAGAGGUAAAA	774
UUGUCUUUGACCUUGGAAUU	308	5529	UUGUCUUUGACCUUGGAAUU	308	5547	AAUUUCCAGGUCUAGGACAA	775
UUGGGCUAAAACUUAAGAA	309	5547	UUGGGCUAAAACUUAAGAA	309	5565	UUUCUAAUUUUAGCCCAA	776
AAAUUCUUAACUUAUAAAC	310	5565	AAAUUCUUAACUUAUAAAC	310	5583	GUUAUAGUUAAGAAUUAU	777
CUCAGUUAUCUUAUCUUA	311	5583	CUCAGUUAUCUUAUCUUA	311	5601	AUGAGUAAGCAUCACUGAG	778
UAGUUUUUGGUGUUUCUCA	312	5601	UAGUUUUUGGUGUUUCUCA	312	5619	UGAGAAACACCAAAAACUA	779
AUAGAUAAAGAUUAAAUCA	313	5619	AUAGAUAAAGAUUAAAUCA	313	5637	UGAUUUUAUUCUUAUCUUA	780
AGCUGGGCGCGGUGGCUCA	314	5637	AGCUGGGCGCGGUGGCUCA	314	5655	UGAGCCACCGCGCCCGAGCU	781
AUGCCUGUAAUCCAGCAC	315	5655	AUGCCUGUAAUCCAGCAC	315	5673	GUGCUGGGAUUACAGGCAU	782
CUUUGGAGGCGGAGGCGG	316	5673	CUUUGGAGGCGGAGGCGG	316	5691	CCGCCUCGGCCUCCCAAAG	783
GGCAGUACACCUAGGUGCG	317	5691	GGCAGUACACCUAGGUGCG	317	5709	CGACCUACAGGUGAUCUGCC	784
GGGAGGUCGAGACCGCCU	318	5709	GGGAGGUCGAGACCGCCU	318	5727	AGGCUUGUCUGACCCUCCC	785
UGACCAACAUUGGAGAAACC	319	5727	UGACCAACAUUGGAGAAACC	319	5745	GGUUUCUCCAUUGUUGGUCA	786
CCCGUCUCUACUAAAAUA	320	5745	CCCGUCUCUACUAAAAUA	320	5763	UAUUUUUAGUAGAGACGGG	787
ACAAAUUUAGCUGGGCGUG	321	5763	ACAAAUUUAGCUGGGCGUG	321	5781	CACGCCCAGCUAAUUUUUG	788
GGUGGCUCAUGCCUGUAAU	322	5781	GGUGGCUCAUGCCUGUAAU	322	5799	AUUACAGGCAUGAGCCACC	789
UCCAGCUACUUGGGAGGC	323	5799	UCCAGCUACUUGGGAGGC	323	5817	GCCUCCCAAGUAGUGGGA	790
CUGAGGCGAGAGAUCCGU	324	5817	CUGAGGCGAGAGAUCCGU	324	5835	AGCGAUUCUCCUGCCUCAG	791
UUGAACCCAGGAGCGCGAG	325	5835	UUGAACCCAGGAGCGCGAG	325	5853	CUCCGCCUCCUGGGUUCAA	792
GGUUGUGGUGAGCGAAGAU	326	5853	GGUUGUGGUGAGCGAAGAU	326	5871	AUCUUCGCUCACCACAACC	793
UCGUGCCAUUGCACUCCAG	327	5871	UCGUGCCAUUGCACUCCAG	327	5889	CUGGAGUGCAUUGGCACGA	794
GCCUGGGCAACAAGAGCAA	328	5889	GCCUGGGCAACAAGAGCAA	328	5907	UUGCUCUUGUUGCCCGGC	795
AAACUCUGUCUCAAAAAA	329	5907	AAACUCUGUCUCAAAAAA	329	5925	UUUUUUUGAGACAGAUUU	796
AAAAAAGAUUAAAUAC	330	5925	AAAAAAGAUUAAAUAC	330	5943	GUGAUUUUAUUCUUUUUU	797
CAUUAUUAAUAGGUCAA	331	5943	CAUUAUUAAUAGGUCAA	331	5961	UUAGCCUUAUUUAUUUAUG	798
AUACAAUUGUAGCCAGGC	332	5961	AUACAAUUGUAGCCAGGC	332	5979	GCCUGGCUAACAUIUUGUJU	799

CGUGGUGGCACAUGCCCAU	333	5979	CGUGGUGGCACAUGCCCAU	333	5997	AUGGGAGUGGCCACCACG	800
UAGUCGACGCUACUCUGGA	334	5997	UAGUCGACGCUACUCUGGA	334	6015	UCCAGAGUAGCUGCGACUA	801
AGGCAGAGGCAGGAGGAUC	335	6015	AGGCAGAGGCAGGAGGAUC	335	6033	GAUCCUCCUGCCUCUGCCU	802
CACUUGAGCCCAUGAAUUA	336	6033	CACUUGAGCCCAUGAAUUA	336	6051	AAAUUCAUGGGCUCAGUG	803
UGAGGCAGCAGUGAGCUAU	337	6051	UGAGGCAGCAGUGAGCUAU	337	6069	AUAGCUCACUGCUGCCUCA	804
UGAUUGUGCCACUGUACUC	338	6069	UGAUUGUGCCACUGUACUC	338	6087	GAGUACAGUGGCACAAUCA	805
CCAGUCUGGGUGACAGAGU	339	6087	CCAGUCUGGGUGACAGAGU	339	6105	ACUCUGACCCAGACUGG	806
UGAGAGCCCAUCUCUAAAU	340	6105	UGAGAGCCCAUCUCUAAAU	340	6123	AUUUAGAGAUUGGGUCUCA	807
UAAUAGGUCAAAACCCUUA	341	6123	UAAUAGGUCAAAACCCUUA	341	6141	UAAAGGUUUUAGCCUUAUUA	808
AAAAUUAUUAAAAUUCUUA	342	6141	AAAAUUAUUAAAAUUCUUA	342	6159	UAAGAAUUUAAAUUUUUUU	809
AAAAAUUUGAAAAGAUUAU	343	6159	AAAAAUUUGAAAAGAUUAU	343	6177	AUAAUCUUUUCAAUUUUUU	810
UUUCUUCUCAAUUUAGUUG	344	6177	UUUCUUCUCAAUUUAGUUG	344	6195	CAACUAAUUUUGAGAAAGAA	811
GAGCUUUUUAAGAGAAGCA	345	6195	GAGCUUUUUAAGAGAAGCA	345	6213	UGCUUCUCUUUAGAAAGCUC	812
AAUUGGCUUUUJCCCAUUA	346	6213	AAUUGGCUUUUJCCCAUUA	346	6231	AAGUGGGAUAAAGCCAAUU	813
UCAAUAUCAUUUUCAGUU	347	6231	UCAAUAUCAUUUUCAGUU	347	6249	AACUGAAAUGAUUUAUUGA	814
UUGACUCAUACAGUUAAACA	348	6249	UUGACUCAUACAGUUAAACA	348	6267	UGUUAACUGUAUGAGUCAAA	815
ACAAUGUGAAUUUUCUCCU	349	6267	ACAAUGUGAAUUUUCUCCU	349	6285	AGGAAGAAUUCACAUUGU	816
UCAGCAUAACAGAGUUUAUA	350	6285	UCAGCAUAACAGAGUUUAUA	350	6303	UAUAACUCUGUUUAUGCUGA	817
AGAAUGACAGGGCUGGAAG	351	6303	AGAAUGACAGGGCUGGAAG	351	6321	CUUCCAGCCUCUGCAUUCU	818
GUGACCUUAGAGAGUAUCC	352	6321	GUGACCUUAGAGAGUAUCC	352	6339	GGAUACUCUCUAAGGUCAC	819
CAGUUCUUUCAUUUACAG	353	6339	CAGUUCUUUCAUUUACAG	353	6357	CUGUAAAAUGAAAGAACUG	820
GGUGAGGCAACUGAGACUC	354	6357	GGUGAGGCAACUGAGACUC	354	6375	GAGUCUCAGUUUGCCUCACC	821
CAAAGGUGAUGUAUUUUGU	355	6375	CAAAGGUGAUGUAUUUUGU	355	6393	ACAAUUUACAUCACCUIUG	822
UGCAAAGAUUAUAGCUAAU	356	6393	UGCAAAGAUUAUAGCUAAU	356	6411	AUUAGCUAUAUUCUUUGCA	823
UUAGUAGCAGAGCCUGAC	357	6411	UUAGUAGCAGAGCCUGAC	357	6429	GUCAGGGCUCUGCUACUAA	824
CUGGGACAUAGUUUGAAGG	358	6429	CUGGGACAUAGUUUGAAGG	358	6447	CCUUCAAACUAUGUCCACG	825
GUGAAAAACUUCACCAAGC	359	6447	GUGAAAAACUUCACCAAGC	359	6465	GCUUGGUGAAGUUUUUCAC	826
CUACCUUUCUUGAAAGGUC	360	6465	CUACCUUUCUUGAAAGGUC	360	6483	GACCUUUCAGAAAGGUGAG	827
CCAAUUGUUUAUGUUUUA	361	6483	CCAAUUGUUUAUGUUUUA	361	6501	UGAAAACAUAAACAUUUUG	828
AACUACUCUUUCCACUGUA	362	6501	AACUACUCUUUCCACUGUA	362	6519	UACAGUGGAAAGAGUAGUU	829
ACCAUAACUUUACACUACAU	363	6519	ACCAUAACUUUACACUACAU	363	6537	AUGUAGUGAAAGUUAUGGU	830
UAUUAAUUGACACUUUAUA	364	6537	UAUUAAUUGACACUUUAUA	364	6555	UAUAAAGUGUCAUUAUAAUA	831
AACUAAUUAUUAAGGACAA	365	6555	AACUAAUUAUUAAGGACAA	365	6573	UUGUCCUUAUUAUUAUAGUU	832
AUCAUCAUUGCAUAUAUAG	366	6573	AUCAUCAUUGCAUAUAUAG	366	6591	CUAUAUAUGCAUUAUGAU	833

GCCAGCCCUCAUAUCUGU	367	6591	GCCAGCCCUCAUAUCUGU	367	6609	ACAGAUAGAAGGGCUGGC	834
UGGUUUUGCAUCCUGGA	368	6609	UGGUUUUGCAUCCUGGA	368	6627	UCCAUUGGAUCAAACCCA	835
AUUAACCAAGGAGAAUU	369	6627	AUUAACCAAGGAGAAUU	369	6645	AUUCCUCCUUGGUUGAAU	836
UUAACACUGAGAAAAA	370	6645	UUAACACUGAGAAAAA	370	6663	UUUUUCUCAGGUUUUCA	837
AAAAAAGACCACAAUA	371	6663	AAAAAAGACCACAAUA	371	6681	UAUUUGUGGUCUUUUUUU	838
AAAAAUAUUUAUAAAA	372	6681	AAAAAUAUUUAUAAAA	372	6699	UUUUGAUUUUUUUUUUUU	839
AUAUAACAAAGAAAAAGCC	373	6699	AUAUAACAAAGAAAAAGCC	373	6717	GGCUUUUCUUUUGAUUAU	840
CAAAUUGUCAUACUGUUG	374	6717	CAAAUUGUCAUACUGUUG	374	6735	CAACAGUAUGACAAUUUG	841
GUUAAGCAACAGUAUACA	375	6735	GUUAAGCAACAGUAUACA	375	6753	UGUUAUACUGUUGCUUAA	842
AACUAUUUAUAGCAUUA	376	6753	AACUAUUUAUAGCAUUA	376	6771	UAAUGCUAUGUAAAUAU	843
AAGGUUGGUGCAAAAUUGC	377	6771	AAGGUUGGUGCAAAAUUGC	377	6789	GCAUUUUUGCACCAACCUU	844
CAAAAAAUAUUUAAGCAAU	378	6789	CAAAAAAUAUUUAAGCAAU	378	6807	AUUGCUUUUUUUUUUUUG	845
UUUUUUUAUAAACCAACCUA	379	6807	UUUUUUUAUAAACCAACCUA	379	6825	UAGGUUGGUUUAAAAUAA	846
AUAUAUUUGUAUAGGUUAU	380	6825	AUAUAUUUGUAUAGGUUAU	380	6843	AUACCUAAUAUAAUAUUA	847
UUAAAGUCAUCUGGACAUG	381	6843	UUAAAGUCAUCUGGACAUG	381	6861	CAUGUCCAGAUAGACUUUAA	848
GAUUAAAGUAUUAUGAUGC	382	6861	GAUUAAAGUAUUAUGAUGC	382	6879	GCAUCAUAUACUUUAAUUC	849
CCAGCCUGGACAAAAAGGCA	383	6879	CCAGCCUGGACAAAAAGGCA	383	6897	UGCCUUUUUGUCCAGGCUGG	850
AAACCCUGUCUUAUACAAA	384	6897	AAACCCUGUCUUAUACAAA	384	6915	UUUGUAAGAGACAGGGUUUU	851
AAAUACAAAAUUUAGCUG	385	6915	AAAUACAAAAUUUAGCUG	385	6933	CAGCUAAUUUUUGUAUUUU	852
GGGCAUGGUGUGUGUGCC	386	6933	GGGCAUGGUGUGUGUGCC	386	6951	GGCACACACCACCAUGCCC	853
CUGUAGUCCUGGCUACUCC	387	6951	CUGUAGUCCUGGCUACUCC	387	6969	GGAGUAGCCAGGACUACAG	854
CGGAGCCUGAGGUGGGAGG	388	6969	CGGAGCCUGAGGUGGGAGG	388	6987	CCUCCACCUCAGGCUCCG	855
GAUCGUUAGAGUCUGGGAG	389	6987	GAUCGUUAGAGUCUGGGAG	389	7005	CUCCACAGACUACGCGAUC	856
GGCAGAGGCGCAUUGAGC	390	7005	GGCAGAGGCGCAUUGAGC	390	7023	GCUCAAUGCAGCCUCUGCC	857
CUAUGAUCAUGGCACUGCA	391	7023	CUAUGAUCAUGGCACUGCA	391	7041	UGCAGUGCCAUUGAUCAUAG	858
AUUCAGCCUGGGUGACAG	392	7041	AUUCAGCCUGGGUGACAG	392	7059	CUGUACCCAGGCUGGGAU	859
GUGCAAGACCUUGUCUCAG	393	7059	GUGCAAGACCUUGUCUCAG	393	7077	CUGAGACAAGGUCUUGCAC	860
GAUUAUUAAAGUAUUGA	394	7077	GAUUAUUAAAGUAUUGA	394	7095	UCACAUACUUUUUUUAUUC	861
AUGAAGAUUGCAUACAUU	395	7095	AUGAAGAUUGCAUACAUU	395	7113	AUUGUAUGCACAUUUCAU	862
UAUAUGCAAAUACUGUUUU	396	7113	UAUAUGCAAAUACUGUUUU	396	7131	AAAAAGUAUUUGCAUUA	863
UUUUUUUUUUAAUUJAAA	397	7131	UUUUUUUUUUAAUUJAAA	397	7149	UUUAAAAUUAAAAAUA	864
ACAGUCUCACUGUGUUGCC	398	7149	ACAGUCUCACUGUGUUGCC	398	7167	GGCAACACAGUGAGACUGU	865
CCAGGAUGGAGUGCAUUGG	399	7167	CCAGGAUGGAGUGCAUUGG	399	7185	CCAUUGCACUCCAUCCUGG	866
GCACAAUCUUGGCUCAUUGG	400	7185	GCACAAUCUUGGCUCAUUGG	400	7203	CCAUGAGCCAAGAUUGUGC	867

GCAACUCUCUGCCUCGCAAG	401	7203	GCAACUCUCUGCCUCGCAAG	401	7221	CUUGCGAGGCAGUUUUGC	888
GCAGCUGGGACUACAGGCA	402	7221	GCAGCUGGGACUACAGGCA	402	7239	UGCCUGUAGUCCACGCGC	889
AUGCUCACGGUGCCCGAGU	403	7239	AUGCUCACGGUGCCCGAGU	403	7257	ACUGGGCACCUGGAGCAU	870
UUAUUUUUUUGUUAUUCU	404	7257	UUAUUUUUUUGUUAUUCU	404	7275	AGAAUACAAAAAAAUAA	871
UUAGUAGAGACAGGGUUUC	405	7275	UUAGUAGAGACAGGGUUUC	405	7293	GAACCCUGUCUCUACUAA	872
CACCAUUUGGCCAGGCUA	406	7293	CACCAUUUGGCCAGGCUA	406	7311	UAGCCUGGCCAACAUUGG	873
AGUCUUAAUUUCUGACCU	407	7311	AGUCUUAAUUUCUGACCU	407	7329	AGGUCAGAAUUUCAAGACU	874
UCAAGUGAUUCAUCUCCCA	408	7329	UCAAGUGAUUCAUCUCCCA	408	7347	UGGGAGAUAAUCACUUGA	875
AAAGUCUGGGAUUACAGG	409	7347	AAAGUCUGGGAUUACAGG	409	7365	CCUGAAUCCCGACACUUU	876
GCGUGAGCCACCACGGCGG	410	7365	GCGUGAGCCACCACGGCGG	410	7383	CGGCCGUGGUGGCUACGCG	877
GGCUAAUUUUUGUUAUUUU	411	7383	GGCUAAUUUUUGUUAUUUU	411	7401	AAAAUACAAAAAUUAGCC	878
UUAGUAGUGACUGGUUUCG	412	7401	UUAGUAGUGACUGGUUUCG	412	7419	CGAAACCAGUCACUACUAA	879
GCGGUGUUGACCGGCGUGG	413	7419	GCGGUGUUGACCGGCGUGG	413	7437	CCAGCCUGGUCAACACCGC	880
GUCUCGAACUCCUGAUCUC	414	7437	GUCUCGAACUCCUGAUCUC	414	7455	GAGAUACAGGAGUUCGAGAC	881
CAGGUGAUCUGCCUGCCUC	415	7455	CAGGUGAUCUGCCUGCCUC	415	7473	GAGGCAGGCAGAUACCCUG	882
CGGCCUCACAAAGUGCUGG	416	7473	CGGCCUCACAAAGUGCUGG	416	7491	CCAGCACUUUGAGGGCGG	883
GGAUUACAGGUGUGAACCA	417	7491	GGAUUACAGGUGUGAACCA	417	7509	UGGUUACACCUGUAAUCC	884
ACUGCUCGCGGCGCUUGUGU	418	7509	ACUGCUCGCGGCGCUUGUGU	418	7527	ACACAAGCGCGGAGCAGU	885
UGAUUUUAUCUAAAGGACU	419	7527	UGAUUUUAUCUAAAGGACU	419	7545	AGUCCCUUAGAUAAAAUCA	886
UUAAGCGUCCUCAGGUCCU	420	7545	UUAAGCGUCCUCAGGUCCU	420	7563	AGGACCUGAGGACGCUUAA	887
UAGGGGUGUCUGAAACCAA	421	7563	UAGGGGUGUCUGAAACCAA	421	7581	UUUGUUUACACGACCCCCUA	888
AAACCCAGGGAUAGCAAG	422	7581	AAACCCAGGGAUAGCAAG	422	7599	CUUGCUAUCCUUGGGUUU	889
GGGACAAUUUGUAUCUCAA	423	7599	GGGACAAUUUGUAUCUCAA	423	7617	UUGAAGAUACAAUUGUCC	890
AAGUAGACAAUUGGCGCG	424	7617	AAGUAGACAAUUGGCGCG	424	7635	CGGCGCAUUUUGUCUACUU	891
GGGCACGGUGGCUACGCGC	425	7635	GGGCACGGUGGCUACGCGC	425	7653	GGCGUGAGCCACCGUGCCC	892
CUGUAAUCCAGCAGUUAUC	426	7653	CUGUAAUCCAGCAGUUAUC	426	7671	GAAACUGCUGGGAUUACAG	893
CCGAGGCGAGGCAGGCGG	427	7671	CCGAGGCGAGGCAGGCGG	427	7689	CCGCCUGCCUCAGCCUCGG	894
GCUCACCCUGAGGUCAGGAG	428	7689	GCUCACCCUGAGGUCAGGAG	428	7707	CUCCUGACCUACGGUGAGC	895
GUUGGAGACAGCCUGGCC	429	7707	GUUGGAGACAGCCUGGCC	429	7725	GGCAGGCGUGGUCUCCAAC	896
CAACAUGCUGAAACCCUGU	430	7725	CAACAUGCUGAAACCCUGU	430	7743	ACAGGGUUCAGCAUGUUG	897
UCUGUACAAAAAUACAAAA	431	7743	UCUGUACAAAAAUACAAAA	431	7761	UUUUGUAUUUUUGUACAGA	898
AAUAGCUGGGCAUGGUGGC	432	7761	AAUAGCUGGGCAUGGUGGC	432	7779	GCCACCAUGCCCGAGCUUU	899
CGCAUGCCUGUAGUCCCG	433	7779	CGCAUGCCUGUAGUCCCG	433	7797	CUGGGACUACAGGCAUGCG	900
GCUACUAGAGCGACUGAGG	434	7797	GCUACUAGAGCGACUGAGG	434	7815	CCUCAGUCGCUUAGUAGC	901

GCAGGAGAAUUGCUUGAAC	435	7815	GCAGGAGAAUUGCUUGAAC	435	7833	GUUCAAAGCAUUCUCCUGC	902
CCUUGGAGGCGGAGGUUGC	436	7833	CCUUGGAGGCGGAGGUUGC	436	7851	GCAACCUCCGCCUCCCGG	903
CAGGAGCCAAAGAUGGCGC	437	7851	CAGGAGCCAAAGAUGGCGC	437	7889	GCGCAUCUUGGCUCCCGC	904
CCACCGCACUCCAGCCUAG	438	7869	CCACCGCACUCCAGCCUAG	438	7887	CUAGGCGGAGGCGCGGUGG	905
GGUGAUAGAGUGAGACUCG	439	7887	GGUGAUAGAGUGAGACUCG	439	7905	GGAGUCUCACUCUAUCACC	906
CCUCUCAAAAACAAAACAA	440	7905	CCUCUCAAAAACAAAACAA	440	7923	UUGUUUUGUUUUUGAGAGG	907
AAACAAAAAUUAGACAA	441	7923	AAACAAAAAUUAGACAA	441	7941	UUGUCUAAUUUUUUUGUUU	908
AUUCUACAUAAUGUUUG	442	7941	AUUCUACAUAAUGUUUG	442	7959	CAACAUAUUAUGUAGCAUU	909
GGUGGUCAGAUUCUACUU	443	7959	GGUGGUCAGAUUCUACUU	443	7977	AAGUAGAUUCUGACCACCC	910
UUGAAUCUGAAGUUUGCAG	444	7977	UUGAAUCUGAAGUUUGCAG	444	7995	CUGCAAACUUUCAGAUUCA	911
GAUUGCCUAUAGAUUUUU	445	7995	GAUUGCCUAUAGAUUUUU	445	8013	AAAAUCUUAUAGGCAUAUC	912
UGGAGUUUACCCAUUUUCUU	446	8013	UGGAGUUUACCCAUUUUCUU	446	8031	AAGAAAUGGUAACCUCCA	913
UAUUCUGUAUCAAUAUGU	447	8031	UAUUCUGUAUCAAUAUGU	447	8049	ACAUAUAUAGUAAGAAUA	914
UAUAUUUUUAAAUUACUUA	448	8049	UAUAUUUUUAAAUUACUUA	448	8067	AUAGUAUUUUAAAAUAUUA	915
UAUAUGUUUACCAUJUUCU	449	8067	UAUAUGUUUACCAUJUUCU	449	8085	AGAAAAUUGGUAACAUAUA	916
UGGAUUUAGUAAGAAAUUU	450	8085	UGGAUUUAGUAAGAAAUUU	450	8103	AAAUUUUCUUAUAAAAUCCA	917
UGCAGUUUUUGUUUGAUGU	451	8103	UGCAGUUUUUGUUUGAUGU	451	8121	ACAUCAAAACCAAAACUGCA	918
UAACAAGGGUUUUUAUGUA	452	8121	UAACAAGGGUUUUUAUGUA	452	8139	UACAUUAAAAACCCUUUGUUA	919
AAUUUAUGUUAGAUUUUGC	453	8139	AAUUUAUGUUAGAUUUUGC	453	8157	GCAAAAUCUAACAUAUAAU	920
CAUUUUUUUUAUUAUGUU	454	8157	CAUUUUUUUUAUUAUGUU	454	8175	AACAGUAUUGAAAAAAUUG	921
UAUAUUUUUAACCUUGACUGA	455	8175	UAUAUUUUUAACCUUGACUGA	455	8193	UCAGUCAGGUUJAAAAUAUA	922
ACUGAUCUAAUUGUAUUAG	456	8193	ACUGAUCUAAUUGUAUUAG	456	8211	CUAAUACAUAUUAAGAUUCAGU	923
GUUUUGUGAAUAUAUCAUGU	457	8211	GUUUUGUGAAUAUAUCAUGU	457	8229	ACAUGAUUAUUCACAAUAC	924
UGAAAUGUUUUUGAGACAGA	458	8229	UGAAAUGUUUUUGAGACAGA	458	8247	UCUGUCUCAAACAAUUAUCA	925
AGUACUAUAUUUGUGAAUA	459	8247	AGUACUAUAUUUGUGAAUA	459	8265	UAUUUCACAAAUAUAGUAU	926
AUAUUUUUAGGUUUUUUU	460	8265	AUAUUUUUAGGUUUUUUU	460	8283	AAAAAACCAUAAAAUUUAU	927
UCACUUAGAACCUCUUCUGU	461	8283	UCACUUAGAACCUCUUCUGU	461	8301	ACAGAAAGGUUUCUAAAGUGA	928
UGUGGAAAAACUAAGAAAAU	462	8301	UGUGGAAAAACUAAGAAAAU	462	8319	AUUUUCUUAAGUUUUUCCACA	929
UUGCUUUUCUGCUGUAUAAU	463	8319	UUGCUUUUCUGCUGUAUAAU	463	8337	AUUUAACAGCAGAAAGCAA	930
UCUGGCAUUAUUAUGAGAU	464	8337	UCUGGCAUUAUUAUGAGAU	464	8355	AUCUACAUAUUAUGCCAGA	931
UUAAGCUUAUUUUUCUGU	465	8355	UUAAGCUUAUUUUUCUGU	465	8373	ACAGAAAAUAAGCUUUUA	932
UGAAUAAAACGUUAUCAAU	466	8373	UGAAUAAAACGUUAUCAAU	466	8391	AUUGAAUACGUUUUAUUA	933
UAAAAUACUAUUCUUUAAA	467	8391	UAAAAUACUAUUCUUUAAA	467	8409	UUUAAAAGAAUAGUAUUUUA	934

The 3'-ends of the Upper sequence and the Lower sequence of the siNA construct can include an overhang sequence, for example about 1, 2, 3, or 4 nucleotides in length, preferably 2 nucleotides in length, wherein the overhanging sequence of the lower sequence is optionally complementary to a portion of the target sequence. The upper sequence is also referred to as the sense strand, whereas the lower sequence is also referred to as the antisense strand. The upper and lower sequences in the Table can further comprise a chemical modification having Formulae I-VII or any combination thereof.

Table III: XIAP Synthetic Modified siNA constructs

XIAP		Target	SeqID	RPI#	Aliases	Sequence	SeqID
94		GCGAAAAGGUGGACAAGUCCUUAU	935		BIRC4:96U21 siRNA sense	GAAAAGGUGGACAAGUCCUUT	939
358		ACUCAGCAGUUGGAAACACACAGG	936		BIRC4:360U21 siRNA sense	UCAGCAGUUGGAAACACACATT	940
353		UGGAGACUCAGCAGUUGGAAGAC	937		BIRC4:355U21 siRNA sense	GAGACUCAGCAGUUGGAAGTT	941
1345		CACUUGAGGUUCUGGUUGCAGAU	938		BIRC4:1347U21 siRNA sense	CUUGAGGUUCUGGUUGCAGTT	942
94		GCGAAAAGGUGGACAAGUCCUUAU	935		BIRC4:114L21 siRNA (96C) antisense	AGGACUUGUCCACCUCUUUUCTT	943
358		ACUCAGCAGUUGGAAACACACAGG	936		BIRC4:378L21 siRNA (360C) antisense	UGUGUCUUUCCAAACUGCUGATT	944
353		UGGAGACUCAGCAGUUGGAAGAC	937		BIRC4:373L21 siRNA (355C) antisense	CUUCCAACUGCUGAGUCUCTT	945
1345		CACUUGAGGUUCUGGUUGCAGAU	938		BIRC4:1365L21 siRNA (1347C) antisense	CUGCAACGAGAACCUCUAAAGTT	946
94		GCGAAAAGGUGGACAAGUCCUUAU	935		BIRC4:96U21 siRNA stab04 sense	B GAAAAGGUGGACAAGUCCUUT B	947
358		ACUCAGCAGUUGGAAACACACAGG	936		BIRC4:360U21 siRNA stab04 sense	B ucAGcAGUUGGAAAGACAcATT B	948
353		UGGAGACUCAGCAGUUGGAAGAC	937		BIRC4:355U21 siRNA stab04 sense	B GAGAcucAGcAGUUGGAAGTT B	949
1345		CACUUGAGGUUCUGGUUGCAGAU	938		BIRC4:1347U21 siRNA stab04 sense	B cuuGAGGuucuuGGuuGcAGTT B	950
94		GCGAAAAGGUGGACAAGUCCUUAU	935		BIRC4:114L21 siRNA (96C) stab05 antisense	AGGAcuuGuccAccuuuuucTsT	951
358		ACUCAGCAGUUGGAAACACACAGG	936		BIRC4:378L21 siRNA (360C) stab05 antisense	uGuGuuuuccAAcuGcuGATsT	952
353		UGGAGACUCAGCAGUUGGAAGAC	937		BIRC4:373L21 siRNA (355C) stab05 antisense	cuuccAAcuGcuGAGucucTsT	953
1345		CACUUGAGGUUCUGGUUGCAGAU	938		BIRC4:1365L21 siRNA (1347C) stab05 antisense	cuGcAAccAGAAccuucAAAGTsT	954
94		GCGAAAAGGUGGACAAGUCCUUAU	935		BIRC4:96U21 siRNA stab07 sense	B GAAAAGGUGGACAAGUCCUUT B	955
358		ACUCAGCAGUUGGAAACACACAGG	936		BIRC4:360U21 siRNA stab07 sense	B ucAGcAGUUGGAAAGAcAcATT B	956
353		UGGAGACUCAGCAGUUGGAAGAC	937		BIRC4:355U21 siRNA stab07 sense	B GAGAcucAGcAGUUGGAAGTT B	957
1345		CACUUGAGGUUCUGGUUGCAGAU	938		BIRC4:1347U21 siRNA stab07 sense	B cuuGAGGuucuuGGuuGcAGTT B	958
94		GCGAAAAGGUGGACAAGUCCUUAU	935		BIRC4:114L21 siRNA (96C) stab11 antisense	AGGAcuuGuccAccuuuuucTsT	959
358		ACUCAGCAGUUGGAAACACACAGG	936		BIRC4:378L21 siRNA (360C) stab11 antisense	uGuGuuuuccAAcuGcuGATsT	960
353		UGGAGACUCAGCAGUUGGAAGAC	937		BIRC4:373L21 siRNA (355C) stab11 antisense	cuuccAAcuGcuGAGucucTsT	961
1345		CACUUGAGGUUCUGGUUGCAGAU	938		BIRC4:1365L21 siRNA (1347C) stab11 antisense	cuGcAAccAGAAccuucAAAGTsT	962

94	GCGAAAAGGUGGACAAGUCCUAU	935	stab1 antisense	BIRCA:96U21 siRNA stab18 sense	B GAAAAAGGUGGACAAGuccuTT B	963
358	ACUCAGCAGUUGGAAGACACAGG	936		BIRCA:360U21 siRNA stab18 sense	B ucaGcAGuUGGAAGACaCATT B	964
353	UGGAGACUCAGCAGUUGGAAGAC	937		BIRCA:355U21 siRNA stab18 sense	B GAGAcucAGcAGuUGGAAGTT B	965
1345	CACUUGAGGUUCUGGUUGCAGAU	938		BIRCA:1347U21 siRNA stab18 sense	B cuuGAGGuucucUGGuUGcAGTT B	966
94	GCGAAAAGGUGGACAAGUCCUAU	935		BIRCA:114L21 siRNA (96C) stab08 antisense	AGGAcuuGuccAccuuuuucTsT	967
358	ACUCAGCAGUUGGAAGACACAGG	936		BIRCA:378L21 siRNA (360C) stab08 antisense	uGuGucuuuccAAcuGcuGATsT	968
353	UGGAGACUCAGCAGUUGGAAGAC	937		BIRCA:373L21 siRNA (355C) stab08 antisense	cuuccAAcuGcuGAGucucTsT	969
1345	CACUUGAGGUUCUGGUUGCAGAU	938		BIRCA:1365L21 siRNA (1347C) stab08 antisense	cuGcAAccAGAAccuucAAAGTsT	970
94	GCGAAAAGGUGGACAAGUCCUAU	935		BIRCA:96U21 siRNA stab09 sense	B GAAAAAGGUGGACAAGUCCUtt B	971
358	ACUCAGCAGUUGGAAGACACAGG	936		BIRCA:360U21 siRNA stab09 sense	B UCAGCAGUUGGAAGACACATT B	972
353	UGGAGACUCAGCAGUUGGAAGAC	937		BIRCA:355U21 siRNA stab09 sense	B GAGACUCAGCAGUUGGAAGTT B	973
1345	CACUUGAGGUUCUGGUUGCAGAU	938		BIRCA:1347U21 siRNA stab09 sense	B CUUGAGGUUCUGGUUGCAGTT B	974
94	GCGAAAAGGUGGACAAGUCCUAU	935		BIRCA:114L21 siRNA (96C) stab10 antisense	AGGACUUGUCCACCuuuuUUCtsT	975
358	ACUCAGCAGUUGGAAGACACAGG	936		BIRCA:378L21 siRNA (360C) stab10 antisense	UGUGUCUUCcAACACUGCUGATsT	976
353	UGGAGACUCAGCAGUUGGAAGAC	937		BIRCA:373L21 siRNA (355C) stab10 antisense	CUUCCAACUGCUGAGUCUCtsT	977
1345	CACUUGAGGUUCUGGUUGCAGAU	938		BIRCA:1365L21 siRNA (1347C) stab10 antisense	CUGCAACcAGAAccUcUAAGTsT	978

Uppercase = ribonucleotide

u,c = 2'-deoxy-2'-fluoro U,C

T = thymidine

B = inverted deoxy abasic

s = phosphorothioate linkage

A = deoxy Adenosine

G = deoxy Guanosine

A = 2'-O-methyl Adenosine

G = 2'-O-methyl Guanosine



**Table V**

Non-limiting examples of Stabilization Chemistries for chemically modified siNA constructs

<b>Chemistry</b>	<b>pyrimidine</b>	<b>Purine</b>	<b>cap</b>	<b>p=S</b>	<b>Strand</b>
"Stab 1"	Ribo	Ribo	-	5 at 5'-end 1 at 3'-end	S/AS
"Stab 2"	Ribo	Ribo	-	All linkages	Usually AS
"Stab 3"	2'-fluoro	Ribo	-	4 at 5'-end 4 at 3'-end	Usually S
"Stab 4"	2'-fluoro	Ribo	5' and 3'-ends	-	Usually S
"Stab 5"	2'-fluoro	Ribo	-	1 at 3'-end	Usually AS
"Stab 6"	2'-O-Methyl	Ribo	5' and 3'-ends	-	Usually S
"Stab 7"	2'-fluoro	2'-deoxy	5' and 3'-ends	-	Usually S
"Stab 8"	2'-fluoro	2'-O-Methyl	-	1 at 3'-end	Usually AS
"Stab 9"	Ribo	Ribo	5' and 3'-ends	-	Usually S
"Stab 10"	Ribo	Ribo	-	1 at 3'-end	Usually AS
"Stab 11"	2'-fluoro	2'-deoxy	-	1 at 3'-end	Usually AS
"Stab 12"	2'-fluoro	LNA	5' and 3'-ends		Usually S
"Stab 13"	2'-fluoro	LNA		1 at 3'-end	Usually AS
"Stab 14"	2'-fluoro	2'-deoxy		2 at 5'-end 1 at 3'-end	Usually AS
"Stab 15"	2'-deoxy	2'-deoxy		2 at 5'-end 1 at 3'-end	Usually AS
"Stab 16"	Ribo	2'-O-Methyl	5' and 3'-ends		Usually S
"Stab 17"	2'-O-Methyl	2'-O-Methyl	5' and 3'-ends		Usually S

(400/124)

"Stab 18"	2'-fluoro	2'-O-Methyl	ends 5' and 3'- ends	1 at 3'-end	Usually S

CAP = any terminal cap, see for example **Figure 10**.

All Stab 1-18 chemistries can comprise 3'-terminal thymidine (TT) residues

All Stab 1-18 chemistries typically comprise 21 nucleotides, but can vary as described herein.

S = sense strand

AS = antisense strand

**Table V****A. 2.5  $\mu$ mol Synthesis Cycle ABI 394 Instrument**

Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time*RNA
Phosphoramidites	6.5	163 $\mu$ L	45 sec	2.5 min	7.5 min
S-Ethyl Tetrazole	23.8	238 $\mu$ L	45 sec	2.5 min	7.5 min
Acetic Anhydride	100	233 $\mu$ L	5 sec	5 sec	5 sec
N-Methyl Imidazole	186	233 $\mu$ L	5 sec	5 sec	5 sec
TCA	176	2.3 mL	21 sec	21 sec	21 sec
Iodine	11.2	1.7 mL	45 sec	45 sec	45 sec
Beaucage	12.9	645 $\mu$ L	100 sec	300 sec	300 sec
Acetonitrile	NA	6.67 mL	NA	NA	NA

**B. 0.2  $\mu$ mol Synthesis Cycle ABI 394 Instrument**

Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time*RNA
Phosphoramidites	15	31 $\mu$ L	45 sec	233 sec	465 sec
S-Ethyl Tetrazole	38.7	31 $\mu$ L	45 sec	233 min	465 sec
Acetic Anhydride	655	124 $\mu$ L	5 sec	5 sec	5 sec
N-Methyl Imidazole	1245	124 $\mu$ L	5 sec	5 sec	5 sec
TCA	700	732 $\mu$ L	10 sec	10 sec	10 sec
Iodine	20.6	244 $\mu$ L	15 sec	15 sec	15 sec
Beaucage	7.7	232 $\mu$ L	100 sec	300 sec	300 sec
Acetonitrile	NA	2.64 mL	NA	NA	NA

**C. 0.2  $\mu$ mol Synthesis Cycle 96 well Instrument**


Reagent	Equivalents:DNA/ 2'-O-methyl/Ribo	Amount: DNA/2'-O- methyl/Ribo	Wait Time* DNA	Wait Time* 2'-O- methyl	Wait Time* Ribo
Phosphoramidites	22/33/66	40/60/120 $\mu$ L	60 sec	180 sec	360sec
S-Ethyl Tetrazole	70/105/210	40/60/120 $\mu$ L	60 sec	180 min	360 sec
Acetic Anhydride	265/265/265	50/50/50 $\mu$ L	10 sec	10 sec	10 sec
N-Methyl Imidazole	502/502/502	50/50/50 $\mu$ L	10 sec	10 sec	10 sec
TCA	238/475/475	250/500/500 $\mu$ L	15 sec	15 sec	15 sec
Iodine	6.8/6.8/6.8	80/80/80 $\mu$ L	30 sec	30 sec	30 sec
Beaucage	34/51/51	80/120/120	100 sec	200 sec	200 sec
Acetonitrile	NA	1150/1150/1150 $\mu$ L	NA	NA	NA

- 5
- Wait time does not include contact time during delivery.
  - Tandem synthesis utilizes double coupling of linker molecule


### ABSTRACT OF THE DISCLOSURE

The present invention concerns methods and reagents useful in modulating inhibitor or apoptosis (IAP) genes, such as XIAP, HIAP1, HIAP2, and/or NAIP gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against XIAP gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of XIAP expression or activity.


**Figure 1**




**Figure 2**



**Figure 3**




**Figure 4**




POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES  
 (eg. THYMIDINE) OR UNIVERSAL BASES  
 B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP  
 THAT IS OPTIONALLY PRESENT  
 L = GLYCERYL MOIETY THAT IS OPTIONALLY PRESENT  
 S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE



**Figure 5**




**Figure 6**








**Figure 9: Target site Selection using siRNA**




**Figure 10**




R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl  
 B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).


**Figure 11: Modification Strategy**




***Figure 12: Phosphorylated siNA constructs***



Phosphates can be modified  
as described herein




Asymmetric duplex  
siNA





**Figure 13: 5'-phosphate modifications**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**